



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07K 5/078, A61K 38/05</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/35163 (43) International Publication Date: 15 July 1999 (15.07.99)</p>
<p>(21) International Application Number: PCT/GB99/00062 (22) International Filing Date: 8 January 1999 (08.01.99) (30) Priority Data: 9800396.5 8 January 1998 (08.01.98) GB 9826499.7 2 December 1998 (02.12.98) GB (71) Applicant (for all designated States except US): CELLTECH THERAPEUTICS LIMITED [GB/GB]; 216 Bath Road, Slough, Berkshire SL1 4EN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): HEAD, John, Clifford [GB/GB]; 4 Dorchester Close, Maidenhead, Berkshire SL6 6RX (GB). ARCHIBALD, Sarah, Catherine [GB/GB]; 5 College Glen, Maidenhead, Berkshire SL6 6BL (GB). WARRELOW, Graham, John [GB/GB]; Oakside, 4 Wieland Road, Northwood, Middlesex HA6 3QU (GB). PORTER, John, Robert [GB/GB]; 7 Farm Place, Henton, Chinnor, Oxfordshire OX9 4AD (GB). (74) Agent: MERCER, Christopher, Paul; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>
<p>(54) Title: PHENYLALANINE DERIVATIVES</p> <div data-bbox="380 1150 1282 1331" data-label="Chemical-Block"> <p style="text-align: right;">(1)</p> </div> <p>(57) Abstract</p> <p>Phenylalanine derivatives of formula (1) are described, in which L¹ is a linker atom or group; A is a chain -[C(R⁷)(R⁸)]_pY[C(R⁹)(R¹⁰)]_q- in which Y is a sulphur atom or a -S(O)- or -S(O)₂- group, R⁷, R⁸, R⁹ and R¹⁰, which may be the same or different, is each a hydrogen atom or a straight or branched alkyl or optionally substituted aromatic group, or R⁷ and R⁸ together with the carbon atom to which they are attached, or R⁹ and R¹⁰ together with the carbon atom to which they are attached, each forms a C₃-cycloalkyl group, and p and q, which may be the same or different, is each zero or an integer 1 or 2, provided that when one of p or q is zero the other is an integer 1 or 2; L² is a linker group selected from -C(O)-, -C(O)O-, -C(S)-, -S(O)₂-, -CON(R¹¹)-, {where R¹¹ is a hydrogen atom or a straight or branched alkyl group}, -CSN(R¹¹)-, -SON(R¹¹)- or SO₂N(R¹¹)-; R is a carboxylic acid or a derivative thereof; and the salts, solvates and hydrates thereof. The compounds are able to inhibit the binding of α₄ integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PHENYLALANINE DERIVATIVES

This invention relates to a series of phenylalanine derivatives, to
5 compositions containing them, to processes for their preparation, and to
their use in medicine.

Over the last few years it has become increasingly clear that the physical
interaction of inflammatory leukocytes with each other and other cells of
10 the body plays an important role in regulating immune and inflammatory
responses [Springer, T A. Nature, 346, 425, (1990); Springer, T. A. Cell
76, 301, (1994)]. Many of these interactions are mediated by specific cell
surface molecules collectively referred to as cell adhesion molecules.

15 The adhesion molecules have been sub-divided into different groups on
the basis of their structure. One family of adhesion molecules which is
believed to play a particularly important role in regulating immune and
inflammatory responses is the integrin family. This family of cell surface
glycoproteins has a typical non-covalently linked heterodimer structure. At
20 least 14 different integrin alpha chains and 8 different integrin beta chains
have been identified [Sonnenberg, A. Current Topics in Microbiology and
Immunology, 184, 7, (1993)]. The members of the family are typically
named according to their heterodimer composition although trivial
nomenclature is widespread in this field. Thus the integrin termed $\alpha 4 \beta 1$
25 consists of the integrin alpha 4 chain associated with the integrin beta 1
chain, but is also widely referred to as Very Late Antigen 4 or VLA4. Not
all of the potential pairings of integrin alpha and beta chains have yet been
observed in nature and the integrin family has been subdivided into a
number of subgroups based on the pairings that have been recognised
30 [Sonnenberg, A. *ibid*].

The importance of cell adhesion molecules in human leukocyte function
has been further highlighted by a genetic deficiency disease called
Leukocyte Adhesion Deficiency (LAD) in which one of the families of
35 leukocyte integrins is not expressed [Marlin, S. D. *et al*/ J. Exp. Med. 164,
855 (1986)]. Patients with this disease have a reduced ability to recruit

leukocytes to inflammatory sites and suffer recurrent infections which in extreme cases may be fatal.

5 The potential to modify adhesion molecule function in such a way as to beneficially modulate immune and inflammatory responses has been extensively investigated in animal models using specific monoclonal antibodies that block various functions of these molecules [e.g. Issekutz, T. B. J. Immunol. 3394, (1992); Li, Z. *et al*/ Am. J. Physiol. 263, L723, (1992); Binns, R. M. *et al*/ J. Immunol. 157, 4094, (1996)]. A number of
10 monoclonal antibodies which block adhesion molecule function are currently being investigated for their therapeutic potential in human disease.

15 One particular integrin subgroup of interest involves the $\alpha 4$ chain which can pair with two different beta chains $\beta 1$ and $\beta 7$ [Sonnenberg, A. *ibid*]. The $\alpha 4\beta 1$ pairing occurs on many circulating leukocytes (for example lymphocytes, monocytes and eosinophils) although it is absent or only present at low levels on circulating neutrophils. $\alpha 4\beta 1$ binds to an adhesion molecule (Vascular Cell Adhesion Molecule-1 also known as VCAM-1)
20 frequently up-regulated on endothelial cells at sites of inflammation [Osborne, L. Cell, 62, 3, (1990)]. The molecule has also been shown to bind to at least three sites in the matrix molecule fibronectin [Humphries, M. J. *et al*. Ciba Foundation Symposium, 189, 177, (1995)]. Based on data obtained with monoclonal antibodies in animal models it is believed
25 that the interaction between $\alpha 4\beta 1$ and ligands on other cells and the extracellular matrix plays an important role in leukocyte migration and activation [Yednock, T. A. *et al*, Nature, 356, 63, (1992); Podolsky, D. K. *et al*. J. Clin. Invest. 92, 373, (1993); Abraham, W. M. *et al*. J. Clin. Invest. 93, 776, (1994)].

30 The integrin generated by the pairing of $\alpha 4$ and $\beta 7$ has been termed LPAM-1 [Holzmann, B and Weissman, I. EMBO J. 8, 1735, (1989)] and like $\alpha 4\beta 1$, binds to VCAM-1 and fibronectin. In addition, $\alpha 4\beta 7$ binds to an adhesion molecule believed to be involved in the homing of leukocytes to
35 mucosal tissue termed MAdCAM-1 [Berlin, C. *et al*, Cell, 74, 185, (1993)]. The interaction between $\alpha 4\beta 7$ and MAdCAM-1 may also be important at

sites of inflammation outside of mucosal tissue [Yang, X-D. *et al*, PNAS, 91, 12604 (1994)].


Regions of the peptide sequence recognised by $\alpha 4\beta 1$ and $\alpha 4\beta 7$ when they
5 bind to their ligands have been identified. $\alpha 4\beta 1$ seems to recognise LDV,
IDA or REDV peptide sequences in fibronectin and a QIDSP sequence in
VCAM-1 [Humphries, M. J. *et al*, *ibid*] whilst $\alpha 4\beta 7$ recognises a LDT
sequence in MAdCAM-1 [Briskin, M. J. *et al*, J. Immunol. 156, 719,
10 (1996)]. There have been several reports of inhibitors of these interactions
being designed from modifications of these short peptide sequences
[Cardarelli, P. M. *et al* J. Biol. Chem. 269, 18668, (1994); Shroff, H. N.
Bioorganic. Med. Chem. Lett. 6, 2495, (1996); Vanderslice, P. J. Immunol.
158, 1710, (1997)]. It has also been reported that a short peptide
sequence derived from the $\alpha 4\beta 1$ binding site in fibronectin can inhibit a
15 contact hypersensitivity reaction in a trinitrochlorobenzene sensitised
mouse [Ferguson, T. A. *et al*, PNAS 88, 8072, (1991)].

Since the alpha 4 subgroup of integrins are predominantly expressed on
leukocytes their inhibition can be expected to be beneficial in a number of
20 immune or inflammatory disease states. However, because of the
ubiquitous distribution and wide range of functions performed by other
members of the integrin family it is very important to be able to identify
selective inhibitors of the alpha 4 subgroup.

25 We have now found a group of compounds which are potent and selective
inhibitors of $\alpha 4$ integrins. Members of the group are able to inhibit $\alpha 4$
integrins such as $\alpha 4\beta 1$ and/or $\alpha 4\beta 7$ at concentrations at which they
generally have no or minimal inhibitory action on α integrins of other
subgroups. The compounds are thus of use in medicine, for example in
30 the prophylaxis and treatment of immune or inflammatory disorders as
described hereinafter.

Thus according to one aspect of the invention we provide a compound of
formula (1)

35



wherein

- R^1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group;
- Alk^1 and Alk^2 , which may be the same or different, is each an optionally substituted aliphatic or heteroaliphatic chain;
- L^1 is a linker atom or group;
- r , s , t and u is each zero or an integer 1;
- Alk^3 is a straight or branched alkylene chain;
- m is zero or an integer 1;
- R^4 is a hydrogen atom or a methyl group;
- R^5 is a hydrogen atom or a straight or branched alkyl group;
- A is a chain $-[C(R^7)(R^8)]_pY[C(R^9)(R^{10})]_q-$ in which Y is a sulphur atom or a $-S(O)-$ or $-S(O)_2-$ group, R^7 , R^8 , R^9 and R^{10} , which may be the same or different, is each a hydrogen atom or a straight or branched alkyl or optionally substituted aromatic group, or R^7 and R^8 together with the carbon atom to which they are attached, or R^9 and R^{10} together with the carbon atom to which they are attached, each forms a C_{3-7} cycloalkyl group, and p and q , which may be the same or different, is each zero or an integer 1 or 2, provided that when one of p or q is zero the other is an integer 1 or 2;
- L^2 is a linker group selected from $-C(O)-$, $-C(O)O-$, $-C(S)-$, $-S(O)_2-$, $-CON(R^{11})-$, [where R^{11} is a hydrogen atom or a straight or branched alkyl group], $-CSN(R^{11})-$, $-SON(R^{11})-$ or $SO_2N(R^{11})-$;
- R^2 and R^3 , which may be the same or different is each an atom or group $-L^3(CH_2)_pL^4(R^{2a})_q$ in which L^3 and L^4 is each a covalent bond or a linker atom or group, p is zero or the integer 1, q is an integer 1, 2 or 3 and R^{2a} is a hydrogen or halogen atom or a group selected from straight or branched alkyl, $-OR^{12}$ [where R^{12} is a hydrogen atom or an optionally

substituted straight or branched alkyl group], -SR¹², -NR¹²R¹³, [where R¹³ is as just defined for R¹² and may be the same or different], -NO₂, -CN, -CO₂R¹², -SO₃H, -SO₂R¹², -OCO₂R¹², -CONR¹²R¹³, -OCONR¹²R¹³, -CSNR¹²R¹³, -COR¹², -N(R¹²)COR¹³, N(R¹²)CS¹³, -SO₂N(R¹²)(R¹³),
 5 -N(R¹²)SO₂R¹³, -N(R¹²)CONR¹³R¹⁴ [where R¹⁴ is a hydrogen atom or an optionally substituted straight or branched alkyl group], -N(R¹²)CSNR¹³R¹⁴ or -N(R¹²)SO₂NR¹³R¹⁴;

R is a carboxylic acid or a derivative thereof;

R⁶ is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group, provided that:

(1) when R¹(Alk¹)_r(L¹)_s- is R¹(Alk¹)_rO-, R¹(Alk¹)_rC(O)O-, R¹(Alk¹)_rNHC(O)O- or R¹(Alk¹)_rS(O)₂O-, [in which R¹ is a hydrogen atom or an optionally substituted aromatic group and Alk¹ is an optionally substituted alkyl group] and R⁶(Alk²)_u(L²)_t- is R⁶(Alk²)_uCO-, R⁶(Alk²)_uC(O)O-, R⁶(Alk²)_uNHCO- or R⁶(Alk²)_uS(O)₂- [in which Alk² is an optionally substituted alkyl chain], then R⁶ is an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic or heteroaromatic group; and

(2) Alk², when present is not a -(CH₂)_nS-, -(CH₂)_nSS- or -(CH₂)_nSC(O)- chain, where n is an integer 1, 2 or 3;

and the salts, solvates and hydrates thereof.

It will be appreciated that compounds of formula (1) may have one or more chiral centres. Where one or more chiral centres is present, enantiomers or diastereomers may exist, and the invention is to be understood to extend to all such enantiomers, diastereomers and mixtures thereof, including racemates. Formula (1) and the formulae hereinafter are intended to represent all individual isomers and mixtures thereof, unless
 25 stated or shown otherwise.

In the compounds of formula (1), derivatives of the carboxylic acid group R include carboxylic acid esters and amides. Particular esters and amides include -CO₂R¹² and CONR¹²R¹³ groups as described herein.

Alk³ in the compounds of the invention may be for example a straight or branched C₁₋₃alkylene chain. Particular examples include -CH₂-, -CH(CH₃)- and -(CH₂)₂-.

- 5 When each of R^{2a}, R⁵, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³ and/or R¹⁴ in the compounds of formula (1) is a straight or branched alkyl group it may be a straight or branched C₁₋₆alkyl group, e.g. a C₁₋₃alkyl group such as a methyl or ethyl group. When the R¹², R¹³ and/or R¹⁴ group is optionally substituted, the substituent may be selected for example from one, two,
10 three or more of the optional substituents described below in relation to the aliphatic groups represented by Alk¹.

When in the compounds of the invention L¹, L³ and/or L⁴ is present as a linker atom or group it may be any divalent linking atom or group.

- 15 Particular examples include -O- or -S- atoms or -C(O)-, -C(O)O-, -C(S)-, -S(O)-, -S(O)₂-, -N(R¹¹)- [where R¹¹ is as defined previously], -CON(R¹¹)-, -OC(O)N(R¹¹)-, -CSN(R¹¹)-, -N(R¹¹)CO-, -N(R¹¹)C(O)O-, -N(R¹¹)CS-, -S(O)N(R¹¹)-, -S(O)₂N(R¹¹)-, -N(R¹¹)S(O)-, -N(R¹¹)S(O)₂-, -N(R¹¹)CON(R¹¹)-, -N(R¹¹)CSN(R¹¹)-, -N(R¹¹)SON(R¹¹)- or
20 -N(R¹¹)SO₂N(R¹¹)- groups. Where the linker group contains two R¹¹ substituents, these may be the same or different.

- When Alk¹ and/or Alk² compounds of formula (1) is an optionally substituted aliphatic chain it may be an optionally substituted C₁₋₁₀
25 aliphatic chain. Particular examples include optionally substituted straight or branched chain C₁₋₆ alkyl, C₂₋₆ alkenyl, or C₂₋₆ alkynyl chains.

- Heteroaliphatic chains represented by Alk¹ or Alk² include the aliphatic chains just described but with each chain additionally containing one, two,
30 three or four heteroatoms or heteroatom-containing groups. Particular heteroatoms or groups include atoms or groups L⁵ where L⁵ is as defined above for L¹ when L¹ is a linker atom or group. Each L⁵ atom or group may interrupt the aliphatic chain, or may be positioned at its terminal carbon atom to connect the chain to the atom or group R¹ or R⁶.
35

Particular examples of aliphatic chains represented by Alk¹ or Alk² include optionally substituted -CH₂-, -CH₂CH₂-, -(CH₂)₂CH₂-, -CH(CH₃)CH₂-, -(CH₂)₃CH₂-, -CH(CH₃)CH₂CH₂-, -CH₂CH(CH₃)CH₂-, -C(CH₃)₂CH₂-, -(CH₂)₄CH₂-, -(CH₂)₅CH₂-, -CHCH-, -CHCHCH₂-, -CH₂CHCH-,
 5 -CHCHCH₂CH₂-, -CH₂CHCHCH₂-, -(CH₂)₂CHCH-, -CC-, -CCCH₂-, -CH₂CC-, -CCCH₂CH₂-, -CH₂CCCH₂-, or -(CH₂)₂CC- chains. Where appropriate each of said chains may be optionally interrupted by one or two atoms and/or groups L⁵ to form an optionally substituted heteroaliphatic chain. Particular examples include optionally substituted
 10 -L⁵CH₂-, -CH₂L⁵CH₂-, -L⁵(CH₂)₂-, -CH₂L⁵(CH₂)₂-, -(CH₂)₂L⁵CH₂-, -L⁵(CH₂)₃- and -(CH₂)₂L⁵(CH₂)₂- chains.

When R¹ and/or R⁶ is present in compounds of formula (1) as an optionally substituted cycloaliphatic group it may be an optionally substituted C₃₋₁₀ cycloaliphatic group. Particular examples include
 15 optionally substituted C₃₋₁₀cycloalkyl, e.g. C₃₋₇cycloalkyl, C₃₋₁₀cycloalkenyl e.g. C₃₋₇cycloalkenyl or C₃₋₁₀cycloalkynyl e.g. C₃₋₇cycloalkynyl groups.

20 Optionally substituted heterocycloaliphatic groups represented by R¹ or R⁶ include the optionally substituted cycloaliphatic groups just described for R¹ and R⁶ but with each group additionally containing one, two, three or four heteroatoms or heteroatom-containing groups L³ as just defined.

25 Optionally substituted polycycloaliphatic groups represented by R¹ and/or R⁶ include optionally substituted C₇₋₁₀ bi- or tricycloalkyl or C₇₋₁₀bi- or tricycloalkenyl groups. Optionally substituted polyheterocycloaliphatic groups represented by R¹ and/or R⁶ include the optionally substituted polycycloalkyl groups just described, but with each group additionally
 30 containing one, two, three or four L³ atoms or groups.

Particular examples of R¹ or R⁶ cycloaliphatic, polycycloaliphatic, heterocycloaliphatic and polyheterocycloaliphatic groups include optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
 35 2-cyclobuten-1-yl, 2-cyclopenten-1-yl, 3-cyclopenten-1-yl, 2,4-cyclopentadien-1-yl, 3,5-cyclohexadien-1-yl, adamantyl, norbornyl,

norbornenyl, pyrroline, e.g. 2- or 3-pyrrolinyl, pyrrolidinyl, pyrrolidinone, oxazolidinyl, oxazolidinone, dioxolanyl, e.g. 1,3-dioxolanyl, imidazolinyl, e.g. 2-imidazolinyl, imidazolidinyl, pyrazolinyl, e.g. 2-pyrazolinyl, pyrazolidinyl, pyranyl, e.g. 2- or 4-pyranyl, piperidinyl, piperidinone, 1,4-dioxanyl, morpholinyl, morpholinone, 1,4-dithianyl, thiomorpholinyl, piperazinyl, 1,3,5-trithianyl, oxazinyl, e.g. 2H-1,3-, 6H-1,3-, 6H-1,2-, 2H-1,2- or 4H-1,4- oxazinyl, 1,2,5-oxathiazinyl, isoxazinyl, e.g. o- or p-isoxazinyl, oxathiazinyl, e.g. 1,2,5 or 1,2,6-oxathiazinyl, or 1,3,5,2-oxadiazinyl groups.

10

The optional substituents which may be present on the Alk¹, Alk², R¹ or R⁶ aliphatic heteroaliphatic, cycloaliphatic, polycycloaliphatic or heterocycloaliphatic or polyheterocycloaliphatic groups include one, two, three or more substituents selected from halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, or hydroxyl, C₁₋₆alkoxy, e.g. methoxy or ethoxy, thiol, C₁₋₆alkylthio e.g. methylthio or ethylthio, amino or substituted amino groups. Substituted amino groups include -NHR¹¹ and -N(R¹¹)₂ groups where R¹¹ is as defined above.

15

In the compounds of formula (1), optionally substituted aromatic groups represented by the group R¹ and/or R⁶ include for example optionally substituted monocyclic or bicyclic fused ring C₆₋₁₂ aromatic groups, such as optionally substituted phenyl, 1- or 2-naphthyl, 1- or 2-tetrahydronaphthyl, indanyl or indenyl groups .

25

Optionally substituted aromatic groups represented by the group R¹ or R⁶ in compounds of formula (1) include for example optionally substituted monocyclic or bicyclic fused ring C₆₋₁₂ aromatic groups, such as optionally substituted phenyl, 1- or 2-naphthyl, 1- or 2-tetrahydronaphthyl, indanyl or indenyl groups .

30

Optionally substituted heteroaromatic groups, represented by the group R¹ or R⁶ in compounds of formula (1) include for example optionally substituted C₁₋₉ heteroaromatic groups containing for example one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. In general, the heteroaromatic groups may be for example

35

monocyclic or bicyclic fused ring heteroaromatic groups. Monocyclic heteroaromatic groups include for example five- or six-membered heteroaromatic groups containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. Bicyclic heteroaromatic groups include for example nine- to thirteen-membered fused-ring heteroaromatic groups containing one, two or more heteroatoms selected from oxygen, sulphur or nitrogen atoms.

Particular examples of heteroaromatic groups of these types include optionally substituted pyrrolyl, furyl, thienyl, imidazolyl, N-methylimidazolyl, N-ethylimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,3,4-thiadiazole, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydro]benzofuryl, isobenzofuryl, benzothienyl, benzoriazolyl, isobenzothienyl, indolyl, isoindolyl, benzimidazolyl, imidazo[1,2-a]pyridyl, benzothiazolyl, benzoxazolyl, benzopyranyl, [3,4-dihydro]benzopyranyl, quinazolinyl, naphthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolinyl, isoquinolinyl, tetrazolyl, 5,6,7,8-tetrahydroquinolinyl, 5,6,7,8-tetrahydroisoquinolinyl, and imidyl, e.g. succinimidyl, phthalimidyl, or naphthalimidyl such as 1,8-naphthalimidyl.

Optional substituents which may be present on aromatic or heteroaromatic groups of the above types include one, two, three or more substituents selected from the group $-L^3(CH_2)_pL^4(R^{2a})_q$ where L^3 , L^4 , p and q are as defined previously and R^{2a} is as previously defined but is other than an hydrogen atom when L^3 and L^4 is each a covalent bond and p is zero.

Examples of the substituents represented by R^2 and R^3 in compounds of formula (1) and which may be present on aromatic or heteroaromatic groups represented by R^1 and R^6 include atoms or groups $-L^3(CH_2)_pL^4R^{2a}$, $-L^3(CH_2)_pR^{2a}$, $-L^3R^{2a}$, $-(CH_2)_pR^{2a}$ and $-R^{2a}$ wherein L^3 , $(CH_2)_p$, L^4 and R^{2a} are as defined above. Particular examples of such substituents include $-L^3CH_2L^3R^{2a}$, $-L^3CH(CH_3)L^4R^{2a}$, $-L^3CH(CH_2)_2L^4R^{2a}$, $-L^3CH_2R^{2a}$, $-L^3CH(CH_3)R^{2a}$, $-L^3(CH_2)_2R^{2a}$, $-CH_2R^{2a}$, $-CH(CH_3)R^{2a}$ and $-(CH_2)_2R^{2a}$ groups.

Thus each of R² and R³ and, where present, substituents on R¹ and R⁶ aromatic or heteroaromatic groups in compounds of the invention may be for example selected from a hydrogen atom, a halogen atom, e.g. a fluorine, chlorine, bromine or iodine atom, or a C₁₋₆alkyl, e.g. methyl, ethyl, n-propyl, i-propyl, n-butyl or t-butyl, C₁₋₆alkylamino, e.g. methylamino or ethylamino, C₁₋₆hydroxyalkyl, e.g. hydroxymethyl, hydroxyethyl or -C(OH)(CF₃)₂, carboxyC₁₋₆alkyl, e.g. carboxyethyl, C₁₋₆alkylthio e.g. methylthio or ethylthio, carboxyC₁₋₆alkylthio, e.g. carboxymethylthio, 2-carboxyethylthio or 3-carboxypropylthio, C₁₋₆alkoxy, e.g. methoxy or ethoxy, hydroxyC₁₋₆alkoxy, e.g. 2-hydroxyethoxy, haloC₁₋₆alkyl, e.g. -CF₃, CCl₃, -CHF₂, -CHCl₂, -CH₂F, -CH₂Cl, haloC₁₋₆alkoxy, e.g. -OCF₃, -OCCl₃, -OCHF₂, -OCHCl₂, -OCH₂F, -OCH₂Cl, C₁₋₆alkyl-amino, e.g. methylamino or ethylamino, amino (-NH₂), aminoC₁₋₆alkyl, e.g. aminomethyl or aminoethyl, C₁₋₆dialkylamino, e.g. dimethylamino or diethylamino, C₁₋₆alkylaminoC₁₋₆alkyl, e.g. ethylaminoethyl, C₁₋₆dialkyl-aminoC₁₋₆alkyl, e.g. diethylaminoethyl, aminoC₁₋₆alkoxy, e.g. aminoethoxy, C₁₋₆alkylaminoC₁₋₆alkoxy, e.g. methylaminoethoxy, C₁₋₆dialkylaminoC₁₋₆alkoxy, e.g. dimethylaminoethoxy, diethylaminoethoxy, isopropylaminoethoxy, or dimethylaminopropoxy, nitro, cyano, amidino, hydroxyl (-OH), formyl [HC(O)-], carboxyl (-CO₂H), -CO₂R¹², C₁₋₆alkanoyl e.g. acetyl, thiol (-SH), thioC₁₋₆alkyl, e.g. thiomethyl or thioethyl, sulphonyl (-SO₃H), C₁₋₆alkylsulphonyl, e.g. methylsulphonyl, aminosulphonyl (-SO₂NH₂), C₁₋₆alkylaminosulphonyl, e.g. methylaminosulphonyl or ethylaminosulphonyl, C₁₋₆dialkylaminosulphonyl, e.g. dimethylaminosulphonyl or diethylaminosulphonyl, phenylaminosulphonyl, carboxamido (-CONH₂), C₁₋₆alkylaminocarbonyl, e.g. methylaminocarbonyl or ethylaminocarbonyl, C₁₋₆dialkylaminocarbonyl, e.g. dimethylaminocarbonyl or diethylaminocarbonyl, aminoC₁₋₆alkylaminocarbonyl, e.g. aminoethylaminocarbonyl, C₁₋₆dialkylaminoC₁₋₆alkylaminocarbonyl, e.g. diethylaminoethylaminocarbonyl, aminocarbonylamino, C₁₋₆alkylaminocarbonylamino, e.g. methylaminocarbonylamino or ethylaminocarbonylamino, C₁₋₆dialkylaminocarbonylamino, e.g. dimethylaminocarbonylamino or diethylaminocarbonylamino, C₁₋₆alkylaminocarbonylC₁₋₆alkylamino, e.g. methylaminocarbonylmethylamino, aminothiocarbonylamino, C₁₋₆alkylaminothiocarbonylamino, e.g. methylaminothiocarbonylamino or ethylaminothiocarbonylamino.

carbonylamino, C₁₋₆dialkylaminothiocarbonylamino, e.g. dimethylamino-thiocarbonylamino or diethylaminothiocarbonylamino, C₁₋₆alkylaminothiocarbonylC₁₋₆alkylamino, e.g. ethylaminothiocarbonylmethylamino, C₁₋₆alkylsulphonylamino, e.g. methylsulphonylamino or ethylsulphonylamino, 5 C₁₋₆dialkylsulphonylamino, e.g. dimethylsulphonylamino or diethylsulphonylamino, aminosulphonylamino (-NH₂SO₂NH₂), C₁₋₆alkylaminosulphonylamino, e.g. methylaminosulphonylamino or ethylaminosulphonylamino, C₁₋₆dialkylaminosulphonylamino, e.g. dimethylaminosulphonylamino or diethylaminosulphonylamino, C₁₋₆alkanoylamino, e.g. 10 acetylamino, aminoC₁₋₆alkanoylamino e.g. aminoacetylamino, C₁₋₆dialkylaminoC₁₋₆alkanoylamino, e.g. dimethylaminoacetylamino, C₁₋₆alkanoylaminoC₁₋₆alkyl, e.g. acetylaminomethyl, C₁₋₆alkanoylaminoC₁₋₆alkylamino, e.g. acetamidoethylamino, C₁₋₆alkoxycarbonylamino, e.g. methoxycarbonylamino, ethoxycarbonylamino or t-butoxycarbonylamino 15 group.

In one group of compounds of the invention R² and R³ may each be a hydrogen or halogen atom or a straight or branched alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyl or nitro group as defined herein. 20

The chain represented by A in compounds of the invention may for example be a chain -Y[C(R⁹)(R¹⁰)]₂-, -[C(R⁷)(R⁸)]Y[C(R⁹)(R¹⁰)]-, -[C(R⁷)(R⁸)]₂Y-, -[C(R⁷)(R⁸)]₂Y[(R⁹)(R¹⁰)]- or -[C(R⁷)(R⁸)]Y[C(R⁹)(R¹⁰)]₂- 25 where Y, R⁷, R⁸, R⁹ and R¹⁰ are as described above for compounds of formula (1). Particular examples of such chains include -Y(CH₂)₂-, -(CH₂)₂Y-, -CH₂YCH₂-, -[C(R⁷)(R⁸)]YCH₂- e.g. -C(CH₃)₂YCH₂- and -CH₂Y[C(R⁹)(R¹⁰)]- e.g. -CH₂YC(CH₃)₂- chains.

When in the chain represented by A, R⁷, R⁸, R⁹ and/or R¹⁰ is an optionally substituted aromatic group it may be an optionally substituted phenyl group. Particular examples of optional substituents include one, two or three substituents selected from halogen atoms, e.g. fluorine, bromine, chlorine or iodine atoms or C₁₋₆alkyl, e.g. methyl or ethyl, C₁₋₆alkoxy, e.g. methoxy or ethoxy, hydroxy, nitro or cyano groups. When one of R⁷, R⁸, 35 R⁹ or R¹⁰ is an optionally substituted aromatic group, the remainder for

example may each be a hydrogen atom or a straight or branched alkyl group as defined herein.

- 5 The presence of certain substituents in the compounds of formula (1) may enable salts of the compounds to be formed. Suitable salts include pharmaceutically acceptable salts, for example acid addition salts derived from inorganic or organic acids, and salts derived from inorganic and organic bases.
- 10 Acid addition salts include hydrochlorides, hydrobromides, hydroiodides, alkylsulphonates, e.g. methanesulphonates, ethanesulphonates, or isethionates, arylsulphonates, e.g. p-toluenesulphonates, besylates or napsylates, phosphates, sulphates, hydrogen sulphates, acetates, trifluoroacetates, propionates, citrates, maleates, fumarates, malonates, succinates, lactates, oxalates, tartrates and benzoates.
- 15

Salts derived from inorganic or organic bases include alkali metal salts such as sodium or potassium salts, alkaline earth metal salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.

20

Particularly useful salts of compounds according to the invention include pharmaceutically acceptable salts, especially acid addition pharmaceutically acceptable salts.

25

R in compounds of the invention is preferably a $-\text{CO}_2\text{H}$ group.

Alk³ in compounds of formula (1) is preferably a $-\text{CH}_2-$ chain and m is preferably an integer 1. In compounds of this type, the carbon atom to which Alk³ and R are attached forms a chiral centre and is preferably in the L configuration.

30

R⁴ and R⁵ in compounds of the invention is each preferably a hydrogen atom.

35

One particular class of compounds of the invention is that wherein each of R^7 , R^8 , R^9 and R^{10} in the chain A is as defined for formula (1) other than an optionally substituted aromatic group. In general in compounds of formula (1) the chain A is one in which Y is preferably a sulphur atom.

5 Particularly useful chains represented by A include $-C(R^7)(R^8)SC(R^9)(R^{10})-$ chains, especially $-CH_2SCH_2-$, $-CH(CH_3)SCH_2-$, $-C(CH_3)_2SCH_2-$, $-CH_2SCH(CH_3)-$ and $-CH_2SC(CH_3)_2-$ chains. Compounds of the invention in which A is $-CH_2SCH_2-$ are particularly preferred.

10

When the linker group L^1 is present in compounds of the invention [i.e. when s is an integer 1] it is preferably an oxygen atom or a $-C(O)O-$, $-C(O)NH-$, $-C(O)N(CH_3)-$, $-C(S)NH-$, $-NH-$, $-N(CH_3)-$, $-NHC(O)O-$, $-SO_2-$, $-SO_2NH-$, $-SO_2N(CH_3)-$, $-OC(O)NH-$, $-NHC(O)NH-$ or $-NHC(S)NH-$ group.

15 Especially useful L^1 groups include $-SO_2NH-$, $-C(O)O-$, $-NH-$ and, in particular, $-CONH-$.

The aliphatic chain represented by Alk^1 in compounds of formula (1) is preferably a $-CH_2-$ chain.

20

In general in compounds of the invention the group R^1 is preferably an optionally substituted aromatic or heteroaromatic group. Particularly useful groups of these types include optionally substituted six-membered monocyclic groups, especially optionally substituted phenyl, pyridyl or pyrimidinyl groups.

25

Compounds of the invention in which a linker group L^2 is present (i.e. when t is an integer 1) are preferred. Compounds of this type in which L^2 is a $-C(O)-$ group are particularly useful.

30


Alk^2 in compounds of formula (1) is preferably present (i.e. u is preferably an integer 1) and in particular is a $-CH_2-$ chain. Compounds of this type in which R^6 is a hydrogen atom or an optionally substituted aromatic or heteroaromatic group, especially an optionally substituted phenyl, pyridyl or imidazolyl group are particularly preferred.

35

A particularly useful class of compounds according to the invention has the formula (1) in which $R^1(Alk^1)_r(L^1)_s$ is a $R^1CH_2L^1$ or R^1L^1 group where R^1 is an optionally substituted aromatic or heteroaromatic group and L^1 is a linker atom or group, Alk^3 is a $-CH_2-$ chain, m is an integer 1, R^4 is a hydrogen atom, R^5 is a hydrogen atom and $-(L^2)_t(Alk^2)_uR^6$ is preferably a $-L^2CH_2R^6$ group where R^6 is a hydrogen atom or an optionally substituted aromatic or heteroaromatic group and is especially a $-C(O)CH_2R^6$ group where R^6 is as just defined. A particular group of compounds in this class include compounds in which R^6 is an optionally substituted heteroaromatic group, particularly an optionally substituted pyridyl group. In general in compounds in this class $R^1CH_2L^1$ is preferably a R^1CH_2S , $R^1CH_2S(O)-$, $R^1CH_2S(O)_2$, $R^1CH_2C(O)$, $R^1CH_2N(R^{11})-$ or, especially, a R^1CH_2O- group; and R^1L^1 is preferably a $R^1CSN(R^{11})-$, $R^1N(R^{11})CO-$, $R^1N(R^{11})CS-$, $R^1S(O)N(R^{11})-$, $R^1S(O)_2N(R^{11})-$, $R^1N(R^{11})SO-$, $R^1N(R^{11})S(O)_2-$ or, especially, a $R^1CON(R^{11})-$ group, particularly a R^1CONH- group.

In the compounds of the just mentioned class R is especially a $-CO_2H$ group.

An especially useful group of compounds according to the invention has the formula (1a):



wherein $-W=$ is $-CH=$ or $-N=$; R^{15} and R^{16} , which may be the same or different, is each an atom or group $-L^3(CH_2)_pL^4(R^{2a})_q$ as defined for R^2 and R^3 in formula (1); Alk^1 , r , L^1 , s , R^2 , R^3 , Alk^3 , m , R , R^4 , R^5 , A , L^2 , t , Alk^2 , u and R^6 are as defined generally and particularly for formula (1); and the salts, solvates, hydrates and N-oxides thereof.

It will be appreciated that the various preferences stated above in relation to groups present in compounds of formula (1) apply equally to the same groups when present in compounds of formula (1a).

- 5 Additionally, in the compounds of formula (1a) the group $(Alk^1)_r(L^1)_s$ is preferably a $-SO_2NH-$, $-C(O)O-$, $-NH-$ or, especially a $-CONH-$ group.

- One of R^{15} or R^{16} in compounds of formula (1a) may be a hydrogen atom and the other a substituent $-L^3(CH_2)_pL^4(R^{2a})_q$ in which R^{2a} is not a
 10 hydrogen atom when L^3 and L^4 is each a covalent bond and p is zero, but preferably each of R^{15} and R^{16} is a substituent $-L^3(CH_2)_pL^4(R^{2a})_q$ as just defined. Particularly useful R^{15} or R^{16} substituents include halogen atoms, especially fluorine or chlorine atoms, methyl, ethyl, methoxy, ethoxy, $-CF_3$, $-OH$, $-CN$, $-NO_2$, $-NH_2$, $-NHCH_3$, $-N(CH_3)_2$, $-COCH_3$, $-SCH_3$,
 15 $-CO_2H$ or $-CO_2CH_3$ groups.

$-W=$ in compounds of formula (1a) is preferably $-N=$.

- Particularly useful compounds according to the invention include the
 20 following:

- N*-(Pyrid-3-ylacetyl)-*D*-thioprolin-(*N*-2,6-dichlorobenzoyl)-*L*-4-aminophenylalanine;
N-Acetyl-*D*-thioprolin-(*N*-3,5-dichloroisonicotinoyl)-*L*-4-amino phenylalanine;
 25 *N*-(Pyrid-3-ylacetyl)-*D*-thioprolin-*O*-(2,4,6-trichlorobenzyl)-*L*-tyrosine;
N-(Pyrid-3-ylacetyl)-*D*-thioprolin-(*O*-2,4,6-trichlorobenzoyl)-*L*-tyrosine;
N-(Pyrid-3-ylacetyl)-*D*-thioprolin-(*O*-2,6-dichlorobenzoyl)-*L*-tyrosine;
N-Acetyl-*D*-thioprolin-(*N*'-2,6-dichlorobenzoyl)-*L*-4-aminophenylalanine;
N-Acetyl-*D*-thioprolin-[*N*'-2-fluoro-6-(trifluoromethyl)benzoyl]-*L*-4-
 30 aminophenylalanine;
N-Acetyl-*D*-thioprolin-(*N*'-2,4,6-trichlorobenzoyl)-*L*-4-aminophenylalanine;
N-Acetyl-*D*-thioprolin-(*N*'-2,6-trichlorobenzyl)-*L*-4-aminophenylalanine;
 and the salts, solvates, hydrates and *N*-oxides thereof.

It will be appreciated that where appropriate the provisos applying to compounds of general formula (1) apply equally to the above-mentioned specific classes of compounds of formula (1).

- 5 Compounds according to the invention are potent and selective inhibitors of $\alpha 4$ integrins. The ability of the compounds to act in this way may be simply determined by employing tests such as those described in the Examples hereinafter.
- 10 The compounds are of use in modulating cell adhesion and in particular are of use in the prophylaxis and treatment of diseases or disorders involving inflammation in which the extravasation of leukocytes plays a role. Diseases or disorders of this type include inflammatory arthritis such as rheumatoid arthritis vasculitis or polydermatomyositis, multiple
- 15 sclerosis, allograft rejection, diabetes, inflammatory dermatoses such as psoriasis or dermatitis, asthma and inflammatory bowel disease.

For the prophylaxis or treatment of disease the compounds according to the invention may be administered as pharmaceutical compositions, and

20 according to a further aspect of the invention we provide a pharmaceutical composition which comprises a compound of formula (1) together with one or more pharmaceutically acceptable carriers, excipients or diluents.

Pharmaceutical compositions according to the invention may take a form

25 suitable for oral, buccal, parenteral, nasal, topical or rectal administration, or a form suitable for administration by inhalation or insufflation.

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by

30 conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets

35 may be coated by methods well known in the art. Liquid preparations for

oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable
5 additives such as suspending agents, emulsifying agents, non-aqueous vehicles and preservatives. The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to give
10 controlled release of the active compound.

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

15 The compounds for formula (1) may be formulated for parenteral administration by injection e.g. by bolus injection or infusion. Formulations for injection may be presented in unit dosage form, e.g. in glass ampoule or multi dose containers, e.g. glass vials. The compositions for injection may take such forms as suspensions, solutions or emulsions in oily or
20 aqueous vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

25 In addition to the formulations described above, the compounds of formula (1) may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation or by intramuscular injection.

30 For nasal administration or administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser, with the use of suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable
35 gas or mixture of gases.

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack or dispensing device may be accompanied by instructions for administration.

5


The quantity of a compound of the invention required for the prophylaxis or treatment of a particular condition will vary depending on the compound chosen, and the condition of the patient to be treated. In general, however, daily dosages may range from around 100ng/kg to 100mg/kg e.g. around 0.01mg/kg to 40mg/kg body weight for oral or buccal administration, from around 10ng/kg to 50mg/kg body weight for parenteral administration and around 0.05mg to around 1000mg e.g. around 0.5mg to around 1000mg for nasal administration or administration by inhalation or insufflation.

15

The compounds of the invention may be prepared by a number of processes as generally described below and more specifically in the Examples hereinafter. In the following process description, the symbols R¹-R⁶, L¹, L², Alk¹, Alk², Alk³, m, r, s, t, u and A when used in the formulae depicted are to be understood to represent those groups described above in relation to formula (1) unless otherwise indicated. In the reactions described below, it may be necessary to protect reactive functional groups, for example hydroxy, amino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice [see, for example, Green, T. W. in "Protective Groups in Organic Synthesis", John Wiley and Sons, 1991]. In some instances, deprotection may be the final step in the synthesis of a compound of formula (1) and the processes according to the invention described hereinafter are to be understood to extend to such removal of protecting groups.

20
25
30
35


Thus according to a further aspect of the invention, a compound of formula (1) may be obtained by hydrolysis of an ester of formula (2):




where R¹⁷ is an alkyl group.

- 5 The hydrolysis may be performed using either an acid or a base depending on the nature of R¹², for example an organic acid such as trifluoroacetic acid or an inorganic base such as lithium hydroxide or potassium carbonate optionally in an aqueous organic solvent such as an amide, e.g. a substituted amide such as dimethylformamide, an ether, e.g.
- 10 a cyclic ether such as tetrahydrofuran or dioxane or an alcohol, e.g. methanol at around ambient temperature. Where desired, mixtures of such solvents may be used.

15 Esters of formula (2) may be prepared by coupling an amine of formula (3):



(where R¹² is as just described) or a salt thereof with an acid of formula (4):



or an active derivative thereof.

Active derivatives of acids of formula (4) include anhydrides, esters and halides. Particular esters include pentafluorophenyl or succinyl esters.

- 5 The coupling reaction may be performed using standard conditions for reactions of this type. Thus for example the reaction may be carried out in a solvent, for example an inert organic solvent such as an amide, e.g. a substituted amide such as dimethylformamide, an ether, e.g. a cyclic ether such as tetrahydrofuran, or a halogenated hydrocarbon, such as
- 10 dichloromethane, at a low temperature, e.g. around -30°C to around ambient temperature, optionally in the presence of a base, e.g. an organic base such as an amine, e.g. triethylamine, pyridine, or dimethylaminopyridine, or a cyclic amine, such as N-methylmorpholine.
- 15 Where an acid of formula (4) is used, the reaction may additionally be performed in the presence of a condensing agent, for example a diimide such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide or N,N'-dicyclohexylcarbodiimide, advantageously in the presence of a catalyst such as a N-hydroxy compound e.g. a N-hydroxytriazole such as 1-hydroxy-
- 20 benzotriazole. Alternatively, the acid may be reacted with a chloroformate, for example ethylchloroformate, prior to reaction with the amine of formula (3).
- 25 Where appropriate the coupling reaction may be carried out earlier in the synthesis of the compound of the invention, for example by using an acid of formula (4) where $\text{R}^6(\text{Alk}^2)_u(\text{L}^2)_t$ is a hydrogen atom and manipulating the resulting ester to introduce any desired $\text{R}^6(\text{Alk}^2)_u(\text{L}^2)_t$ group. Similarly, intermediate esters of formula (2), or compounds of formula (1), may be manipulated to introduce particular $\text{R}^6(\text{Alk}^2)_r(\text{L}^1)_s$, R^2 and/or R^3
- 30 groups or modify existing R^1 and/or R^6 substituents. Typically, such manipulation may involve standard substitution approaches employing for example alkylation, arylation, acylation, halogenation, sulphonylation, nitration or coupling reactions.
- 35 Thus in one example, a compound wherein $\text{R}^1(\text{Alk}^1)_r(\text{L}^1)_s$ is a $-\text{L}^1\text{H}$ group may be alkylated or arylated using a reagent $\text{R}^1(\text{Alk}^1)_r\text{X}$ in which R^1 is

other than a hydrogen atom and X is a leaving atom or group such as a halogen atom, e.g. a fluorine, bromine, iodine or chlorine atom or a sulphonyloxy group such as an alkylsulphonyloxy, e.g. trifluoromethylsulphonyloxy or arylsulphonyloxy, e.g. p-toluenesulphonyloxy group.

5

The alkylation or arylation reaction may be carried out in the presence of a base such as a carbonate, e.g. caesium or potassium carbonate, an alkoxide, e.g. potassium t-butoxide, or a hydride, e.g. sodium hydride, in a dipolar aprotic solvent such as an amide, e.g. a substituted amide such as dimethylformamide or an ether, e.g. a cyclic ether such as tetrahydrofuran.

10

In another example, a compound where $R^1(Alk^1)_r(L^1)_s$ is a $-L^1H$ group and/or $R^6(Alk^2)_2(L^2)_2$ is a hydrogen atom may be functionalised by acylation, for example by reaction with a reagent $R^1(Alk^1)_rL^1X$ [wherein L^1 is a $-C(O)-$, $-CH_2C(O)-$ or $-NHC(O)-$ group], $R^6(Alk^2)_uCOX$ or $R^6(Alk^2)_uNHCOX$ in the presence of a base, such as a hydride, e.g. sodium hydride or an amine, e.g. triethylamine or N-methylmorpholine, in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane or carbon tetrachloride or an amide, e.g. dimethylformamide, at for example ambient temperature, or by reaction with $R^1(Alk^1)_rCO_2H$ or $R^6(Alk^2)_uCO_2H$ or an activated derivative thereof, for example as described above for the preparation of esters of formula (2).

15

20

In a further example a compound may be obtained by sulphonylation of a compound where $R^1(Alk^1)_r(L^1)_s$ is an $-OH$ group by reaction with a reagent $R^1(Alk^1)_rL^1Hal$ [in which L^1 is $-SO_2-$ and Hal is a halogen atom such as a chlorine atom] in the presence of a base, for example an inorganic base such as sodium hydride in a solvent such as an amide, e.g. a substituted amide such as dimethylformamide at for example ambient temperature.

30

In another example, a compound where $R^1(Alk^1)_r(L^1)_s$ is a $-L^1H$ group, may be coupled with a reagent R^1OH (where R^1 is other than a hydrogen atom) or R^1Alk^1OH in a solvent such as tetrahydrofuran in the presence of a phosphine, e.g. triphenylphosphine and an activator such as diethyl,

35

diisopropyl- or dimethylazodicarboxylate to yield a compound containing a $R^1(Alk^1)_rO-$ group.

- Intermediates of formulae (3) and (4), $R^1(Alk^1)_rX$, $R^1(Alk^1)_rL^1X$, $R^6(Alk^2)_uCOX$, $R^6(Alk^2)_uNHCOX$, $R^1(Alk^1)_rCO_2H$, $R^6(Alk^2)_uCO_2H$, R^1OH and R^1Alk^1OH are either known compounds or may be prepared from known starting materials by use of analogous processes to those used for the preparation of the known compounds and/or by treating known compounds using standard substitution approaches, for example by one or more of the alkylation, acylation, arylation, sulphonylation, hydrogenation and other manipulations described herein, such as particularly described for the preparation of the Intermediates in the exemplification section hereinafter.
- 15 Salts of compounds of formula (1) may be prepared by reaction of a compound of formula (1) with an appropriate base in a suitable solvent or mixture of solvents e.g. an organic solvent such as an ether e.g. diethylether, or an alcohol, e.g. ethanol using conventional procedures.
- 20 Where it is desired to obtain a particular enantiomer of a compound of formula (1) this may be produced from a corresponding mixture of enantiomers using any suitable conventional procedure for resolving enantiomers.
- 25 Thus for example diastereomeric derivatives, e.g. salts, may be produced by reaction of a mixture of enantiomers of formula (1) e.g. a racemate, and an appropriate chiral compound, e.g. a chiral base. The diastereomers may then be separated by any convenient means, for example by crystallisation and the desired enantiomer recovered, e.g. by treatment with an acid in the instance where the diastereomer is a salt.
- 30
- In another resolution process a racemate of formula (1) may be separated using chiral High Performance Liquid Chromatography. Alternatively, if desired a particular enantiomer may be obtained by using an appropriate chiral intermediate in one of the processes described above.
- 35

The following Examples illustrate the invention. All temperatures are in °C. The following abbreviations are used:

- | | | |
|----|---|--------------------------------|
| | EDC - 1-(3-dimethylaminopropyl)3-ethylcarbodiimide; | DMSO - dimethylsulphoxide; |
| | DMF - dimethylformamide; | THF - tetrahydrofuran; |
| 5 | HOBT - 1-hydroxybenzotriazole; | NMM - N-methylmorpholine; |
| | TFA - trifluoroacetic acid; | Ph - phenyl; |
| | DCM - dichloromethane; | EtOAc - ethyl acetate; |
| | Boc - <u>tert</u> -butoxycarbonyl; | LDA - lithium diisopropylamide |
| | MeOH - methanol; | Ar - aryl; |
| 10 | tyr - tyrosine; | pyr - pyridine; |
| | HetAr - heteroaryl; | Bu - butyl |
| | thioprop - thioproline; | AcOH - acetic acid; |
| | app. - apparent; | sym. - symmetrical; |
| | Et ₂ O - diethylether; | |
| 15 | EtOH - ethanol | |
| | DBU - 1,8-diazabicyclo[5.4.0]undec-7-ene | |

INTERMEDIATE 1

N-Boc-D-thiopropine-L-4-aminophenylalanine methyl ester

- 20 EDC (11.31g, 59mmol) was added over a period of 5mins to an ice cold solution of 4-aminophenylalanine methyl ester dihydrochloride (14.3g, 54mmol), HOBT (8.67g, 64mmol), NMM (16.2g, 17.6ml, 160mmol) and N-Boc-D-thiopropine (13.74g, 59mmol) in DMF (150ml). The reaction was warmed to room temperature and stirred for 16h. The volatiles were
- 25 evaporated *in vacuo* and the residue partitioned between EtOAc (200ml) and saturated Na₂CO₃ solution (100ml). The organic layer was separated, washed with saturated Na₂CO₃ (2x100ml) and brine (50ml), dried over MgSO₄ and the solvent evaporated *in vacuo*. The product was purified by chromatography (SiO₂; DCM MeOH 97:3) to give the title compound as a
- 30 pale orange foam (15g, 64%). δ H (DMSO-d₆, 360K) 7.87 (1H, d, \downarrow 8.0Hz, NH), 6.84 (2H, d, \downarrow 8.3Hz, Ar-H), 6.50 (2H, d, \downarrow 8.3Hz, Ar-H), 4.62 (1H, d, \downarrow 9.1Hz, NCH_AH_BS), 4.60 (1H, m, CH _{α} -thioprop), 4.48 (1H, dt, \downarrow 5.8, 8.2Hz, CH _{α} Ph), 4.27 (1H, d, \downarrow 9.1Hz, NCH_AH_BS), 3.62 (3H, s, CO₂CH₃), 3.23 (1H, dd, \downarrow 7.5, 11.6Hz, CHCH_AH_BS), 2.91-2.75 (3H, m, CHCH_ACH_BS and CH₂Ar) and 1.40 (9H, s, ¹Bu). m/z (ESI, 15V) 410 (MH⁺).
- 35

INTERMEDIATE 2**N-Boc-D-thiopropine-(N-2,6-dichlorobenzoyl)-L-4-aminophenylalanine methyl ester**

2,6-Dichlorobenzoyl chloride (0.61g, 2.9mmol) was added to a solution of Intermediate 1 (1.0g, 2.4mmol) and NMM (0.28g, 2.88mmol) in DCM (10ml). The reaction was stirred at room temperature for 16h then partitioned between DCM (50ml) and saturated Na₂CO₃ solution (20ml). The aqueous layer was separated and extracted with DCM (2x50ml). The combined organic layers were washed with brine (50ml), dried over MgSO₄ and the solvent evaporated *in vacuo* to give a foam which was purified by chromatography (SiO₂; DCM/MeOH 97:3) to give the title compound as a white foam (1.3g, 91%). δ H (DMSO-d₆, 350K) 10.41 (1H, s, NH), 8.08 (1H, d, \downarrow 8.2Hz, NH), 7.59 (2H, d, \downarrow 8.5Hz, Ar-H), 7.55-7.44 (3H, m, Ar-H), 7.19 (2H, d, \downarrow 8.5Hz, Ar-H), 4.62-4.56 (2H, m, CH α -thioprop and CH α -Ph), 4.62 (1H, d, \downarrow 9.1Hz, NCH α H β S), 4.27 (1H, d, \downarrow 9.1Hz, NCH α H β S), 3.66 (3H, s, CO₂CH₃), 3.23 (1H, dd, \downarrow 11.5, 7.5Hz, CHCH α H β S), 2.91-2.75 (3H, m, CHCH α H β S and CH₂Ar) and 1.39 (9H, s, ¹Bu). m/z (ESI, 15V) 582 (MH⁺).

INTERMEDIATE 3**D-Thiopropine-(N-2,6-dichlorobenzoyl)-L-4-aminophenylalanine methyl ester hydrochloride**

A solution of Intermediate 2 (1.3g, 2.2mmol) in EtOAc (20ml) was treated with a solution of anhydrous EtOAc/hydrochloric acid (~4M, 10ml) and stood for 2.5h at room temperature. The volatiles were evaporated *in vacuo* to give the title compound as an off-white solid (1.2g, 98%). δ H (CD₃OD) 8.86 (1H, d, \downarrow 8.6Hz, NH), 7.61 (2H, d, \downarrow 8.6Hz, Ar-H), 7.50-7.39 (3H, m, Ar-H), 7.23 (2H, d, \downarrow 8.6Hz, Ar-H), 4.87 (1H, m, CH α -thioprop), 4.49 (1H, t, \downarrow 7.4Hz, CH α -Ph), 4.35 (2H, s, NCH₂S), 3.64 (3H, s, CO₂CH₃), 3.42-3.27 (2H, m, CHCH α H β S and ArCH α H β), and 3.00-2.73 (2H, m, CHCH α H β S and ArCH α H β). m/z (ESI, 15V), 482, 484 (MH⁺)

INTERMEDIATE 4**N-(Pyrid-3-ylacetyl)-D-thiopropine-(N-2,6-dichlorobenzoyl)-L-4-aminophenylalanine methyl ester**

EDC (0.48g, 2.5mmol) was added to a solution of Intermediate 3 (1.2g, 2.3mmol), HOBT (0.38g, 2.8mmol) NMM (0.51g, 5.1mmol) and 3-pyridylacetic acid hydrochloride (0.40g, 2.3mmol) in DMF (10ml) and the reaction stirred at room temperature for 16h. The volatiles were evaporated *in vacuo* and the residue partitioned between saturated Na₂CO₃ solution (30ml) and EtOAc (50ml). The organic layer was separated, washed with saturated Na₂CO₃ solution (30ml) and brine (30ml) and dried over MgSO₄. The solvent was evaporated *in vacuo* and the residue was purified by chromatography (SiO₂; DCM/MeOH 95:5) to give the title compound as a white foam (1.06g, 76%). δ H (DMSO-d₆, 390K) 10.20 (1H, s, NH), 8.44 (2H, m, Ar-H), 7.63-7.17 (9H, m, pyr-H, Ar-H), 4.93 (1H, dd, \downarrow 4.0, 7.4Hz, CH α -thioprop), 4.87 (1H, d, \downarrow 9.2Hz, NCH α H β S), 4.61 (1H, dt, \downarrow 5.7, 8.2Hz, CH α -Ph), 4.46 (1H, d, \downarrow 9.2Hz, NCH α H β S), 3.74 (2H, m, CH₂pyr), 3.66 (3H, s, CO₂CH₃) and 3.32-2.95 (4H, m, CHCH₂S and Ar-CH₂). m/z (ESI, 15V), 601 (MH⁺).

INTERMEDIATE 5**N-Acetyl-D-thiopropine-L-4-aminophenylalanine methyl ester**

NMM (1.13g, 1.24ml, 11.19mmol), HOBT (0.61g, 4.52mmol), N-acetyl-D-thiopropine (0.72g, 4.11mmol) and EDC (0.79g, 4.11mmol) were added sequentially to a stirred solution of L-4-aminophenylalanine methyl ester dihydrochloride (1.0g, 3.75mmol) in dry DMF (10ml). After stirring at room temperature for 4h the solvent was removed *in vacuo*. The residue was partitioned between EtOAc (70ml) and 10% aqueous Na₂CO₃ (30ml). The phases were separated and the aqueous phase repeatedly extracted with EtOAc (4x30ml). The combined organic extracts were washed with brine (10ml), dried (Na₂SO₄) and evaporated *in vacuo*. The resulting oil was chromatographed (SiO₂; 3:97 to 5:95 MeOH/DCM) affording the title compound as a white foamy solid (0.97g, 74%): δ H (CD₃OD) (two rotameric species) 6.93 (d, \downarrow 8.3Hz), and 6.91 (d, \downarrow 8.3Hz) together (2H, ArH), 6.64 (2H, d, \downarrow 8.3Hz, ArH), 4.81-4.60 (3H, m, CH α -thioprop, CH α -Ph, NCH α H β S), 4.53 (d, \downarrow 10Hz), and 4.43 (d, \downarrow 10Hz) together (1H, NCH α H β S), 3.71 (s) and 3.69 (s) together (3H, CO₂CH₃), 3.37-2.81 (4H,

m, CHCH_2S and CH_2Ar), 2.14 (s) and 1.90 (s) together (3H, COCH_3); m/z (ESI, 27V) 352 (MH^+).

INTERMEDIATE 6

5 3,5-Dichloro-isonicotinic acid

A solution of 3,5-dichloropyridine (5.00g, 33.8mmol) in THF (25ml) was added to a solution of LDA [generated from nBuLi (2.5M solution in hexanes, 14.9ml, 37.2mmol) and diisopropylamine (4.10g, 5.7ml, 40.6mmol)] in THF (25ml) at -78° under nitrogen, to give a yellow/brown slurry. The reaction was stirred for 30min at -78° then CO_2 gas was bubbled through to give a clear brown solution that slowly gave a precipitate, warmed to room temperature over 2h, then quenched with water (20ml) and partitioned between diethylether (100ml) and 1M NaOH (100ml). The aqueous layer was separated and acidified to pH1 with concentrated hydrochloric acid and then extracted with 10% MeOH in DCM (100ml x 3). The combined organic layers were dried over MgSO_4 and the solvent removed under vacuum to give a brown solid that was recrystallised from ethanol and dried under vacuum to give the title compound as pinkish crystals (2.63g, 41%). δH ($\text{DMSO}-d_6$) 8.74 (2H, s, pyr-H). δC ($\text{DMSO}-d_6$) 163.5, 147.7, 141.0, 126.7

INTERMEDIATE 7

N-Acetyl-*D*-thioprolin-*N*-(3,5-dichloro-isonicotinoyl)-*L*-4-aminophenylalanine methyl ester

25 A suspension of Intermediate 6 (0.50g, 2.6mmol) in DCM (10ml) was treated with thionyl chloride (1.55g, 0.95ml, 13.0mmol) and a drop of DMF, then heated to reflux for 1.5h. The volatiles were removed under vacuum to give a yellow solid that was dissolved in DCM. NMM (0.53g, 0.57ml, 5.2mmol) was added followed by Intermediate 5 (0.40g, 1.37mmol). The reaction was stirred for 16h then partitioned between DCM (20ml) and water (20ml). The aqueous layer was extracted with DCM, the combined organic layers washed with NaHCO_3 solution (50ml), dried over MgSO_4 and the solvent removed under vacuum, to give a brown gum, which was triturated with boiling methanol to give the title compound as a pale brown solid (0.13g). δH ($\text{DMSO}-d_6$, 300K) two rotamers observed: 10.85 (1H, s, NH), 8.79 (2H, s, pyr-H), 8.59 (d, \downarrow 8.2Hz) and 8.32 (d, \downarrow 8.2Hz), together

(1H, NH), 7.56 (2H, m, Ar-H), 7.22 (2H, m, Ar-H), 4.80-4.70 (m), and 4.58-4.44 (m) and 4.47 (d, \downarrow 8.6Hz) and 4.24 (d, \downarrow 9.6Hz), together (4H, 2xCH α and NCH $_2$ S), 3.31 (3H, s, CO $_2$ CH $_3$), 3.20-2.82 (4H, m, CH α CH $_2$ Ar and CH α CH $_2$ S), 2.06 (s) and 1.85 (s) together (3H, COCH $_3$). m/z (ESI, 60V) 525 (MH $^+$).

INTERMEDIATE 8

N-Boc-D-thioprolino-L-tyrosine methyl ester

NMM (0.39g, 0.43ml, 3.9mmol), HOBT (0.57g, 4.2mmol), Boc-D-thioprolino (0.91g, 3.9mmol), and EDC (0.75g, 3.9mmol) were added sequentially to a stirred solution of L-tyrosine methyl ester hydrochloride (0.82g, 3.5mmol) in dry DMF (10ml). The reaction mixture was stirred at room temperature for 0.75h. The DMF was removed *in vacuo* and the residue partitioned between EtOAc (70ml) and 10% aqueous Na $_2$ CO $_3$ (30ml). The phases were separated and the aqueous phase re-extracted with EtOAc (2 x 20ml). The combined organic extracts were washed with brine (10ml), dried (Na $_2$ SO $_4$) and evaporated *in vacuo* to afford the crude product as a viscous oil. Purification by flash chromatography (SiO $_2$; 5:95 MeOH/DCM) afforded the title compound as a white solid (1.1g, 76%): δ H (CDCl $_3$) 6.96 (2H, d, \downarrow 8.5Hz, ArH), 6.85 (1H, br s NH), 6.72 (2H, d, \downarrow 8.5Hz, ArH), 5.95 (1H, br s, OH), 4.81 (1H, apparent dt, \downarrow 5.8, 8Hz, CH α -tyr), 4.73 (1H, br s, CH α -thiopro), 4.63 (1H, br d, \downarrow 9.0Hz, NCH $_2$ Ar), 4.28 (1H, d, \downarrow 9.0Hz, NCH $_2$ Ar), 3.71 (3H, s, CO $_2$ CH $_3$), 3.37-3.28 (1H, br m, CHCH $_2$ Ar), 3.21-3.10 (1H, m, CHCH $_2$ Ar), 3.09-2.97 (2H, m, CH $_2$ Ar), and 1.45 (9H, s, tBu); m/z (ESI, 27V) 411 (MH $^+$).

INTERMEDIATE 9

D-Thioprolino-L-tyrosine methyl ester hydrochloride

Hydrogen chloride gas was briefly bubbled through a stirred solution of Intermediate 8 [1.0g in warm EtOAc (50ml)]. The reaction mixture was stirred at ambient temperature for 1h during which time the product precipitated from the solution. The solvent was removed *in vacuo* to afford the title compound as a white powder (0.85g): δ H (CD $_3$ OD) 8.83 (1H, d, \downarrow 8.3Hz, NH), 7.02 (2H, d, \downarrow 8.5Hz, ArH), 6.71 (2H, d, \downarrow 8.5Hz, ArH), 4.74 (1H, m, CH α -tyr), 4.54 (1H, apparent t, 7.2Hz, CH α -thiopro), 4.36 (2H, m, NCH $_2$ S), 3.73 (3H, s, CO $_2$ CH $_3$), 3.42 (1H, dd, \downarrow 7.4, 12Hz, CHCH $_2$ Ar),

3.15 (1H, dd, \downarrow 5.2, 14Hz, $\text{CH}_\text{A}\text{H}_\text{B}\text{Ar}$), 2.88 (1H, dd, \downarrow 9.6, 14Hz, $\text{CH}_\text{A}\text{H}_\text{B}\text{Ar}$) and 2.79 (1H, dd, \downarrow 7.0, 12.0Hz, $\text{CHCH}_\text{A}\text{H}_\text{B}\text{S}$); m/z (ESI, 27V) 311 MH^+).

INTERMEDIATE 10

5 *N*-(Pyrid-3-ylacetyl)-*D*-thioproline-*L*-tyrosine methyl ester

NMM (532mg, 580 μ L, 5.27mmol), HOBT (388mg, 2.87mmol) 3-pyridylacetic acid hydrochloride (457mg, 2.63mmol) and EDC (506mg, 2.63mmol) were added sequentially to a stirred solution of Intermediate 9 in dry DMF (15ml). The reaction mixture was stirred at room temperature for 5h. The solvent was removed *in vacuo* and the residue partitioned between EtOAc (75ml) and saturated aqueous NaHCO_3 (30ml). The phases were separated and the aqueous phase re-extracted with EtOAc (3 x 30ml). The combined organic extracts were washed with brine (10ml) dried (Na_2SO_4) and evaporated *in vacuo* to afford an off-white solid (1.06g). This was heated in boiling EtOAc (40ml) and, after cooling, the title compound was filtered off as a white powder (0.66g, 64%) δH ($\text{DMSO}-d_6$, 400K) 8.64 (1H, br s, OH), 8.44 (2H, m, pyr-H), 7.84 (1H, br d, \downarrow 7Hz, NH), 7.60 (1H, dd, \downarrow 2.1, 7.8Hz, pyrH), 7.28 (1H, dd, \downarrow 4.7, 7.8Hz, pyrH), 6.98 (2H, d, \downarrow 8.3Hz, ArH) 6.86 (2H, d, \downarrow 8.3Hz, ArH), 4.93 (1H, dd, \downarrow 4, 7.4Hz, $\text{CH}\alpha\text{thiopro}$), 4.85 (1H, d, \downarrow 9.2Hz, $\text{NCH}_\text{A}\text{H}_\text{B}\text{S}$), 4.54 (1H, ddd, \downarrow 6.0, 7.3, 8.2Hz, $\text{CH}\alpha\text{tyr}$), 4.45 (1H, d, \downarrow 9.2Hz, $\text{NCH}_\text{A}\text{H}_\text{B}\text{S}$), 3.75 (1H, d, \downarrow 16Hz, $\text{CH}_\text{A}\text{H}_\text{B}\text{pyr}$), 3.66 (1H, d, \downarrow 16Hz, $\text{CH}_\text{A}\text{H}_\text{B}\text{pyr}$), 3.64 (3H, s, CO_2CH_3), 3.29 (1H, dd, \downarrow 7.4, 11.5Hz, $\text{CHCH}_\text{A}\text{H}_\text{B}\text{S}$), 3.05-2.97 (2H, m, $\text{CHCH}_\text{A}\text{H}_\text{B}\text{S}$ and $\text{CH}_\text{A}\text{H}_\text{B}\text{Ar}$) and 2.88 (1H, dd, \downarrow 8.2, 14.2Hz, $\text{CH}_\text{A}\text{H}_\text{B}\text{Ar}$); m/z (ESI, 27V) 430 (MH^+).

INTERMEDIATE 11

N-(Pyrid-3-ylacetyl)-*D*-thioproline-(*O*-2,4,6-trichlorobenzoyl)-*L*-tyrosine methyl ester

30 Sodium hydride (61mg, 1.5mmol) was added to a solution of Intermediate 10 (0.50g, 1.2mmol) in anhydrous DMF (10ml). When the vigorous reaction had ceased 2,4,6-trichlorobenzoyl chloride (0.35g, 1.44mmol) was added and the reaction stirred for 16h at room temperature. The reaction was poured into saturated NaHCO_3 solution (50ml) and extracted with
35 EtOAc (3x50ml). The combined organic layers were washed with saturated NaHCO_3 solution (2x20ml), brine (20ml) and dried over MgSO_4 .

The solvent was evaporated *in vacuo* and the residue purified by chromatography (SiO₂; DCM/MeOH 95:5) to give the title compound as an orange oil (0.65g, 74%) containing about 30% of the diastereomer at the thioproline stereocentre. δ H (DMSO-d₆, 390K) 8.43 (2H, m, pyr-H), 7.97 (1H, m, NH), 7.77 (2H, s, Ar-H), 7.62 (1H, m, pyr-H), 7.36-7.16 (5H, m, pyr-H, Ar-H), 4.92 (1H, m, CH α -thioprop), 4.86 (1H, m, NCH α H β S), 4.65 (1H, m, CH α -tyr), 4.47 (1H, m, NCH α H β S), 3.74 (2H, m, CH₂pyr), 3.66 (3H, s, CO₂CH₃), 3.36-2.98 (4H, m, ArCH₂ and CHCH₂S). m/z (ESI, 30V) 638 (MH⁺).

INTERMEDIATE 12

N-Boc-(O-pyrimidin-2-yl)-L-tyrosine methyl ester

A solution of N-Boc tyrosine methyl ester (591mg, 2mmol) in DMF (5ml) was added to a suspension of sodium hydride (60% in oil, 88mg, 2.2mmol) in DMF (5ml) at room temperature. After 5min, a solution of 2-chloropyrimidine (288mg, 2.5mmol) in DMF (3ml) was added and the mixture stirred for 5h. The reaction mixture was quenched with water and the DMF evaporated *in vacuo*. The residue was dissolved in EtOAc (150ml) and washed with water (2 x 50ml) and brine (50ml), dried (Na₂SO₄) and evaporated *in vacuo*. The residue was purified by chromatography (SiO₂; EtOAc/hexane 60:40) to give the title compound as a colourless gum (470mg, 63%): δ H (CDCl₃) 8.55 (2H, d, \downarrow 4.7Hz, HetArH), 7.21-7.11 (4H, m, ArH), 7.02 (1H, t, \downarrow 4.7Hz, HetArH), 5.00 (1H, br d, CONH), 4.62 (1H, br q, CH α), 3.72 (3H, s, CO₂CH₃), 3.17-3.06 (2H, m, CH₂Ar) and 1.42 (9H, s, tBu); m/z (ESI, 15V) 374 (MH⁺).

INTERMEDIATE 13

(O-Pyrimidin-2-yl)-L-tyrosine methyl ester hydrochloride

Gaseous HCl was bubbled through a solution of Intermediate 12 (460mg, 1.23mmol) in EtOAc (25ml) for about 30 seconds. After 20 min the EtOAc was removed *in vacuo* to give the title compound as a white foam. δ H (DMSO, 300K) 8.63 (2H, d, \downarrow 4.9Hz, HetArH), 7.32-7.25 (3H, m, ArH + HetArH), 7.15 (2H, d, \downarrow 8.5Hz, ArH), 4.29 (1H, br q, CH α), 3.69 (3H, s, CO₂CH₃), 3.22 (1H, dd, \downarrow 6.0, 14.1Hz, CH α H β Ar) and 3.14 (1H, dd, \downarrow 7.1, 14.1Hz, CH α H β Ar).

INTERMEDIATE 14**N-Acetyl-D-thiopropine-(O-pyrimidin-2-yl)-L-tyrosine methyl ester**

EDC (259mg, 1.35mmol) was added to a solution of Intermediate 13 (1.23mmol), N-acetyl-D-thiopropine (215mg, 1.23mmol), HOBT (182mg, 1.35mmol) and NMM (285μl, 2.6mmol) in DCM (15ml). The reaction mixture was stirred at room temperature overnight then diluted with DCM (150ml). The DCM solution was washed with 10% citric acid (50ml), saturated aqueous NaHCO₃ (50ml) and water (50ml), dried (Na₂SO₄) and evaporated *in vacuo*. The residue was purified by chromatography (SiO₂; DCM/MeOH, 93:7) to give the title compound as a slightly yellow gum (484mg, 92%). δH (DMSO-d₆, 400K) 8.60 (2H, dd, \downarrow 4.8Hz, HetArH), 7.25 (2H, s, \downarrow 8.7Hz, ArH), 7.20 (1H, t, \downarrow 4.8Hz, HetArH), 7.09 (2H, d, \downarrow 8.7Hz, ArH), 4.83 (1H, dd, \downarrow 4.0, 7.4Hz, CHαthioprop), 4.77 (1H, d, \downarrow 9.2Hz, NCHAHBS), 4.63 (1H, dt, \downarrow 5.6, 8.3Hz, CHαtyr), 4.39 (1H, d, \downarrow 9.1Hz, NCHAHBS), 3.68 (3H, s, CO₂CH₃), 3.26 (1H, dd, \downarrow 7.4, 11.6Hz CHCHAHBS), 3.16 (1H, dd, \downarrow 5.7, 14.1Hz, CHAHBAr), 3.09-2.99 (2H, m, CHAHBAr + CHCHAHBS) and 2.00 (3H, s, CH₃CO); m/z (ESI, 27V) 431 (MH⁺).

INTERMEDIATE 15**N-(Pyrid-3-ylacetyl)-D-thiopropine-(O-2,6-dichlorobenzoyl)-L-tyrosine methyl ester**

To a suspension of NaH (60%, 103mg, 2.56mmol) in anhydrous DMF (25ml) under argon was added Intermediate 10 (1.0g, 2.33mmol) in one portion. After 3 min. 2,6-dichlorobenzoyl chloride (0.54mg, 0.37ml, 2.56mmol) was added and the mixture allowed to warm up to room temperature. After 2h at room temperature a further portion of NaH (60%, 19mg, 0.47mmol) and 2,6-dichlorobenzoyl chloride (0.067ml, 98mg, 0.47mmol) was added to the pale yellow mixture and the reaction stirred at room temperature over the weekend (60h). The reaction mixture was poured into half-saturated NH₄Cl/ice and EtOAc added. The layers were separated and the aqueous layer extracted with EtOAc (2 x 50ml). The combined organic layers were washed with saturated NaHCO₃ (1 x 100ml), brine (1 x 100ml) and dried over MgSO₄. The solvent was removed *in vacuo* to afford a pale yellow foam. Purification by flash chromatography (SiO₂; 1:99 to 3:97 MeOH/DCM) gave the title compound

as an off-white foam (1.1g, 78%). δ H (DMSO- d_6 , 400K) 8.48-8.43 (2H, m, pyr-H), 8.01 (1H, br d, NH), 7.63-7.52 (4H, m, Ar(Cl)-H and pyrH), 7.34 (2H, d, \downarrow 8.6Hz, ArH), 7.34-7.26 (1H, m, pyrH), 7.19 (2H, d, \downarrow 8.6Hz, ArH), 4.93 (1H, dd, \downarrow 7.3, 4.0Hz, CH α thioprop), 4.86 (1H, d, \downarrow 9.2Hz, NCH α HBS), 4.68-4.61 (1H, m, CH α tyr), 4.46 (1H, d, \downarrow 9.2Hz, NCH α HBS), 3.76 (1H, d, \downarrow 16Hz, CH α H β pyr), 3.68 (1H, d, \downarrow 16Hz, CH α H β pyr), 3.67 (3H, s, CO₂CH₃), 3.29 (1H, dd, \downarrow 11.6, 7.3Hz, CHCH α HBS), 3.19 (1H, dd, \downarrow 14, 5.7Hz, CH α HBSAr) and 3.09-3.00 (2H, m, CHCH α HBS and CH α HBSAr).

10 INTERMEDIATE 16

N-Acetyl-*D*-thiopropine-(*N'*-2,6-dichlorobenzoyl)-*L*-4-aminophenyl alanine methyl ester

NMM (104 μ g, 113ml, 1.02mmol), 2,6-dichlorobenzoyl chloride (216mg, 148 μ L, 1.02mmol) and 4-dimethylaminopyridine (10mg) were added sequentially to a stirred solution of Intermediate 5 (302mg, 0.86mmol) in dry DCM (10ml). The reaction mixture was stirred at room temperature for 18h under N₂. The solvent was removed *in vacuo* and the residue treated with 5% aqueous hydrochloric acid (~50ml). The obtained solid was collected by filtration, with further aqueous hydrochloric acid washing followed by water and diethyl ether washing. The product was treated with hot MeOH (~10ml) then cooled and filtered off to afford the title compound as a white powder (205mg, 45%): δ H (DMSO- d_6) (two rotamers observed) 10.95 (1H, s, ArNHCO), 8.58 (d, \downarrow 7.9Hz) and 8.31 (d, \downarrow 8.2Hz) together (1H, CHNHCO), 7.69-7.45 (5H, m, ArH), 7.23-7.12 (2H, m, ArH), 4.81-4.65 (m) and 4.58-4.48 (m) and 4.23 (d, \downarrow 9.5Hz), together (4H, NCH₂S and CH α -thioprop and CH α Ph), 3.64 (3H, s, CO₂CH₃), 3.18-2.75 (4H, m, CHCH₂S and CH₂Ar), 2.05 (s) and 1.84 (s) together (3H, COCH₃); m/z (ESI, 27V) 524 (MH⁺).

30 INTERMEDIATE 17

N-Boc-*D*-thiopropine-(*O*-benzyl)-*L*-tyrosine methyl ester

NMM (1.73g, 1.9ml, 17.13mmol), HOBT (2.53g, 18.74mmol) *N*-Boc-*D*-thiopropine (4.0g, 17.17mmol) and EDC (3.30g, 17.19mmol) were added sequentially to a stirred solution of *O*-benzyl-*L*-tyrosine methyl ester hydrochloride (5.02g, 15.59mmol) in dry DMF (50ml). The reaction mixture was stirred at room temperature under N₂ for 3h. The DMF was

removed *in vacuo* and the residue partitioned between EtOAc (150ml) and 5% aqueous Na₂CO₃ (50ml). The phases were separated and the aqueous phase re-extracted with EtOAc (2 x 50ml). The combined organic extracts were washed consecutively with 5% aqueous hydrochloric acid (30ml), 5% aqueous Na₂CO₃ (30ml) and brine (20ml) then dried (Na₂SO₄) and evaporated *in vacuo* to afford the title compound as a straw coloured oil (7.8g). This was used without further purification but can be purified by flash chromatography (SiO₂; 2:98 MeOH/DCM). δ H (DMSO-d₆), 7.48-7.28 (5H, m, ArH), 7.03 (2H, d, \downarrow 8.6Hz, ArH), 6.88 (2H, d, \downarrow 8.6Hz, ArH), 6.82 (1H, br s NH), 5.02 (2H, s, PhCH₂O), 4.81 (1H, apparent, dt, \downarrow 5.8Hz, CH α -tyr), 4.73 (1H, m, CH α -thioprop), 4.64 (1H, br d \downarrow 9Hz, NCH_AH_BS), 4.25 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 3.69 (3H, s, CO₂CH₃), 3.34 (1H, br d, \downarrow 11Hz, CHCH_AH_BS), 3.13 (1H, br d, CHCH_AH_BS) 3.06 (1H, d, \downarrow 5.8Hz, CH₂Ar) and 1.45 (9H, s ¹Bu); m/z (ESI, 15V) 501 (MH⁺).

INTERMEDIATE 18

D-Thiopropine-(O-benzyl)-L-tyrosine methyl ester

Intermediate 17 (8.2g) was stirred in trifluoroacetic acid (50ml) and DCM (50ml) at room temperature for 1h. The solvent was removed *in vacuo* and the residue partitioned between EtOAc (150ml) and saturated aqueous NaHCO₃ (50ml). The phases were separated and the aqueous phase re-extracted with EtOAc (32 x 50ml). The combined organic extracts were washed with brine (30ml), dried (Na₂SO₄) and evaporated *in vacuo*. The obtained solid was treated with diethyl ether (50ml) and filtered off with a little ether washing affording the title compound as white needles (5.3g, 81%): m.p. 138-140°. δ H (1:1, CDCl₃/CD₃OD) 7.42-7.23 (5H, m, PhH), 7.03 (2H, d, \downarrow 8Hz, ArH), 6.86 (2H, d, \downarrow 8.7Hz, ArH), 5.02 (2H, s, OCH₂Ph), 4.68 (1H, dd, \downarrow 7.5, 5.5Hz, CH α -tyr), 4.10 (1H, d, \downarrow 9.6Hz, NCH_AH_BS), 3.96 (1H, d, \downarrow 9.6Hz, NCH_AH_BS), 3.96-3.94 (1H, m, CH α -thioprop), 3.69 (3H, s, CO₂CH₃), 3.13-3.04 (2H, m) and 3.01-2.92 (2H, m) together (4H, CHCH₂S and CH₂Ar). m/z (ESI, 27V) 401 (MH⁺).

INTERMEDIATE 19

N-(Pyrid-3-ylacetyl)-D-thiopropine-(O-benzyl)-L-tyrosine methyl ester

HOBT (134mg, 0.99mmol), 3-pyridylacetic acid hydrochloride (157mg, 0.90mmol), and EDC (175mg, 0.90mmol) were added sequentially to a

stirred solution of Intermediate 18 (330mg, 0.83mmol) in dry DMF(5ml). The reaction mixture was stirred at room temperature for 6h. The DMF was removed *in vacuo* and the residue partitioned between EtOAc (50ml) and 5% aqueous Na₂CO₃ (30ml). The phases were separated and the aqueous phase re-extracted with EtOAc (2 x 30ml). The combined organic extracts were washed with brine (10ml), dried (Na₂SO₄) and evaporated *in vacuo*. The obtained glassy solid was chromatographed (SiO₂; 2.5:97.5 MeOH/DCM) to yield the title compound as a colourless foam (240mg, 56%): δ H (CDCl₃) (two rotameric species) 8.52-8.31 (2H, br m, pyrH), 7.56-7.43 (distorted br d, \downarrow ~8Hz) and 7.40-7.23 (br m) and 7.27 (m) together (7H, PhH, pyrH and CONH), 7.01 (1H, m, pyrH), 6.98 (2H, d, \downarrow 8.3Hz, ArH), 6.84 (2H, d, \downarrow 8.3Hz, ArH), 5.08-4.88 (m) and 4.82-4.38 (m) together (6H, CH₂O, NCH₂S, CH α -thioprop and CH α -tyr), 3.78-3.62 (m and br s) and 3.44-2.92 (m) together (9H, CO₂CH₃, CH₂pyr, CH₂Ar and CHCH₂S); m/z (ESI) 520 (MH⁺).

INTERMEDIATE 20

N-Acetyl-*D*-thiopropine-*L*-(4-benzoylphenylalanine) methyl ester

HOBT (240mg, 1.78mmol), *N*-acetyl-*D*-thiopropine (286mg, 1.63mmol) and EDC (313mg, 1.63mmol) were added sequentially to a stirred solution of *L*-4-benzoylphenylalanine methyl ester (420mg, 1.48mmol) in dry DMF (10ml). The reaction mixture was stirred at room temperature under N₂ for 2h. The DMF was removed *in vacuo* and the residue partitioned between EtOAc (70ml) and 5% aqueous Na₂CO₃ (30ml). The phases were separated and the aqueous phase re-extracted with EtOAc (2 x 20ml). The combined organic extracts were washed consecutively with 5% aqueous HCl (20ml), 5% aqueous Na₂CO₃ (10ml) and brine (10ml), then dried (Na₂SO₄) and evaporated *in vacuo* to afford the crude product. Chromatography (silica; 55:95 MeOH/EtOAc) afforded the title compound as a colourless oil (610mg, 93%): δ H (CDCl₃,) (approximate 3:1 mixture of rotameric species) 7.8-7.7 (4H, m), 7.62-7.57 (1H, m), 7.52-7.45 (2H, m), 7.29-7.22 (2H, m), 7.10 and 6.70 (1H, d, \downarrow 7.7Hz), 5.05-5.00 (1H, narrow m), 4.94-4.82 (1H, m), 4.72 and 4.58 (1H, d, \downarrow 8.7Hz), 4.50 and 4.43 (1H, d, \downarrow 8.7Hz), 3.77 and 3.73 (3H, s), 3.45 (1H, dd, \downarrow 11.6, 2.9Hz), 3.40-3.05 (3H, m's), 2.16 and 1.90 (3H, s); and m/z (ESI, 27V) 441 (MH⁺).

INTERMEDIATE 21**N-Acetyl-D-thiopropine-(N'-2,6-dichlorobenzyl)-L-4-aminophenylalanine methyl ester**

A solution of Intermediate 5 (1g, 2.85mmol), NMM (374mg, 407μl, 3.7mmol) and 2,6-dichlorobenzyl bromide (889mg, 3.70mmol) in dry DCM (20ml) was stirred at room temperature under N₂ for 18h. The reaction was diluted with DCM (80ml) and washed with saturated aqueous NaHCO₃ (30ml). The phases were separated and the aqueous layer extracted with DCM (2x30ml). The combined organic extracts were washed with brine (10ml), dried (Na₂SO₄) and evaporated *in vacuo*. The obtained yellow oil was purified by flash chromatography (silica; EtOAc) affording the title compound as a colourless glass (0.78g, 54%). δH (DMSO-d₆) (0.66:0.33 ratio of rotamers) 7.32 (2H, app.d, J 7.8Hz), 7.16 (1H, app.t, J 7.8Hz), 6.92 (2H, distorted t, J 8.4Hz), 6.83 and 6.48 (1H, br d, J 8.0Hz), 6.67 (2H, d, J 8.4Hz), 5.08-5.04 (0.66H, m), 4.81-4.68 (1.33H, m), 4.59-4.55 (2H, br, s), 4.55-4.4 (2H, m), 4.02-3.94 (0.66H, br s), 3.75 and 3.70 (3H, s), 3.42 (0.66H, dd), 3.27 (0.66H, dd), 3.16-2.90 (3H m), 2.15 and 1.84 (3H, s); m/z (ESI, 30V) 510 and 510 (MH⁺).

INTERMEDIATE 22**N-(N-Acetyl-D-5,5-dimethyl-1,3-thiazolia-4-oyl)**

NMM (111mg, 120μl, 1.10mmol), HOBT (162mg, 1.20mmol), Intermediate 42 (b) (223mg, 1.10mmol) and EDC (211mg, 1.10mmol) were added sequentially to a stirred solution of O-benzyl-L-tyrosine methyl ester hydrochloride (322mg, 1mmol) in dry DMF (5ml). The reaction mixture was stirred at room temperature for 3h and crude product obtained therefrom as described for Intermediate 17. Chromatography (SiO₂, 60:40 to 90:10 EtOAc/ hexane) afforded the title compound as a colourless glass (355mg, 76%). δH (CDCl₃) 7.43-7.28 (5H, m), 7.03-6.94 (2H, m), 6.93-6.82 (2H, m), 6.64 and 6.32 (1H, d, J 8.0Hz), 5.04 and 5.03 (2H, s), 4.86-4.80 (1H, m), 4.64-4.46 (2H, m), 4.37 and 4.00 (1H, s), 3.74 and 3.72 (3H, s), 3.13-2.91 (2H, m's), 2.04 and 1.81 (3H, s), 1.48, 1.42 and 1.35 (6H, s); m/z (ESI, 60V) 471 (MH⁺).

INTERMEDIATE 23***N*-(4-Morpholinoacetyl)-*D*-thiopropine-*O*-(2,6-dichlorobenzyl)-*L*-tyrosine methyl ester**

Bromoacetyl bromide (1.20g, 0.52ml, 5.97 mmol) was added dropwise to a stirred, ice-bath cooled solution of *D*-thiopropine-*O*-(2,6-dichlorobenzyl) tyrosine methyl ester (2.80g, 5.97mmol) and NMM (0.603g, 0.66ml, 5.97 mmol) in dry DCM (40ml). The reaction mixture was stirred under N₂ for 2h. The reaction was partitioned between DCM (100ml) and 10% aqueous HCl (40ml). The phases were separated and the aqueous phase re-extracted with DCM (40ml). The combined organic extracts were washed consecutively with 10% aqueous HCl (20ml), water (20ml) and brine (10ml), dried (Na₂SO₄) and evaporated *in vacuo*. The obtained oil was chromatographed (SiO₂; 50:50 to 65:35, EtOAc/hexane; applied in DCM) to afford the *N*-bromoacetyl derivative as a white foam (1.95g, 55%). (ESI, 60V) 589 (MH⁺). This intermediate (840mg, 1.42mmol) was stirred with morpholine (248mg, 250μl, 2.84mmol) in MeOH (10ml) for 18h. The solvent was removed *in vacuo* and the residue partitioned between saturated aqueous NaHCO₃ (30ml) and EtOAc (70ml). The phases were separated and the aqueous phase re-extracted with EtOAc (3x30ml). The combined organic extracts were washed with brine (10ml), dried (Na₂SO₄) and evaporated *in vacuo*. The obtained crude oil was chromatographed [silica; DCM (400), MeOH (20), AcOH (3), H₂O (2)] to afford the title compound as a foam (620mg, 73%). δH (DMSO-d₆) (1:1 mixture of rotamers) 8.51 and 8.30 (1H, d, J 8.0Hz), 7.52 (2H, d, J 8.0Hz), 7.42 (1H, d, J 8.0Hz), 7.13 (2H, t, J 8.0Hz), 6.95 (2H, d, J 8.0Hz), 5.18 (2H, s), 5.19-5.10 (0.5H, m), 4.90 (0.5H, d, J 9.0Hz), 4.80-4.72 (1H, m), 4.62-4.47 (1.5H, m), 4.24 (0.5H, d, J 9.0Hz), 3.62 (3H, s), 3.6-3.46 (4H, br m), 3.35-2.6 (6H, m) and 2.48-2.25 (4H, br m).

INTERMEDIATE 24***L*-4-(Methylamino)phenylalanine methyl ester dihydrochloride**

Iodomethane (7.75g, 3.4ml, 54.6mmol) was added to a stirred solution of *N*-Boc-*L*-4-aminophenylalanine methyl ester (10.7g, 36.4mmol) in dry DCM (60ml), and stirred at room temperature for 24h. NMM (1.83g, 1.99ml, 18.1mmol) was added and the reaction stirred for 18h. The volatiles were removed *in vacuo* and the residue partitioned between

EtOAc (150ml) and saturated aqueous NaHCO₃ (100ml). The phases were separated and the aqueous phase extracted with EtOAc (100ml). The combined organic extracts were washed with brine (20ml), dried (Na₂SO₄) and evaporated *in vacuo* to afford a dark oil. This was a mixture of the desired mono N-methylated product contaminated with more polar starting material and less polar N,N-dimethylated by-product. Chromatography (SiO₂, 40:60 to 75:25 Et₂O/hexane) afforded the desired *N*-Boc-L-4-(methylamino)phenyl alanine methyl ester (3.1g) as a white crystalline solid. δ H (CDCl₃) 6.92 (2H, d, \downarrow 8.0Hz), 6.53 (2H, d, \downarrow 8.0Hz), 4.94 (1H, br d, \downarrow 7.0Hz), 4.50 (1H, m), 3.70 (3H, s), 2.98 (1H, d, \downarrow 5.5Hz), 2.81 (3H, s) and 1.42 (9H, s). This intermediate (3.05g) was dissolved in methanol (100ml) and HCl gas bubbled through the solution for 30 seconds. The reaction mixture was allowed to stand for 1h. The volatiles were removed *in vacuo* to afford the title compound as an off white solid (2.56g, 25% over 2 steps). δ H (CD₃OD) 7.60 (2H, d, \downarrow 8.0Hz), 7.52 (2H, d, \downarrow 8.0Hz), 4.41 (1H, t, \downarrow 6.8Hz), 3.80 (3H, s), 3.34 (2H, m) and 3.08 (3H, s).

INTERMEDIATE 25

N-Acetyl-*D*-thioprolin-L-4-(methylamino)phenylalanine methyl ester

Intermediate 24 was reacted with *N*-acetyl-*D*-thioprolin in a similar manner to that described for Intermediate 5. Chromatography (SiO₂; 3:97 to 5:95 MeOH/DCM) afforded the title compound as a white foam (1.34g). δ H (CDCl₃) (0.66:0.33 ratio of rotamers) 6.98-6.82 (3H, m), 6.52 (2H, d, \downarrow 8.4Hz), 5.09-5.04 (0.66H, m), 4.80-4.70 (0.66H, m), 4.55 (0.66H, d, \downarrow 8.7Hz), 4.50-4.40 (0.33H x 2, obscured m), 4.41 (0.66H, d, \downarrow 8.7Hz), 3.74 (3H x 0.33, s), 3.70 (3H, x 0.66, s), 3.42 (0.66H, dd), 3.27 (0.66H, dd), 3.14-2.93 (2.66H, m), 2.79 (3H, s), 2.16 (3H x 0.66, s) and 1.88 (3H x 0.33); m/z (ESI) 366 (MH⁺).

INTERMEDIATE 26

N-(Diphenylmethylene)-4-(carbobenzyloxy)phenylalanine ethyl ester

A mixture of *N*-(diphenylmethylene)glycine ethyl ester (6.6g, 24.9mmol), benzyl 4-(bromomethyl)benzoic acid (7.61g, 24.9mmol) and potassium carbonate (50mmol, 6.9g) in acetonitrile (300ml) was refluxed overnight. The solvent was removed *in vacuo* and the residue partitioned between

EtOAc and water. The aqueous layer was extracted with EtOAc and the combined organic extracts were dried (Na_2SO_4) and concentrated *in vacuo* to give the title compound as an oil (13.0g) δH (CDCl_3) 7.90 (2H, d, \downarrow 8.3Hz), 7.58 (2H, d, \downarrow 7.3Hz), 7.50-7.25 (11H, m), 7.14 (2H, d, \downarrow 8.1Hz), 6.65 (2H, d, \downarrow 6.8Hz), 5.33 (2H, m), 4.30-4.15 (3H, br m), 3.32 (2H, v br s) and 1.26 (3H, t, \downarrow 7.1Hz); m/z (ESI, 60V) 492 (MH^+).

INTERMEDIATE 27

4-(Carbobenzyloxy)phenylalanine ethyl ester

10 A solution of Intermediate 26 (13.0g) in dilute hydrochloric acid (2M, 20ml) and THF (200ml) was stirred for 2h at room temperature. The solvent was removed *in vacuo*. The residue was triturated with Et_2O to give a white solid, and recrystallisation from EtOH/EtOAc gave the HCl salt of the title compound as a white solid (4.24g, 46.8%). The mother liquors were
15 concentrated *in vacuo* to give a glassy solid, which was dissolved in EtOAc and washed with saturated NaHCO_3 . The aqueous layer was re-extracted with EtOAc and the combined organic extracts dried (Na_2SO_4) and evaporated *in vacuo*. Chromatography (SiO_2 , EtOAc) gave the title compound as a glassy solid (2.75g, 33.8%). For the HCl salt: δH (DMSO-
20 d_6) 7.96 (2H, dd, \downarrow 6.6, 1.7Hz), 7.48-7.37 (7H, m), 5.35 (2H, s), 4.29 (1H, dd, \downarrow 7.7, 5.1Hz), 4.10 (2H, q, \downarrow 7.1Hz), 3.27 (1H, dd, \downarrow 14.0, 5.9Hz), 3.15 (1H, dd, \downarrow 14.0, 7.7Hz) and 1.08 (3H, t, \downarrow 7.1Hz); m/z (ESI, 60V) 328 (MH^+).

INTERMEDIATE 28

N-Boc-4-(carbobenzyloxy)phenylalanine ethyl ester

NaOH (1M, 15.1ml) was added to Intermediate 27 (5g, 13.75mmol) in *tert*-butanol (110ml). After a solution had been obtained, a solution of di-*tert*-butyl dicarbonate (3.6g, 1 equivalent) in *tert*-butanol (50ml) was added in
30 portions. The reaction mixture was stirred at room temperature overnight then the solvent removed *in vacuo*. The resulting oil was taken up in water (200ml) and the pH adjusted to pH3 with citric acid (10%). After extraction [EtOAc (3 x 250ml)], the combined organic extracts were washed with saturated NaHCO_3 and water, dried (Na_2SO_4) and concentrated *in vacuo*
35 to give the title compound as a yellow oil (6.1g, 100%). δH (CDCl_3 , 300MHz) 7.9 (2H, d, \downarrow 8.2Hz), 7.5-7.35 (7H, m containing d, \downarrow 8.2Hz), 5.3

(2H, s), 4.20-4.0 (3H, m), 3.1-2.9 (2H,m), 1.3 (9H, s) and 1.2 (3H, m); m/z (ESI, 60V) 450 (MNa⁺).

INTERMEDIATE 29

5 *N*-Boc-4-carboxyphenylalanine ethyl ester

A mixture of Intermediate 28 (6.1g, 14.3mmol) and palladium on charcoal (10%Pd, 610mg) in ethanol (150ml) was stirred under a hydrogen atmosphere (balloon) at room temperature overnight. The catalyst was removed by filtration and the filtrate concentrated *in vacuo* to give the title compound as a white waxy solid (4.2g, 87%) δH (CDCl₃) 8.0 (2H, d, \downarrow 8.0Hz), 7.3 (2H, d, \downarrow 8.0Hz), 4.8 (1H, s), 4.4 (1H, m), 4.1 (2H,m), 3.2-3.1 (1H, m), 3.0-2.8 (1H, m), 1.3 (9H, s) and 1.2 (3H,m); m/z (ESI) 360 (MNa⁺).

15 INTERMEDIATE 30

N-Boc-4-[(3,5-dichlorophenyl)carboxamido]phenylalanine ethyl ester

Carbon tetrachloride (4.3ml, 44.5mmol) was added to a solution of Intermediate 29 (1.5g, 4.45mmol) and triphenylphosphine (1.4g, 5.34mmol) in acetonitrile (80ml). The mixture was stirred for 2h at room temperature. 3,5-Dichloroaniline (1.44g, 8.9mmol) was added and the reaction continued at room temperature for 20h. The solvent was removed *in vacuo* and the residue partitioned between water and EtOAc. The aqueous layer was re-extracted with EtOAc and the combined organic extracts washed with dilute HCl, water and saturated NaHCO₃, dried (Na₂SO₄) and concentrated *in vacuo*. Chromatography (SiO₂; EtOAc/hexane, 1:4) gave the title compound as an off-white solid (1.20g, 56%), δH (CDCl₃) 7.96 (1H, brs), 7.76 (2H, d, \downarrow 8.3Hz), 7.62 (2H, d, \downarrow 1.5Hz), 7.24 (2H, d, \downarrow 8.5Hz), 7.13 (1H, t, \downarrow 1.5Hz), 5.03 (1H, v br), 4.55 (1H, br m), 4.17 (2H,q, \downarrow 7.1Hz), 3.2-3.0 (2H, br m), 1.42 (9H, s) and 1.42 (3H, t, \downarrow 7.1Hz); m/z (ESI, 60V) 503 (MNa⁺).

INTERMEDIATE 31

N-Boc-4-(*N*-thioacetyl)amino-*L*-phenylalanine methyl ester

To a solution of *N*-Boc-4-(*N*-acetyl)amino-*L*-phenylalanine methyl ester (1.64g, 4.88mmol) in THF was added Lawesson's Reagent (1.08g, 2.68mmol, 0.55 eq). The resulting suspension was heated to reflux for 3h

and then the reaction mixture was left stirring at room temperature overnight. The volatiles were then removed *in vacuo* and the oil obtained purified by column chromatography (SiO₂; DCM/EtOAc 100:0 to 80:20) to give the title compound as a yellow oil (1.72g, 100%) δ H (CDCl₃) 9.93 (br s) and 9.52 (br s) together (1H, NHAr), 7.60 (2H, d, \downarrow 8.3Hz, ArH), 7.16-7.03 (2H, m, ArH), 5.13-5.05 (1H, m, NHBoc), 4.54-4.43 (1H, m, CH), 3.65 (s) and 3.67 (s) together (3H, CO₂Me), 3.13-2.90 (2H, m, CH₂), 2.62 (s) and 2.52 (s) together (3H, CSCH₃) and 1.36 (9H, s, ¹Bu); m/z (ESI, 60V) 353 (MH⁺).

INTERMEDIATE 32

N-Boc-O-(trifluoromethylsulphonyl)-L-tyrosine methyl ester

Trifluoromethanesulphonic anhydride (4ml, 23mmol) was added to a mixture of N-Boc tyrosine methyl ester (5.9g, 20mmol) and pyridine (8ml, 100mmol) in DCM (30ml) at 0°. After 30min the reaction mixture was diluted with water (60ml) and DCM (100ml) and washed with aqueous NaOH (0.5M, 50ml), water (60ml), citric acid (10% solution, 2 x 75ml) and water (60ml), dried (Na₂SO₄) and evaporated *in vacuo*. Purification by column chromatography (SiO₂; EtOAc/hexane, 2:1) gave the title compound (7.76g, 91%) as a colourless oil which solidified on standing. δ H (CDCl₃) 7.25-7.18 (4H, m, ArH), 5.01 (1H, br d, CONH), 4.60 (1H, br q, CH α), 3.71 (3H, s, CO₂Me), 3.17 (1H, dd, \downarrow 13.8, 5.8Hz, CH_AH_BAr), 3.03 (1H, dd, \downarrow 13.6, 6.3 Hz, CH_AH_BAr) and 1.41 (9H, s, ¹Bu); m/z (ESI, 15V) 428 (MH⁺).

INTERMEDIATE 33

N-Boc-4-phenyl-L-phenylalanine methyl ester

Tetrakis(triphenylphosphine)palladium (0) (3 mol %, 69mg) was added to a nitrogen purged mixture of Intermediate 32 (854mg, 2mmol), phenylboronic acid (488mg, 4mmol) and potassium carbonate (414mg, 3mmol) in toluene (20ml). The mixture was heated at 85-90° for 2h then diluted with EtOAc (150ml) and washed with saturated aqueous NaHCO₃ (50ml), water (50ml), citric acid (10%, 50ml), water (50ml) and brine (50ml), dried (Na₂SO₄) and evaporated *in vacuo*. Column chromatography (SiO₂; EtOAc/hexane; 20:80) gave the title compound (685mg, 96%) as a colourless oil which solidified on standing. δ H (CDCl₃,

300MHz) 7.60-7.20 (9H, m, ArH), 5.07 (1H, br d, \downarrow 8.0Hz, CONH), 4.65 (1H, br q, CH α), 3.75 (3H, s, CO₂Me), 3.19 (1H, dd, \downarrow 13.8, 5.8Hz, CH_AH_BAr), 3.10 (1H, dd, \downarrow 13.8, 6.1Hz, CH_AH_BAr) and 1.44 (9H, s, ^tBu); m/z (ESI, 15V) 356 (MH⁺),

5

INTERMEDIATE 34

N-Boc-4-(3-prop-1-enyl)-L-phenylalanine methyl ester

Bistriphenylphosphine palladium (II) chloride (70mg, 0.1mmol) was added to a nitrogen purged mixture of Intermediate 32 (21.4g, 5mmol), allyltributyltin (1.55ml, 5mmol), and lithium chloride (425mg, 10mmol) in DMF (15ml). The mixture was heated at 90° for 1h then evaporated *in vacuo*. The residue was dissolved in Et₂O (200ml) and washed with water (2 x 50ml) and saturated potassium fluoride (50ml), dried (Na₂SO₄) and evaporated *in vacuo*. Purification by column chromatography (SiO₂; EtOAc/hexane; 10:90 to 20:80) gave the title compound (1.49g, 94%) as a colourless oil which solidified on standing. δ H (CDCl₃) 7.12 (2H, d, \downarrow 8.1Hz, ArH), 7.05 (2H, d, \downarrow 8.0Hz, ArH), 6.02-5.88 (1H, m, CH₂CH=CH₂), 5.10-5.04 (2H, m, CH₂CH=CH₂), 4.95 (1H, v br d, CONH), 4.57 (1H, br q, CH α), 3.71 (3H, s, CO₂Me), 3.36 (2H, br d, \downarrow 6.7Hz, CH₂CH=CH₂), 3.12-2.95 (2H, m, CHCH₂Ar), and 1.42 (9H, s, ^tBu); m/z (ESI, 15V) 320 (MH⁺).

20

INTERMEDIATE 35

N-Boc-4-(2-benzo[b]furanyl)-L-phenylalanine methyl ester

Tetrakis(triphenylphosphine)palladium(0) (347mg, 30mol%) was added to a nitrogen purged mixture of Intermediate 32 (427mg, 1mmol) benzo[b]furan-2-boronic acid (324mg, 2mmol) and potassium carbonate (207mg, 1.5mmol) in toluene (10ml). The mixture was heated at 90° for 4h, diluted with EtOAc (100ml), washed with saturated NaHCO₃ (30ml), water (30ml), citric acid (10%, 30ml), water (30ml) and brine (30ml), dried (Na₂SO₄) and evaporated *in vacuo*. Column chromatography (SiO₂; DCM) gave the title compound (277mg, 70%) as a white waxy solid. δ H (CDCl₃) 7.79 (2H, d, \downarrow 8.3Hz, ArH), 7.59-7.50 (2H, m, ArH), 7.31-7.20 (4H, m, ArH), 6.99 (1H, s, C=CH), 5.04 (1H, br d \downarrow 7.7Hz, CONH), 4.63 (1H, br q, CH α), 3.73 (3H, s, CO₂Me), 3.17 (1H, dd, \downarrow 13.8, 5.7Hz, CH_AH_BAr), 3.08 (1H, dd, \downarrow 13.7, 6.0Hz, CH_AH_BAr) and 1.43 (9H, s, ^tBu); m/z (ESI, 15V) 396 (MH⁺).

30

35

INTERMEDIATE 36**N-Boc-4[2-(1-phenylethenyl)]phenylalanine methyl ester**

A mixture of *N*-Boc-4-iodo-*L*-phenylalanine methyl ester (1.22g, 3mmol)
5 (Lei, H *et al*, J. Org. Chem (1994), 59, 4206-4210), palladium (II) acetate (67mg, 0.3mmol), tetrabutylammonium chloride (1.07g, 3.6mmol), tri(*O*-tolyl)phosphine (183mg, 0.6mmol), potassium carbonate (2.07g, 15mmol) and styrene (51mg, 4.5mmol) was heated in DMF (20ml) at 90° for 22h. The solvent was removed *in vacuo*, the residue dissolved in EtOAc
10 (100ml) and washed with water (30ml), dilute HCl (1M, 30ml), saturated NaHCO₃ (30ml) and water (30ml), dried (Na₂SO₄) and evaporated *in vacuo*. Column chromatography (SiO₂; MeOH/DCM, 1:99) gave the title compound (500mg, 44%) as a light brown solid. δ H (CDCl₃) 7.52-7.08 (11H, m, ArH + CH=CH), 4.97 (1H, br d, CONH), 4.60 (1H, br q, CH α),
15 3.72 (3H, s, CO₂Me), 3.20-3.00 (2H, m, CH₂Ar) and 1.49 (9H, s, ^tBu); m/z (ESI, 27V) 382 (MH⁺).

INTERMEDIATE 37**N-Boc-4-(3-pyridyl)phenylalanine methyl ester**

A mixture of *N*-Boc-4-iodo-*L*-phenylalanine methyl ester (810mg, 2mmol, Lei, H *et al*, *ibid*) tetrakis(triphenylphosphine)palladium (0) (231mg, 0.2mmol), aqueous sodium carbonate (4mmol, 2ml of a 2M solution) and diethyl(3-pyridyl)borane (294mg, 2mmol) in dimethoxyethane (30ml) was refluxed for 6hr. The solvent was removed *in vacuo*, the residue dissolved
25 in EtOAc (100ml) and washed with water (30ml) aqueous sodium thiosulphate (20ml) and brine (30ml) dried (Na₂SO₄) and evaporated *in vacuo*. Purification by column chromatography (SiO₂, EtOAc/hexane 30:70) gave the title compound (335mg, 47%) as a yellow oil. δ H (CDCl₃) 8.81 (1H, d, \downarrow 1.7Hz, PyrH), 8.56 (1H, dd, \downarrow 4.8, 1.6Hz, PyrH), 7.84 (1H, dt, \downarrow 7.9, 2.0Hz, PyrH), 7.49 (2H, d, \downarrow 8.2Hz, ArH), 7.34 (1H, ddd, \downarrow 7.9, 4.8, 0.6Hz, PyrH), 7.23 (2H, d, \downarrow 8.2Hz, ArH), 5.09 (1H, br d, \downarrow 7.8Hz, CONH), 4.62 (1H, br q, \downarrow 6.8Hz, CH α), 3.73 (3H, s, CO₂Me), 3.18 (1H, dd, \downarrow 13.8, 5.6Hz, CH_AH_BAr), 3.07 (1H, dd, \downarrow 13.8, 5.8Hz, CH_AH_BAr) and 1.40 (9H, s, ^tBu); m/z (ESI, 15V) 357 (MH⁺).

35

INTERMEDIATE 38**2,6-Dichlorophenylacetylene**

The title compound was prepared from 2,6-dichlorobenzaldehyde by the method of E. J. Corey and P. L. Fuchs, Tetrahedron Letters, (1972), 3769-3772 as off-white needles (hexane). m.p. 97-98°. δ H (CDCl₃) 7.35-7.32 (2H, m, ArH), 7.20 (1H, dd, J 8.9, 7.2Hz, ArH) and 3.68 (1H, s, C \equiv CH); m/z (ESI) 170 (MH⁺).

INTERMEDIATE 39

10 **N-Acetyl-D-thiopropine-4-(2,6-dichlorophenylacetylene)-L-phenylalanine methyl ester**

A solution of *N*-acetyl-*D*-thiopropine-4-iodo-*L*-phenylalanine methyl ester (4.62mg, 1mmol), [prepared from *N*-Boc-4-iodo-*L*-phenylalanine methyl ester (Lei, H *et al*, *ibid*) deprotected by a similar method to that described for Intermediate 13 and then reacted with *N*-acetyl-*D*-thiopropine according to the method described for Intermediate 14] in triethylamine (5ml) and toluene (10ml) was purged with nitrogen. Bis(triphenylphosphine) palladium dichloride (36mg, 5mol%) and copper (I) iodide (20mg, 10 mol%) were added. A solution of Intermediate 38 (257mg, 1.5mmol) in toluene (5ml) was added over a period of 2h via syringe pump. The mixture was stirred for a further 1h at room temperature, then diluted with EtOAc (100ml) and washed with dilute HCl (30ml) and brine (30ml), dried (Na₂SO₄) and evaporated *in vacuo*. Purification by column chromatography (SiO₂; MeOH/DCM, 3:97 to 5:95) gave the title compound (452mg, 90%) as an orange solid. Recrystallisation from EtOAc gave an off-white solid (220mg). δ H (DMSO-*d*₆, 300K) (mixture of two rotameric species observed) 8.62 (d, J 8.3Hz) and 8.34 (d, J 8.1Hz) (together 1H, CONH), 7.60 (2H, d, J 8.3Hz, Cl₂ArH), 7.51-7.49 (2H, m, ArH), 7.43 (1H, dd, J 8.9, 7.5Hz, Cl₂ArH), 7.35-7.29 (2H, m, ArH), 4.8-4.7 (2H, m, CH α + NCH_AH_BS), 4.57-4.5 (1H, m, CH α), 4.47 (d, J 8.7Hz) and 4.23 (d, J 9.5Hz) (together 1H, NCH_AH_BS), 3.65 (3H, s, CO₂Me), 3.35-2.80 (4H, m, 2 \times CHCH₂) and 2.06 and 1.85 (3H, each s, COCH₃); m/z (ESI) 505 (MH⁺).

INTERMEDIATE 40**N-Boc-4-(phenylacetylene)-L-phenylalanine methyl ester**

The title compound was prepared in a similar manner to Intermediate 39 using N-Boc-4-iodo-L-phenylalanine methyl ester and phenylacetylene.

- 5 Purification by column chromatography (SiO₂; EtOAc/hexane, 20:80) gave the title compound as a yellow gum (1.45g, 77%). δ H (DMSO-d₆) 7.55-7.27 (10H, m, ArH + CONH), 4.25-4.18 (1H, m, CH α), 3.62 (3H, s, CO₂Me), 3.04 (1H, dd, \downarrow 13.8, 5.1Hz, CH_AH_BAr), 2.89 (1H, dd, \downarrow 13.7, 10.1Hz, CH_AH_BAr) and 1.33 (9H, s, ^tBu); m/z (ESI, 30V) 380 (MH⁺).

10

INTERMEDIATE 41**N-Boc-4-[2-(1-phenylethyl)]-L-phenylalanine methyl ester**

A mixture of Intermediate 40 (340mg, 0.9mmol) and palladium on charcoal (10% Pd wt/wt. 300mg) in methanol (10ml) was stirred under a hydrogen

- 15 atmosphere (balloon) overnight. The catalyst was filtered off and the filtrate evaporated *in vacuo*. Column chromatography (SiO₂, EtOAc/hexane, 20:80) gave the title compound as a colourless gum (255mg, 74%). δ H (CDCl₃, 300MHz) 7.31-7.02 (9H, m, ArH), 4.96 (1H, br d, CONH), 4.59 (1H, br q, CH α), 3.71 (3H, s, CO₂Me), 3.12-2.98 (2H, m, CHCH₂Ar), 2.90 (4H, s, CH₂CH₂) and 1.43 (9H, s, ^tBu); m/z (ESI, 15V) 384 (MH⁺).

20

INTERMEDIATE 42**a) N-Acetyl-5,5-L-dimethyl-1,3-thiazolidine-4-carboxylic acid**

- 25 Acetic anhydride (614 μ l, 6.5mmol) was added to a suspension of L-5,5-dimethylthiazolidine-4-carboxylic acid (1g, 6.20mmol) in DMF (6ml). The mixture was stirred for 2h at room temperature to give a colourless solution. The solvent was removed *in vacuo* to give a white solid. Recrystallisation (acetone) gave the title compound as white cubes
- 30 (585mg, 47%). δ H (DMSO-d₆, 300K) (2 rotameric species observed) 4.80 (d \downarrow 8.8Hz) and 4.70 (d, \downarrow 9.9Hz) together (1H, NCH_AH_BS), 4.71 (d, \downarrow 8.7Hz) and 4.50 (3, \downarrow 9.9Hz) together (1H, NCH_AH_BS), 4.47 (s) and 4.25 (s) together (1H, CH α), 2.06 (s) and 1.93 (s) together (3H, COCH₃), 1.53 (s) and 1.51 (s) together (3H, CMe_AMe_BS), 1.41 (s) and 1.37 (s) together
- 35 (3H, CMe_AMe_BS) (acid proton not observed).

b) N-Acetyl-5,5-D-dimethyl-1,3-thiazolidine-4-carboxylic acid

The title compound was prepared using the same procedure from the corresponding *D*-acid.

5 INTERMEDIATE 43

N-(Pyrid-3-ylacetyl)-D-thiopropine-O-(2,4,6-trichlorobenzyl)-L-tyrosine methyl ester

A solution of Intermediate 10 (429mg, 1mmol) in DMF (5ml) was added to a suspension of sodium hydride (60% in mineral oil, 44mg, 1.1mmol) in DMF (5ml) at 0°. After 10min a solution of Intermediate 45 (302mg, 1.1mmol) in DMF (5ml) was added. The reaction mixture was stirred at 0° for 2h then at room temperature for 1h, quenched with water (~1ml) and the solvents removed *in vacuo*. The residue was dissolved in EtOAc (150ml) and washed with water (2 x 50ml) and brine (50ml), dried (Na₂SO₄) and evaporated *in vacuo*. Column chromatography (SiO₂: MeOH/CH₂Cl₂, 8:92) gave the title compound (435mg, 70%). δ H (DMSO-d₆, 300K) (2 rotameric species observed) 8.75 (d, \downarrow 7.9Hz, CONH) and 8.44-8.35 (m) together (3H, 2 x PyrH + CONH), 7.76 (2H,s, Cl₃ArH₂), 7.63-7.54 (1H, m, PyrH), 7.34-7.30 (1H, m, PyrH), 7.20-7.11 (2H, m, ArH), 6.94-6.90 (2H, m, ArH), 5.13 (s) and 5.11 (s) together (2H, OCH₂Ar), 4.88-4.74 (2H, m, CH α + NCH_AH_BS), 4.6-4.45 (m) and 4.29 (d, \downarrow 9.7Hz) together (2H, NCH_AH_BS + CH α), 3.83 (2H, s, PyrCH₂CO), 3.63 (3H, s, CO₂Me), 3.20-2.69 (4H, m, 2 x CHCH₂) (acid proton not observed); m/z (ESI, 60V) 622 (MH⁺).

25

INTERMEDIATE 44

2,4,6-Trichlorobenzylalcohol

A solution of lithium aluminium hydride (1M in THF, 18ml, 18mmol) was added to a solution of 2,4,6-trichlorobenzoyl chloride (4.35g, 17.8mmol) in THF (70ml) at 0°. After 1h, water (685 μ l), aqueous NaOH (3M, 685 μ l) and water (2.06ml) were added. The mixture was stirred vigorously for 1h, the precipitate filtered off and the filtrate evaporated *in vacuo* to give a yellow solid. Recrystallisation from diisopropylether gave the title compound as white needles (2.63g, 70%), m.p. 100-101°. δ H (CDCl₃) 7.35 (2H, s, ArH), 4.91 (2H, br s, CH₂OH), 2.07 (1H, br s, CH₂OH).

35

INTERMEDIATE 45**2,4,6-Trichlorobenzylbromide**

Triphenylphosphine (1.57g, 6mmol) and carbon tetrabromide (1.99g, 6mmol) were added to a solution of Intermediate 44 (1.06g, 5mmol) in Et₂O (25ml). The mixture was stirred at room temperature overnight. The precipitate was filtered off and the filtrate evaporated *in vacuo*. Chromatography (SiO₂, DCM) gave the title compound as a mobile colourless oil which crystallised on standing (1.17g, 85%) m.p. 51-52°, δ H (CDCl₃) 7.35 (2H, s, ArH) and 4.70 (2H, s, CH₂Br).

INTERMEDIATE 46**N-Acetyl-D-thiopropine-O-(2-chloropyrimidin-4-yl)-L-tyrosine methyl ester**

A solution of *N*-acetyl-*D*-thiopropine-*L*-tyrosine methyl ester (1.76g, 5mmol), [prepared from *N*-acetyl-*D*-thiopropine and tyrosine methyl ester by a similar method to the preparation of Intermediate 5] in DMF (10ml) was added to a suspension of sodium hydride (60% in mineral oil, 210mg, 5.25mmol) in DMF (5ml) at room temperature. After 10 min a solution of 2,4-dichloropyrimidine (782mg, 5.25mmol) in DMF (5ml) was added. After 1h water (1ml) was added and the solvent evaporated *in vacuo*. The residue was dissolved in EtOAc (200ml) and washed with water (3 x 50ml) and brine (30ml), dried (Na₂SO₄) and evaporated *in vacuo*. Chromatography (SiO₂, MeOH/DCM 5:95) gave the title compound as a white foam (1.59g, 68%). δ H (DMSO-d₆, 400K) 8.56 (1H, d, \downarrow 5.7Hz, PyrH), 7.9 (1H, br d, CONH), 7.32 (2H, d, \downarrow 8.7Hz, ArH), 7.15 (2H, d, \downarrow 8.7Hz, ArH), 6.99 (1H, d, \downarrow 5.7Hz, PyrH), 4.83 (1H, dd, \downarrow 7.4, 3.9Hz, CH α thioprop), 4.77 (1H, d, \downarrow 9.2Hz, NCHH_BS), 4.64 (1H, dt, \downarrow 8.5, 5.6Hz, CH α tyr), 4.39 (1H, d, \downarrow 9.2Hz, NCHAH_BS), 3.67 (3H, s, CO₂Me), 3.26 (1H, dd, \downarrow 11.6, 7.4Hz, CHCHAH_BS), 3.19 (1H, dd, \downarrow 14.0, 5.7Hz, CHCHAH_BAr), 3.09-3.00 (2H, m, CHCHAH_BS + CHCHAH_BAr) and 2.00 (3H, s, COCH₃); m/z (ESI, 15V) 465 (MH⁺).

INTERMEDIATE 47**N-Acetyl-D-thioprolin-O-[2-(4-methoxythiophenoxy)pyrimidin-4-yl]L-tyrosine methyl ester**

- 5 4-Methoxythiophenol (129 μ l, 1.05mmol) was added to a suspension of sodium hydride (42mg, 1.05mmol) in DMF(5ml) at 0°. After 10 min a solution of Intermediate 46 (465mg, 1mmol) in DMF (5ml) was added. The mixture was stirred at room temperature overnight. The solvent was removed *in vacuo*, the residue dissolved in EtOAc (100ml) and washed
- 10 with water (2 x 50ml) and brine (30ml), dried (Na₂SO₄) and evaporated *in vacuo*. Column chromatography (SiO₂, MeOH/DCM, 5:95) gave the title compound as a colourless gum (327mg, 58%). δ H (DMSO-d₆, 300K) (2 rotameric species observed) 8.63 (d, \downarrow 7.9Hz) and 8.4 (d) together (1H, CONH), 8.40 (1H, d, \downarrow 5.7Hz, pyrH), 7.40 (2H, d, \downarrow 8.1Hz, ArH), 7.22 (2H, t, \downarrow 7.5Hz, ArH), 7.05-7.01 (2H, m, ArH), 6.93 (2H, d, \downarrow 8.9Hz, ArH), 6.69 (1H, d, \downarrow 5.7Hz, PyrH), 4.78-4.68 (2H, m, CH α + NCH_AH_BS), 4.6-4.45 (1H, m, CH α tyr), 4.46 (d, \downarrow 8.6Hz) and 4.23 (d, \downarrow 9.7Hz) together (1H, NCH_AH_BS), 3.80 (3H, s, ArOMe), 3.65 (s) and 3.64 (s) together (3H, CO₂Me), 3.18-2.72 (4H, m, 2 x CHCH₂), 2.05 (s) and 1.84 (s) together (3H, COCH₃); m/z
- 15 (ESI, 15V) 569 (MH⁺).
- 20

INTERMEDIATE 48**N-Boc-N'-phthaloyl-4-amino-L-phenylalanine methyl ester**

- Phthaloyl dichloride (3.78ml, 26.25mmol) was added to a mixture of N-
- 25 Boc-4-amino-L-phenylalanine methyl ester (7.35g, 25mmol), NMM (6.05ml, 55ml) and 4-dimethylaminopyridine (300mg, 2.5mmol) in THF (125ml) at room temperature. The mixture was stirred at room temperature for 5 days. The bulk of the THF was removed *in vacuo*, the residue diluted with EtOAc (800ml) and washed with dilute HCl (100ml)
- 30 and brine (100ml), dried (Na₂SO₄) and evaporated *in vacuo* to give a pale yellow solid. Recrystallisation from EtOAc gave the title compound as white needles (7.91g, 75%) m.p. 171-172°. δ H (DMSO-d₆) 8.76-8.11 (4H, m, ArH), 7.35-7.23 (5H, m, ArH + CONH), 4.2 (1H, m, CH α), 3.62 (3H, s, CO₂Me), 3.05-2.84 (2H, m, CH₂Ar) and 1.33 (9H, s, ^tBu); m/z (ESI, 60V)
- 35 425 (MH⁺).

INTERMEDIATE 49**N-Boc-N-methyl-N'-phthaloyl-4-amino-L-phenylalanine methyl ester**

- A solution of Intermediate 48 (7.96, 18.8mmol) in DMF (90ml) was added via cannula to a suspension of sodium hydride (60% in mineral oil, 827mg, 20.68mmol) and methyl iodide (2.34ml, 37.6mmol) in DMF (100ml) at 0°. The mixture was allowed to warm to room temperature and stirred overnight. Water (~2ml) was added and the solvent removed *in vacuo*. The residue was dissolved in EtOAc (400ml) and washed with water (2 x 100ml) and brine (50ml), dried (Na₂SO₄) and evaporated *in vacuo*. Column chromatography (SiO₂; EtOAc/hexane, 40:60) gave the title compound as a pale yellow gum. Recrystallisation from MeOH/isopropanol gave the title compound as pale yellow needles (5.44g, 66%) m.p, 110-111°. δ H (DMSO-d₆, 390K,) 7.94-7.86 (4H, m, ArH(CO)₂), 7.37 (4H, s, ArH), 4.78 (1H, dd, \downarrow 10.0, 5.4Hz, CH α), 3.71 (3H, s, CO₂Me), 3.29 (1H, dd, \downarrow 14.4, 5.4Hz, CH α H β Ar), 3.11 (1H, dd, \downarrow 14.4, 10.0Hz, CH α H β Ar), 2.72 (3H, s, NMe) and 1.36 (9H, s, ¹Bu); m/z (ESI, 60V) 461 (MNa⁺).

INTERMEDIATE 50**N-Boc-N-methyl-L-4-amino-L-phenylalanine methyl ester**

- Hydrazine monohydrate (366 μ l, 7.54mmol) was added to Intermediate 49 (3.00g, 6.85mmol) in absolute EtOH (70ml). The mixture was stirred overnight at room temperature then refluxed for 4h. After cooling to room temperature, the solid was filtered off and the filtrate evaporated *in vacuo*. DCM was added to the residue, the solid filtered off and the filtrate evaporated *in vacuo*. Column chromatography (SiO₂, EtOAc/hexane, 50:50) gave the title compound (2.04g, 97%) as a colourless oil. δ H (DMSO-d₆, 390K) 6.86 (2H, d, \downarrow 8.4Hz, ArH), 6.53 (2H, d, \downarrow 8.4Hz, ArH), 4.59 (1H, dd, \downarrow 9.9, 5.5Hz, CH α), 4.45 (2H, br s, ArNH₂), 3.66 (3H, s, CO₂Me), 3.04 (1H, dd, \downarrow 14.4, 5.5Hz, CH α H β Ar), 2.86 (1H, dd, \downarrow 14.4, 9.9Hz, CH α H β Ar), 2.67 (3H, s, NMe) and 1.35 (9H, s, ¹Bu); m/z (ESI, 60V) 331 (MNa⁺).

INTERMEDIATE 51**N-Boc-N-methyl-N'-(3,5-dichloro-isonicotinoyl)-L-4-amino phenylalanine methyl ester**

A solution of 3,5-dichloro-isonicotinoyl chloride (1.53g, 7.29mmol) in THF (30ml) was added to a solution of Intermediate 50 (2.04g, 6.62mmol) and NMM (800µl, 7.29mmol) in THF (40ml) at 0°. The mixture was stirred overnight at room temperature and the bulk of the THF removed *in vacuo*. The residue was dissolved in DCM (200ml) and washed with dilute HCl (50ml) and saturated NaHCO₃ (50ml), dried (Na₂SO₄) and evaporated *in vacuo*. Column chromatography (SiO₂, MeOH/CH₂Cl₂ 5:95 to 7:93) gave a white foam. Recrystallisation from EtOAc gave the title compound (2.53g, 80%) as small white crystals m.p. 167-168°. δH (DMSO-d₆, 390K) 10.38 (1H, br s, CONH), 8.67 (2H, s, PyrH), 7.54 (2H, br d, \downarrow 7.4Hz, ArH), 7.22 (2H, d, \downarrow 8.4Hz, ArH), 4.71 (1H, dd, \downarrow 9.9, 5.4Hz, CH α), 3.70 (3H, s, CO₂Me), 3.21 (1H, dd, \downarrow 14.4, 5.4Hz, CH_AH_BAr), 3.02 (1H, dd, \downarrow 14.4, 10.0Hz, CH_AH_BAr), 2.70 (3H, s, NMe) and 1.38 (9H, s, ^tBu); m/z (ESI, 60V) 504 (MNa⁺).

INTERMEDIATE 52**2-Phenyl-D-1,3-thiazolidine-4-carboxylic acid**

A solution of D-cysteine (5g, 28.5mmol) in pyridine (50ml) was treated with benzaldehyde (4.61ml, 45.4mmol) and stirred at 50° for 4h. The mixture was concentrated *in vacuo* and triturated with MeOH to give the title compound as a white solid (4.1g, 69%) (55:45 mixture of diastereoisomers) δH (DMSO-d₆) 7.39 (5H, m), 5.68 (s) and 5.51 (s) together (1H, NCH(Ph)S), 4.24 (t, \downarrow 4.6Hz) and 3.91 (dd, \downarrow 8.4, 7.4Hz) together (1H, CH α), 3.39 (1H, m, CH_AH_BS) and 3.17 (1H, m, CH_AH_BS).

INTERMEDIATE 53**N-Acetyl-2-phenyl-D-1,3-thiazolidine-4-carboxylic acid**

A suspension of Intermediate 52 (3.6g, 17.2mmol) in DMF (50ml) was treated dropwise with acetic anhydride (1.8ml., 18.9mmol) and stirred for 3h at room temperature. The reaction was concentrated *in vacuo* to give a solid that was recrystallised from EtOAc/Et₂O to give the title compound as a single diastereomer (3.30g, 76%) δH (DMSO-d₆, 390K) 7.64 (2H, d, \downarrow 7.1Hz, Ar-H), 7.32 (3H, m, Ar-H), 6.31 (1H, s, NCH(Ph)S), 4.97 (1H, t, \downarrow

6,2Hz, CH α), 3.44 (1H, dd, \downarrow 11.8, 6.8 Hz, CHCH α H β S), 3.26 (1H, dd, \downarrow 11.8, 5.9Hz, CHCH α H β S) and 1.94(3H, s, COMe). m/z (ESI, 60V) 252 (MH $^+$).

5 INTERMEDIATE 54

5-Phenyl-1,3-thiazolidine-4-carboxylic acid

A mixture of β -phenyl-DL-cysteine hydrochloride [HT Nagasawa *et al*, J. Med. Chem (1987) 30, 1373] (1.32g, 5.65mmol) in acetic acid (11ml) and formaldehyde (37wt% aqueous solution, 0.43ml) was heated to 80° to give
10 a cloudy solution that was cooled to 30° and stirred for 2.5h, then stood at room temperature for 16h. The white precipitate was collected by filtration, washed with Et₂O and dried *in vacuo* to give the title compound (1.04g, 88%). δ H (DMSO-d₆) 7.57-7.54 (2H, m, Ar-H), 7.40-7.29 (3H, m, Ar-H), 4.90 (1H, d, CH α -Thioprop), 4.59 (2H, d, \downarrow 9.3Hz, NCH₂S), 4.46 (1H, d, \downarrow
15 9.8Hz, CHPh). m/z (ESI, 60V) 210 (MH $^+$).

INTERMEDIATE 55

N-Acetyl-5-phenyl-1,3-thiazolidine-4-carboxylic acid

Acetic anhydride (0.27g, 0.25ml, 2.6mmol) was added to a solution of
20 Intermediate 54 (0.50g, 2.4mmol) in NMM (0.30g, 0.33ml, 3.0mmol) and DMF (10ml) and stirred for 7h at room temperature. The solvent was removed *in vacuo*, the residue partitioned between DCM and 5% HCl, the organic layer dried (MgSO₄) and concentrated *in vacuo* to give a solid that
25 was recrystallised from EtOAc to afford the title compound as a white solid (0.29g, 48%) δ H (CDCl₃) (two diastereomeric species observed) 7.38-7.26 (5H, m, Ar-H), 5.19 (d, \downarrow 3.8Hz) and 5.08 (d, \downarrow 9.6Hz) together (1H, CH α -thioprop), 4.87 (d, \downarrow 3.8Hz) and 4.60 (d, \downarrow 9.6Hz) together (1H, CHPh), 4.74 (2H, s, NCH₂S), 2.22 (s) and 2.01 (s) together (3H, COMe).

30 INTERMEDIATE 56

1-Thia-3-azaspiro[4.4]nonane-4-carboxylic acid

A mixture of β,β -tetramethylene-DL-cysteine (1.09g, 5.15mmol); [H. T. Nagasawa *et al, ibid*] in acetic acid (10ml) and formaldehyde (37% aqueous solution, 0.39ml) was heated to 80°, cooled to 30° when solution
35 had occurred then stirred at this temperature for 1h. The reaction was concentrated *in vacuo* to give the title compound as a white solid that was

used without further purification (0.72g, 75%). δ H (DMSO- d_6) 4.44 (1H, s, CH α), 4.36 (2H, dd, J 13.6, 9.9Hz, NCH $_2$ S) and 2.33-1.69 (8H, m, CH $_2$).

INTERMEDIATE 57

5 N-Acetyl-1-thia-3-azaspiro[4.4]nonane carboxylic acid

A solution of Intermediate 56 (300mg, 1.60mmol) in DMF (15ml) and acetic anhydride (172mg, 1.69mmol) was stirred overnight at room temperature, concentrated *in vacuo* and partitioned between water (25ml) and DCM (25ml). The organic fraction was dried (MgSO $_4$) and concentrated *in vacuo* to give the title compound as a brown oil (0.31g, 85%) which was used without further purification. δ H (CDCl $_3$) 4.68 (3H, m, CH α and NCH $_2$ S), 2.19 (3H, s, COMe) and 2.17-1.71 (8H,m).

INTERMEDIATE 58

15 3,5-Dichloro-4-hydroxymethyl-pyridine

A solution of 3,5-dichloropyridine-4-carboxaldehyde (1.34g, 7.6mmol) in MeOH (10ml) was treated with NaBH $_4$ (0.29g, 7.6mmol) and stirred at room temperature for 2h. The reaction was quenched with water (5ml) and concentrated *in vacuo*. The residue was partitioned between EtOAc (20ml) and 10% HCl (10ml). The aqueous layer was extracted with EtOAc and the combined organic extracts, washed with 10% NaHCO $_3$ solution, dried (MgSO $_4$) and concentrated *in vacuo* to give the title compound as a white solid (1.05g, 78%). δ H (CDCl $_3$) 8.52 (2H, s, pyr-H), 4.94 (2H, br s, CH $_2$ OH) and 2.28 (1H, br s, OH).

25

INTERMEDIATE 59

3,5-Dichloroisonicotinyl bromide

A solution of Intermediate 58 (0.50g, 2.80mmol) in DCM (10ml) was treated with thionyl bromide (3.51g, 1.32ml, 16.9mmol) and heated to reflux for 3h. The reaction was quenched with 10% NaHCO $_3$ solution (10ml) and extracted with DCM (25ml). The organic layer was dried (MgSO $_4$) and concentrated *in vacuo* to give the title compound as a yellow oil that solidified on standing (0.65g, 96%) and was used without further purification. δ H (CDCl $_3$) 8.50 (2H, s, pyr-H), 4.63 (2H, s, CH $_2$ Br). m/z (ESI, 60V) 242 (MH $^+$).

35

INTERMEDIATE 60**N-Acetyl-D-thiopropine-(O-3,5-dichloroisonicotinoyl)-L-tyrosine methyl ester**

To a slurry of NaH (88mg, 2.2mmol, 60% dispersion) in THF (4ml) was added a solution of N-acetyl-D-thiopropine-L-tyrosine methyl ester (0.70g, 2.0mmol) in DMF (6ml). The reaction was stirred for 20 min at room temperature then a solution of Intermediate 59 (0.65g, 2.7mmol) in THF (6ml) was added and the reaction stirred for 16h, quenched with water (5ml) and concentrated *in vacuo*. The residue was partitioned between water (20ml) and DCM (20ml), the organic layer dried (MgSO₄) and concentrated *in vacuo* to give an oil that was purified by chromatography (SiO₂; EtOAc) to give the title compound as a white solid (0.45g, 44%). δ H (CDCl₃) 8.55 (2H, s, pyr-H), 7.09 (2H, d, \downarrow 8.5Hz, Ar-H), 6.93 (2H, d, \downarrow 8.5Hz, Ar-H), 5.22 (2H, s, OCH₂), 5.04 (1H, m, CH α -Thioprop), 4.80 (1H, m, CH α -tyr), 4.59-4.40 (2H, m, NCH₂S), 3.73 (3H, s, CO₂Me), 3.47-3.03 (4H, m, CHCH₂Ar + CHCH₂S) and 1.73 (3H, s, COMe). m/z (ESI, 60V) 512 (MH⁺).

INTERMEDIATE 61**N-Acetyl-D-thiopropine-(N-benzenesulphonyl)-L-4-aminophenyl alanine methyl ester**

A solution of Intermediate 5 (0.50g, 1.71mmol) in THF (10ml) and triethylamine (0.21g, 0.29ml, 2.05mmol) was treated with benzene sulphonyl chloride (0.30g, 0.22ml, 1.71mmol) and stirred at room temperature for 16h. The mixture was partitioned between EtOAc (20ml) and water (20ml), the organic layer separated and washed with 10% NaHCO₃ solution (20ml), 10% HCl (10ml), and brine (20ml), dried (MgSO₄) and evaporated *in vacuo* to give a foam that was purified by chromatography (SiO₂; 1:99 AcOH/EtOAc) to give the title compound as a white foam (0.63g, 80%). δ H (CDCl₃), (2 rotamers observed) 7.75 (3H, m, Ar-H + NH), 7.54-7.40 (3H, m, Ar-H), 7.00 (4H, m, Ar-H), 5.00 (m) and 4.79-4.65 (m) and 4.56 (d, \downarrow 8.8Hz) and 4.45 (d, \downarrow 8.8Hz) together (4H, 2 x CH α and NCH₂S), 3.73 and 3.66 (together 3H, s, CO₂Me), 3.35-2.94 (4H, m, CH α CH₂Ar and CH α CH₂S), 2.09 and 2.05 (together 3H, s, COMe).

INTERMEDIATE 62**N-Acetyl-D-thiopropine-4-(N-isobutyloxycarbonyl)amino-L-phenylalanine methyl ester**

- To a solution of Intermediate 5 (351mg, 1.0mmol) in DCM (10ml) cooled to 0° was added NMM (121μl, 1.1mmol). After 15min isobutylchloroformate (156μl, 1.2mmol) was added dropwise. The reaction mixture was stirred for a further 15min at 0°, diluted with DCM (10ml) and then washed with aqueous HCl (1M, 10ml), saturated aqueous NaHCO₃ (10ml) and brine (10ml), dried (Na₂SO₄) and evaporated under reduced pressure.
- Purification of the residue by column chromatography (SiO₂; EtOAc/DCM, 1:1) gave the title compound as a white foam (400mg, 89%). δH (CDCl₃) 7.48-6.82 (6H, m, ArH and 2 x NH), 5.00- 4.30 (4H, m, NCH₂S and 2 x α-CH), 3.87 (2H, d, J 6.7Hz, OCH₂), 3.69 (s) and 3.64 (s) together (3H, CO₂CH₃), 3.36-2.87 (4H, m, CH₂Ar and SCH₂CH), 2.10 (s) and 1.81 (s) together (3H, COCH₃), 1.90 (1H, quin, J 6.7Hz, CH₂CH(CH₃)₂) and 0.89 (6H, d, J 6.7Hz, CH(CH₃)₂); m/z (ESI, 60V) 452 (MH⁺).

INTERMEDIATE 63

- N-Acetyl-D-thiopropine-4-(methylthioureido)-L-phenylalanine methyl ester**

- A solution of Intermediate 5 (351mg, 1.0mmol) and methyl isothiocyanate (73mg, 1.0mmol) in Et₂O (10ml) and EtOH (10ml) was refluxed for 18h. The solvents were removed under reduced pressure and the cream foam obtained purified by column chromatography (SiO₂; MeOH/DCM 5:95) to give the title compound as a white foam (401mg, 94%). δH (CDCl₃) 8.47 (s) and 8.21 (s) together (1H, NH), 7.17-6.48 (6H, m, ArH and 2 x NH), 4.88-4.45 (4H, m, NCH₂S and 2 x α-CH), 3.73 (s) and 3.69 (s) together (3H, CO₂CH₃), 3.33-2.92 (7H, m, CH₂Ar, SCH₂CH and CSNHCH₃) and 2.02 (3H, s, COCH₃); m/z (ESI, 60V) 425 (MH⁺).

INTERMEDIATE 64**N-Acetyl-D-thiopropine-4-(t-butylureido)-L-phenylalanine methyl ester**

- To a solution of Intermediate 5 (351mg, 1.0mmol) in acetonitrile (10ml) was added t-butylisocyanate (113μl, 1.0mmol). The reaction mixture was heated to reflux for 24h. The solvent was then removed and the residue

obtained purified by column chromatography (SiO₂; DCM/MeOH, 96:4) to give the title compound as a colourless oil (320mg, 71%). δ H (DMSO-d₆) 8.55 (d, \downarrow 8.0Hz) and 8.26 (d, \downarrow 8.2Hz) together (1H, NH), 8.14 (1H, s, NH), 7.25-6.99 (4H, m, ArH), 5.91 (1H, s, NH), 4.82-4.19 (4H, m, SCH₂N and 2 x α -CH), 3.62 (s) and 3.61 (s) together (3H, CO₂Me), 3.49-2.72 (4H, m, CH₂Ar and SCH₂CH), 2.08 (s) and 2.05 (s) and 1.85 (s) together (3H, COCH₃) and 1.27 (9H, s, C(CH₃)₃); m/z (ESI, 60V) 451 (MH⁺).

INTERMEDIATE 65

10 *N*-Acetyl-*D*-thioproline-4-(isopropylureido)-*L*-phenylalanine methyl ester

To a solution of Intermediate 5 (351mg, 1.0mmol) in DCM (10ml) was added isopropylisocyanate (118 μ l, 1.0mmol). The solution was stirred overnight at room temperature. The resulting white precipitate was
 15 collected and washed with DCM and dried to give the title compound (150mg, 35%). δ H (DMSO-d₆) 8.55 (d, \downarrow 8.1Hz) and 8.26 (d, \downarrow 7.9Hz) together (1H, NH), 8.19 (1H, s, NH), 7.32-7.20 (2H, m, ArH), 7.10-6.99 (2H, m, ArH), 5.92 (1H, d, \downarrow 7.4Hz, NH), 4.82-4.20 (4H, m, NCH₂S and 2 x CH α -H), 3.80-3.68 (1H, m, CH(CH₃)₂), 3.62 (s) and 3.61 (s) together (3H, CO₂Me), 3.25-2.75 (4H, m, CH₂Ar and SCH₂CH), 2.05 (s) and 1.84 (s); together (3H, COCH₃) and 1.08 (6H, d, \downarrow 6.5Hz, CH(CH₃)₂); m/z (ESI, 60V) 437(MH⁺).

INTERMEDIATE 66

25 Methyl 2-azido-3-(4-[2-hydroxyhexafluoroisopropyl]phenyl)prop-2-enoate

To a solution of 4-(2-hydroxyhexafluoroisopropyl)benzaldehyde (1.0g, 3.68mmol) and methyl α -azidoacetate (4.23g, 36.8mmol) in MeOH (50ml) cooled to -78 $^{\circ}$ was added a methanolic sodium methoxide solution (0.5M,
 30 58.8ml, 29.4mmol). The reaction mixture was allowed to warm slowly to room temperature and left stirring overnight. Saturated brine (100ml) was then added and the solution thoroughly extracted with Et₂O. The combined organics were dried (Na₂SO₄) and evaporated under reduced pressure. The solid obtained was triturated with hexane:chloroform and
 35 the solution obtained reduced *in vacuo* to leave the title compound as a pale yellow solid (840mg, 62%) δ H (CDCl₃) 7.88 (2H, d, \downarrow 8.5Hz, ArH),

7.73 (2H, d, \downarrow 8.5Hz, ArH), 6.90 (1H, s, C=CH) and 3.93 (3H, s, CO₂Me); m/z (ESI, 60V) 342 (MH⁺-N₂).

INTERMEDIATE 67

5 4-(2-Hydroxyhexafluoroisopropyl)-DL-phenylalanine methyl ester

A solution of Intermediate 66 (840mg, 2.27mmol) in MeOH (50ml) was degassed thoroughly. Palladium on activated carbon (140mg) was added and the reaction placed under a hydrogen atmosphere (H₂ balloon). The solution was stirred rapidly overnight. DCM (5ml) was added and the catalyst removed by filtration through Celite®. Solvent was evaporated under reduced pressure to give the title compound (600mg, 77%). δ H (CDCl₃) 7.66 (2H, d, \downarrow 8.2Hz, ArH), 7.22 (2H, d, \downarrow 8.2Hz, ArH), 4.05 (2H, br s, NH₂) 3.76 (1H, dd, \downarrow 6.3, 6.3Hz, CH α), 3.67 (3H, s, CO₂Me), 3.10 (1H, dd, \downarrow 13.8, 5.5Hz, CH_AH_B) and 2.98 (1H, dd, \downarrow 13.8 and 7.1Hz, CH_AH_B); m/z (ESI, 60V) 346 (MH⁺).

INTERMEDIATE 68

20 Methyl 4-[(2,6-dichlorophenyl)sulphonyl]methyl}benzoate

2,6-Dichlorobenzenesulphonylchloride (1g, 4.07mmol) was added to a solution of sodium sulphite (1.02g, 8.14mmol) in water (15ml). The solution was made basic with the addition of 10% sodium hydroxide solution. The solution was then heated briefly and then cooled and any remaining solids removed by filtration. The solution was then acidified by the addition of 50% sulphuric acid and the resulting white precipitate collected by filtration and dried to give the sulphinic acid (0.86g, 4.07mmol). The acid (0.86g) was then dissolved in acetonitrile (6ml) and DBU (6.2ml, 4.07mmol) followed by the addition of methyl 4-(bromomethyl) benzoate (1.03g, 4.48mmol). The reaction mixture was stirred overnight at room temperature. Water (50ml) was then added and the mixture extracted with DCM (3 x 25ml). The combined organics were dried (Na₂SO₄) and evaporated under reduced pressure. Purification by column chromatography (SiO₂; DCM) gave the title compound as a white solid (300mg, 21%). δ H (CDCl₃) 7.99-7.89 (2H, m, ArH), 7.43-7.28 (5H, m, ArH), 4.69 (2H, s, CH₂) and 3.87 (3H, s, CO₂Me); m/z (ESI, 60V) 359 (MH⁺).

INTERMEDIATE 69**4-{[(2,6-Dichlorophenyl)sulphonyl]methyl}benzyl alcohol**

- Intermediate 68 (300mg, 0.83mmol) was dissolved in THF (5ml). Lithium aluminium hydride (1M in THF, 0.83ml, 0.83mmol) was added dropwise.
- 5 The resulting orange solution was stirred for 1h at room temperature and then quenched with the dropwise addition of water (15ml). The mixture was extracted with DCM (3x25ml) and the combined organics dried (Na₂SO₄), filtered through a pad of Celite® and evaporated under reduced pressure to give the title compound as a colourless oil (284mg, 100%) δ H (CDCl₃) 7.40-7.20 (7H, m, ArH), 4.72-4.60 (4H, m, CH₂ x 2) and 2.18 (1H, br s, OH); m/z (ESI, 60V) 348 (MNH₄⁺).
- 10

INTERMEDIATE 70**4-{[(2,6-Dichlorophenyl)sulphonyl]methyl}benzyl bromide**

- 15 Intermediate 69 (200mg, 0.58mmol) was dissolved in toluene (5ml) and thionyl bromide (0.5ml) was added. The resulting reaction mixture was stirred for 3h. The volatiles were removed under reduced pressure and the residue azeotroped with toluene (x 2). Purification by column chromatography (SiO₂; DCM/Hexane 1:1) gave the title compound as a colourless oil (180mg, 79%) δ H (CDCl₃) 7.41-7.20 (7H, m, ArH), 4.65 (2H, s, CH₂) and 4.43 (2H, s, CH₂) m/z (ESI, 60V) 412 (MNH₄⁺).
- 20

INTERMEDIATE 71**Ethyl 2 amino-3-(4-{[(2,6-dichlorophenyl)sulphonyl]methyl}propanoate**

- 25 LDA (2M in heptane/THF/ethylbenzene, 2.10ml, 4.19mmol) was added to a stirred solution of *N*-(diphenylmethylene)glycine ether ester (1.07g, 3.99mmol) in THF (40ml) cooled to -78°. The reaction mixture was stirred at this temperature for 40min. A solution of Intermediate 70 (1.5g, 3.81mmol) in THF (20ml) was then added dropwise. The reaction mixture was stirred for a further hour at -78°, then warmed slowly to ambient temperature, and quenched with saturated aqueous NH₄Cl (50ml). Ethyl acetate (75ml) was added and the organic phase separated. The aqueous layer was extracted with EtOAc (x 2) and the combined organics dried (Na₂SO₄) and evaporated under reduced pressure. The residue was then dissolved in EtOH (50ml) and 1M HCl (20ml) was added. After 30min the
- 30
- 35

solvents were removed and the resulting residue partitioned between EtOAc (100ml) and saturated aqueous NaHCO₃. The phases were separated and the aqueous phase extracted with EtOAc (2x). The combined organics were dried (Na₂SO₄) and evaporated under reduced pressure. The resulting oil was purified by column chromatography (SiO₂; EtOAc) to give the title compound as a colourless oil (1.00g, 60%) δ H (CDCl₃) 7.61 (2H, d, \downarrow 8.2Hz, ArH), 7.27 (2H, d, \downarrow 8.2Hz, ArH), 7.22-7.19 (2H, m, ArCl₂H), 7.12 (1H, dd, \downarrow 9.2, 6.5Hz, ArCl₂H), 4.73 (2H, s, SO₂CH₂), 4.10 (2H, q, \downarrow 7.1Hz, CH₂CH₃), 3.65 (1H, dd, \downarrow 7.5, 5.5Hz, CH), 3.06 (1H, dd, \downarrow 13.5, 5.5Hz, CH_AH_B), 2.87 (1H, dd, \downarrow 13.5, 7.5Hz, CH_AH_B), 1.45 (2H, br s, NH₂) and 1.16 (3H, t, \downarrow 7.1Hz, CH₂CH₃); m/z (ESI, 60V) 416 (MH⁺).

INTERMEDIATE 72

Ethyl 2-amino-3-[4-[(2,6-dichlorobenzyl)sulphonyl]phenyl]propanoate
The title compound was prepared in a similar manner to Intermediate 71 from 4-[(2,6-dichlorobenzyl)sulphonyl]benzyl bromide *N*-(diphenylmethylene)glycine ethyl ester. δ H (CDCl₃) 7.38-7.29 (3H, m, ArH), 7.15-7.06 (4H, m, ArH), 4.60 (2H, s, CH₂SO₂), 4.11 (2H, q, \downarrow 7.1Hz, CH₂CH₃), 3.63 (1H, dd, \downarrow 7.7, 5.3Hz, CH), 3.01 (1H, dd, \downarrow 13.5, 5.3Hz, CH_AH_B), 2.80 (1H, dd, \downarrow 13.5, 7.7Hz, CH_AH_B), 1.53 (2H, br sm NH₂) and 1.21 (3H, t, \downarrow 7.12Hz, CH₂CH₃); m/z (ESI, 60V) 416 (MH⁺).

EXAMPLE 1

N-(Pyrid-3-ylacetyl)-*D*-thioprolin-(*N'*-2,6-dichlorobenzoyl)-*L*-4-aminophenylalanine

A solution of Intermediate 4 (1.06g, 1.08mmol) in dioxane/MeOH (1:1, 60ml) and water (30ml) was treated with lithium hydroxide monohydrate (53.0mg, 1.3mmol) and stirred at room temperature for 1.5h. The reaction was acidified to pH 4.5 with glacial acetic acid to give a precipitate which was isolated by filtration, washed with dilute acetic acid and hexane then dried *in vacuo* to give the title compound as a white solid (0.67g, 65%). δ H (DMSO-d₆, 390K) 10.19 (1H, s, CO₂H), 8.43 (2H, m, Ar-H), 7.88 (1H, br s, NH), 7.62-7.41 (6H, m, Ar-H, pyr-H), 7.28 (1H, m, Ar-H), 7.20 (2H, d, \downarrow 8.4Hz, Ar-H), 4.94 (1H, dd, \downarrow 4.1, 7.4Hz, CH _{α} -thiopro), 4.86 (1H, d, \downarrow

9.2Hz, $\text{NCH}_\text{A}\text{H}_\text{BS}$), 4.55 (1H, m, $\text{CH}_\alpha\text{-Ph}$), 4.45 (1H, d, \downarrow 9.2Hz, $\text{NCH}_\text{A}\text{H}_\text{BS}$), 3.74 (2H, m, CH_2pyr) and 3.31-2.96 (4H, m, ArCH_2 , CHCH_2S). m/z (ESI, 30V) 587 (MH^+).

5 EXAMPLE 2

a) *N*-Acetyl-*D*-thioproline-(*N*-3,5-dichloroisonicotinoyl)-*L*-4-aminophenylalanine

A solution of Intermediate 7 (120mg, 0.23mmol) in THF (4ml) and water (3ml) was treated with lithium hydroxide monohydrate (14.4mg, 0.34mmol) and stirred for 2h at room temperature. The reaction was acidified to pH1 with 10% hydrochloric acid and the volatiles were removed *in vacuo*. The solid residue was triturated with water, isolated by filtration and washed with water and dried *in vacuo* to give the title compound as an off-white solid (100mg, 85%). δH (DMSO-d_6 , 390K) 10.41 (1H, s, NH), 8.68 (2H, s, pyr-H), 7.77 (1H, br s, NH), 7.54 (2H, br d, \downarrow 7.9Hz, Ar-H), 7.23 (2H, d, \downarrow 8.4Hz, Ar-H), 4.83 (1H, dd, \downarrow 4.0, 7.4Hz, $\text{CH}_\alpha\text{-Thioprop}$), 4.76 (1H, d, \downarrow 9.2Hz, $\text{NCH}_\text{A}\text{H}_\text{BS}$), 4.54 (1H, dt, \downarrow 5.4, 8.3Hz, $\text{CH}_\alpha\text{-Ph}$), 4.38 (1H, d, \downarrow 9.2Hz, $\text{NCH}_\text{A}\text{H}_\text{BS}$), 3.25 (1H, dd, \downarrow 7.4, 11.5Hz, $\text{CHCH}_\text{A}\text{H}_\text{BS}$), 3.15 (1H, dd, \downarrow 5.4, 14.1Hz, $\text{ArCH}_\text{A}\text{H}_\text{B}$), 3.04-2.92 (2H, m, $\text{CHCH}_\text{A}\text{H}_\text{BS}$ and $\text{ArCH}_\text{A}\text{H}_\text{B}$) and 1.99 (3H, s, COCH_3). m/z (ESI, 70V) 511, (MH^+).

The following compounds were prepared in a similar manner to the compound of Example 2a):

25 b) *N*-Acetyl-*D*-thioproline-*O*-[2-(4-methoxythiophenoxy)pyrimidin-4-yl]-*L*-tyrosine

from Intermediate 47: δH (DMSO-d_6 , 400K) 8.39 (1H, d, \downarrow 5.6Hz, PyH), 7.75 (1H, br d, CONH), 7.41 (2H, d, \downarrow 8.9Hz, ArH), 7.21 (2H, d, \downarrow 8.6Hz, ArH), 7.00 (2H, d, \downarrow 8.6Hz, ArH), 6.92 (2H, d, \downarrow 8.9Hz, ArH), 6.64 (1H, d, \downarrow 5.6Hz, PyrH), 4.83 (1H, dd, \downarrow 7.3, 3.9Hz, $\text{CH}_\text{A}\text{thioprop}$), 4.77 (1H, d, \downarrow 9.2Hz, $\text{NCH}_\text{A}\text{H}_\text{BS}$), 4.57 (1H, dt, \downarrow 8.3, 5.4Hz, $\text{CH}_\text{A}\text{tyr}$), 4.39 (1H, d, \downarrow 9.1Hz, $\text{NCH}_\text{A}\text{H}_\text{BS}$), 3.83 (3H, s, OMe), 3.26 (1H, dd, \downarrow 11.4, 7.4Hz, $\text{CHCH}_\text{A}\text{H}_\text{BS}$), 3.18 (1H, dd, \downarrow 14.1, 5.4Hz, $\text{CHCH}_\text{A}\text{H}_\text{BAr}$), 3.04-2.97 (2H, m, $\text{CHCH}_\text{A}\text{H}_\text{BS}$ + $\text{CHCH}_\text{A}\text{H}_\text{BAr}$) and 1.99 (3H, s, COCH_3) (acid signal not observed at 400K); m/z (ESI, 30V) 555 (MH^+).

- c) *N*-Acetyl-*D*-thiopropine-*O*-(2-chloropyrimidin-4-yl)-*L*-tyrosine
from Intermediate 46 as a white solid δ H (DMSO- d_6 , 400K) 8.56 (1H, d, \downarrow 5.7Hz, PyH), 7.72 (1H, br s, CONH), 7.33 (2H, d, \downarrow 8.7Hz, ArH), 7.13 (2H, d, \downarrow 8.7Hz, ArH), 6.98 (1H, d, \downarrow 5.7Hz, PyH), 4.83 (1H, dd, \downarrow 7.4, 4.0Hz, CH α thiopro), 4.77 (1H, d, \downarrow 9.2Hz, NCH α H β S), 4.56 (1H, br m, CH α tyr), 4.38 (1H, d, \downarrow 9.3Hz, NCH α H β S), 3.29-3.18 (2H, m, 2 x CHCH α H β), 3.07-3.00 (2H, m, 2 x CHCH α H β) and 1.99 (3H, s, COCH $_3$) (acid signal not observed at 400K); m/z (ESI, 15V) 451 (MH $^+$).
- 10 d) *N*-(Pyrid-3-ylacetyl)-*D*-thiopropine-*O*-(2,4,6-trichlorobenzyl)-*L*-tyrosine
from Intermediate 43 as an off-white solid. δ H (DMSO- d_6 , 400K) 8.51 (2H, br s PyH), 7.8 (1H, br d, CONH), 7.65 (1H, d, PyH), 7.61 (2H, s, Cl $_3$ ArH), 7.3 (1H, dd, PyH), 7.16 (2H, d, \downarrow 8.4Hz, ArH), 6.93 (2H, d, \downarrow 8.5Hz, ArH), 5.22 (2H, s, OCH $_2$ Ar), 4.93 (1H, dd, \downarrow 7.4, 4.0Hz, CH α thiopro), 4.86 (1H, d, \downarrow 9.2Hz, NCH α H β S), 4.55 (1H, dt, CH α tyr), 4.44 (1H, d, \downarrow 9.3Hz, NCH α H β S), 3.73 (2H, m, COCH $_2$ Py) and 3.09-2.94 (4H, m, 2x CHCH $_2$) (acid proton not observed at 400K); m/z (ESI) 608 (MH $^+$).
- 20 e) *N*-Acetyl-*D*-thiopropine-4-(2,6-dichlorophenylacetylene)-*L*-phenylalanine
from Intermediate 39 as a white solid. δ H (DMSO- d_6 , 390K) 7.83 (1H, br d, CONH), 7.55-7.48 (3H, m, ArH + Cl $_2$ ArH), 7.40 (1H, dd, \downarrow 8.9, 7.3Hz, Cl $_2$ ArH), 7.32 (2H, d, \downarrow 8.3Hz, ArH), 4.83 (1H, dd, \downarrow 7.3, 3.9Hz, CH α thiopro), 4.77 (1H, d, \downarrow 9.2Hz, NCH α H β S), 4.57 (1H, dt, \downarrow 8.4, 5.3Hz, CH α Ph), 4.38 (1H, d, \downarrow 9.1Hz, NCH α H β S), 3.26 (1H, dd, \downarrow 11.5, 7.4Hz, CHCH α H β S), 3.20 (1H, dd, \downarrow 14.1, 5.3Hz, CHCH α H β Ar), 3.08-2.99 (2H, m, CHCH α H β S + CHCH α H β Ar) and 1.99 (3H, s, COCH $_3$) (acid proton not observed at 390K); m/z (ESI, 15V) 491 (MH $^+$).
- 30 f) *N*-Acetyl-*D*-thiopropine-4-(*N*'-thioacetyl)amino-*L*-phenylalanine
from intermediate 31: δ H (DMSO- d_6) (2 rotamers observed) 11.50 (1H, s, CO $_2$ H), 8.46 (d, \downarrow 8.3Hz) and 8.19 (d, \downarrow 8.3Hz) together (NH), 7.68 (2H, d, \downarrow 8.5Hz, ArH), 7.21 (2H, dd, \downarrow 8.5, 8.5Hz, ArH), 4.85-4.69 (2H, m, NCH $_2$ S), 4.53-4.19 (2H, m, 2 x α CH), 3.31-2.71 (4H, m, CH $_2$ Ar and SCH $_2$ CH), 2.58

(3H, s, CSCH_3) and 2.05 (s) and 1.82 (s) together (3H, COCH_3); m/z (ESI, 60V) 396 (MH^+).

g) N-Acetyl-D-thiopropine-4-(N'-thiobenzoyl)amino-L-phenylalanine

5 from the corresponding methyl ester prepared in a similar manner to Intermediate 31: δH (DMSO-d_6) 8.50 (d, \downarrow 8.1Hz) and 8.22 (d, \downarrow 8.4Hz) together (1H, NH), 7.85-7.72 (4H, m, ArH), 7.56-7.48 (3H, m, ArH), 7.32-7.18 (2H, m, ArH), 4.80-4.65 (2H, m, NCH_2S), 4.52-4.20 (2H, m, 2 x $\text{CH}\alpha$), 3.24-2.73 (4H, m, CH_2Ar and SCH_2CH) and 2.06 (s) and 1.85 (s) together
10 (3H, COCH_3); m/z (ESI, 60V) 458 (MH^+).

h) N-Acetyl-D-thiopropine-4-(t-butylureido)-L-phenylalanine

from Intermediate 64: δH (DMSO-d_6) 8.42-8.05 (2H, m, 2 x NH), 7.28-6.99 (4H, m, ArH), 5.92 (1H, s, NH), 4.83-4.18 (4H, m, NCH_2S and 2 x $\alpha\text{-CH}$),
15 3.22-2.21 (4H, m, CH_2Ar and SCH_2CH) 2.0(s) and 1.84 (s); together (3H, COCH_3) and 1.27 (9H, s, $\text{C}(\text{CH}_3)_3$); m/z (ESI, 60V) 437 (MH^+).

i) N-Acetyl-D-thiopropine-4-(isopropylureido)-L-phenylalanine

from Intermediate 65: δH (DMSO-d_6) 8.39 (d, \downarrow 8.1Hz) and 8.10 (d, \downarrow
20 8.1Hz) together (1H, NH), 8.18 (1H, s, NH), 7.31-7.20 (2H, m, ArH), 7.10-6.98 (2H, m, ArH), 5.92 (1H, d, \downarrow 7.5Hz, NH), 4.83-4.20 (4H, m, NCH_2S and 2 x $\text{CH}\alpha$), 3.82-3.68 (1H, m, $\text{CH}(\text{CH}_3)_2$), 3.22, 2.72 (4H, m, C_2Ar and SCH_2CH), 2.05 (s) and 1.84 (s) together (3H, COCH_3) and 1.08 (6H, d, \downarrow 6.5Hz, $\text{CH}(\text{CH}_3)_2$); m/z (ESI, 60V) 423 (MH^+).

l) N-Acetyl-D-thiopropine-4-(methylthioureido)-L-phenylalanine

from Intermediate 63: δH (DMSO-d_6) 9.48 (1H, br s, NH), 8.48 (d, \downarrow
25 8.3Hz) and 8.11 (d, \downarrow 8.3Hz) together (1H, NH), 7.60 (1H, br s, NH), 7.35-7.10 (4H, m, ArH), 4.82-4.18 (4H, m, NCH_2S and 2 x $\alpha\text{-CH}$), 3.40-2.75
30 (7H, m, CH_2Ar , SCH_2CH and CSNHCH_3) and 2.05 (s) and 1.83 (s) together (3H, COCH_3); m/z (ESI, 60V) 411 (MH^+).

k) N-Acetyl-D-thiopropine-(O-3,5-dichloroisonicotinoyl)-L-tyrosine

from Intermediate 60: δH (DMSO-d_6 , 400K) 8.63 (2H, s, pyr-H), 7.55 (1H,
35 br s, NH), 7.16 (2H, AB d, \downarrow 8.7Hz, Ar-H), 6.93 (2H, AB d, \downarrow 8.7Hz, Ar-H), 5.26 (2H, s, CH_2O), 4.80 (1H, m, $\text{CH}\alpha\text{-thioprop}$), 4.77 (1H, d, \downarrow 9.2Hz,

NCH_AH_BS), 4.41 (1H, m, CH_α-Tyr), 4.36 (1H, d, J 9.2Hz, NCH_AH_BS), 3.23 (1H, dd, J 11.4, 7.4Hz, CHCH_AH_BS), 3.14-2.91 (3H, m, CHCH_AH_BS + CHCH₂Ar) and 1.97 (3H, s, COMe). *m/z* (ESI, 60V) 498 (MH⁺).

5 **l) N-Acetyl-D-thiopropine-4-(N'-isobutyloxycarbonyl)amino-L-phenylalanine**

from Intermediate 62: δH (DMSO-d₆) 9.50 (1H, s, NH), 8.41 (d, J 8.0Hz) and 8.11 (d, J 8.1Hz; together (1H, NH), 7.39-7.29 (2H, m, ArH), 7.15-7.03 (2H, m, ArH), 4.83-4.19 (4H, m, NCH₂S and 2 x α-CH), 3.85 (2H, d, J 6.7Hz, OCH₂), 3.22-2.70 (4H, m, CH₂Ar and SCH₂CH), 2.05 (s) and 1.83 (s); together (3H, COCH₃), 1.91 (1H, quin. J 6.7Hz, CH₂CH(CH₃)₂) and 0.92 (6H, d, J 6.7Hz, CH₂CH(CH₃)₂); *m/z* (ESI, 60V) 438 (MH⁺).

EXAMPLE 3

15 **a) N-(Pyrid-3-ylacetyl)-D-thiopropine-(O-2,4,6-trichlorobenzoyl)-L-tyrosine**

A solution of the methyl esters, Intermediate 11 (0.65g, 1.0mmol) in dioxane/MeOH (1:1, 40ml) and water (20ml) was treated with lithium hydroxide monohydrate (44mg, 1.1mmol). The reaction was stirred at
20 room temperature for 1.5h then glacial acetic acid was added to adjust the pH to 4.5. The solvent was removed *in vacuo* and the residue purified by chromatography [SiO₂; DCM (200), MeOH (20), ethanol (3) and water (2)], to give two products: the title compound (132mg, 21%) and *N*-(pyrid-3-ylacetyl)-*L*-thiopropine-(*O*-2,4,6-trichlorobenzoyl)-*L*-tyrosine (55mg), 9%.
25 (*D*-isomer) δH (DMSO-d₆, 390K) 8.42 (2H, m, pyr-H), 7.89 (1H, br s, NH), 7.77 (2H, s, chloro-Ar-H), 7.61 (1H, d, J 7.7Hz, pyr-H), 7.35 (2H, d, J 8.5Hz, Ar-H), 7.28 (1H, m, pyr-H), 7.18 (2H, d, J 8.5Hz, Ar-H), 4.93 (1H, dd, J 4.0, 7.4Hz, CH_α-thio), 4.86 (1H, d, J 9.2Hz, NCH_ACH_BS), 4.57 (1H, m, CH_α-tyr), 4.46 (1H, d, J 9.2Hz, NC_ACH_BS), 3.72 (2H, m, CH₂-pyr) and
30 3.31-2.99 (4H, m). *m/z* (ESI, 15V) 622, (MH⁺).

L-isomer (DMSO-d₆, 390K) 8.41 (1H, m, pyr-H), 7.87 (1H, br s, NH), 7.77 (2H, s, chloro-Ar-H), 7.59 (1H, d, J 7.8Hz, pyr-H), 7.37 (2H, d, J 8.6Hz, Ar-H), 7.26 (1H, dd, J 4.9, 7.8Hz, pyr-H), 7.17 (2H, d, J 8.6Hz, Ar-H), 4.93 (1H, dd, J 3.8, 7.4Hz, CH_α thiopro), 4.84 (1H, d, J 9.2Hz, NCH_ACH_BS),
35 4.61 (1H, m, CH_αtyr), 4.45 (1H, d, J 9.2Hz, NCH_ACH_BS), 3.69 (2H, m,

CH₂-pyr) and 3.01-2.98 (4H, m, Ar-CH₂ and CHCH₂S). m/z (ESI, 15V) 622 (MH⁺).

The following compounds were prepared in a similar manner from the corresponding methyl ester. Each ester starting material was prepared from intermediate 10 and either 2,6-dimethoxybenzoyl chloride or 2,4-dimethoxybenzoyl chloride in a similar manner to Intermediate 11:

b) N-(Pyrid-3-acetyl)-L-thioprolin-(O-2,6-dimethoxybenzoyl)-L-tyrosine

10 δ H (DMSO-d₆, 390K) 8.43 (2H, m, pyr-H), 7.77 (1H, br s, NH), 7.60 (1H, m, pyr-H), 7.40 (1H, t, \downarrow 8.4Hz Ar(OMe)₂H), 7.29 (3H, m, Ar (OMe)₂H and pyr-H), 7.06 (2H, ABd, \downarrow 8.5Hz, Ar-H), 6.77 (2H, ABd, \downarrow 8.5Hz, Ar-H), 4.95 (1H, dd, \downarrow 7.4, 3.8Hz, CH α -thio), 4.85 (1H, d, \downarrow 9.3Hz, NCH_AH_BS), 4.58 (1H, m, CH α -tyr), 4.45 (1H, d, \downarrow 9.3Hz, NCH_AH_BS), 3.87 (6H, s OMe), 3.72 (2H, m, CH₂CO), 3.33 (1H, dd, J 11.6, 7.4Hz, CHCH_AH_BS), 3.18 (1H, dd, \downarrow 14.2, 5.4Hz, CH_AH_BAr), 3.15 (1H, dd, \downarrow 11.6, 3.8Hz, CHCH_AH_BS) and 3.04 (1H, dd, \downarrow 14.2, 8.0Hz, CH_AH_BAr). m/z (ES⁺, 70V), 580 (MH⁺).

c) N-(Pyrid-3-acetyl)-D-thioprolin-(O-2,4-dimethoxybenzoyl)-L-tyrosine

20 δ H (DMSO-d₆, 390K) 8.43 (2H, m, pyr-H), 7.83 (1H, br s, NH), 7.62 (1H, m, pyr-H), 7.41 (1H, t, \downarrow 8.4Hz, Ar(OMe)₂-H), 7.30 (3H, m, Ar(OMe)₂-H, pyr-H), 7.09 (2H, ABd, \downarrow 8.5Hz, Ar-H), 6.77 (2H, ABd, \downarrow 8.5Hz, Ar-H), 4.95 (1H, dd, \downarrow 7.4, 4.0Hz, CH α -Thiopro), 4.87 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 25 4.57 (1H, m, CH α -tyr), 4.46 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 3.87 (6H, s, OMe), 3.79-3.67 (2H, m, CH₂O), 3.29 (1H, dd, \downarrow 11.6, 7.4Hz, CHCH_AH_BS), 3.06-3.00 (2H, m, CHCH_AH_BS) and CHCH_AH_BAr, m/z (ES⁺, 70V), 580 (MH⁺).

30 EXAMPLE 4

N-Acetyl-D-thioprolin-(O-pyrimidin-2-yl)-L-tyrosine

Lithium hydroxide (51mg, 1.2mmol) was added to a solution of Intermediate 14 (470mg, 1.09mmol) in a mixture of THF (10ml) and water (10ml). The mixture was stirred at room temperature for 30min, then the 35 THF was evaporated *in vacuo*. The aqueous residue was acidified (1M, hydrochloric acid) and the precipitate obtained filtered off, washed with

water and dried to give the title compound as a white powdery solid (269mg, 59%). δ H (DMSO- d_6 , 400K) 8.60 (2H, d, \downarrow 4.8Hz, 2 x HetArH), 7.74 ((1H, br d, CONH), 7.26 (2H, d, \downarrow 8.7Hz, CH₂ArH), 7.20 (1H, t, \downarrow 4.7Hz, HetArH), 7.08 (2H, d, \downarrow 8.7Hz, CH₂ArH), 4.83 (1H, dd, \downarrow 4.1, 7.3Hz, CH α thioprop), 4.78 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 4.57 (1H, dt, \downarrow 5.4, 8.3Hz, CH α tyr), 4.38 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 3.25 (1H, dd, \downarrow 7.4, 11.6Hz, CHCH_AH_BS), 3.18 (1H, dd, \downarrow 5.4, 14.1Hz, CH_AH_BAr), 3.04-2.97 (2H, m, CHCH_AH_BS + CH_AH_BAr) and 2.00 (3H, s, CH₃CO); m/z (ESI, 27V) 417 (MH⁺).

EXAMPLE 5

N-(Pyrid-3-ylacetyl)-D-thiopropine-(O-2,6-dichlorobenzoyl)-L-tyrosine

Lithium hydroxide monohydrate (6mg, 0.14mmol) was added to an ice-bath cooled solution of Intermediate 15 (100mg, 0.17mmol) in dioxane (4ml), methanol (2ml), and water (3ml). The cooling bath was removed and the reaction mixture stirred at room temperature for 1h. The pH was made slightly acidic by addition of two drops of acetic acid and the solvent removed *in vacuo*. The obtained solid was chromatographed [SiO₂; DCM (002), MeOH (2), ethanol (3), H₂O (2)] which yielded a colourless oil. This was dissolved in a small volume of methanol, diluted with water, and freeze-dried to afford the title compound as a white amorphous solid (60mg, 68%): δ H (DMSO- d_6 , 400K), 8.45-8.40 (2H, m, pyrH), 7.83 (1H, br s, NH), 7.63-7.52 (4H, m, Ar(Cl)H and pyrH), 7.34 (2H, d, \downarrow 8.6Hz, ArH), 7.26 (2H, dd, \downarrow 4.7, 7.7Hz, pyrH), 7.17 (1H, d, \downarrow 8.6Hz, ArH), 4.94 (1H, dd, \downarrow 7.4, 4Hz, CH α thioprop), 4.86 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 4.58-4.49 (1H, m, CH α tyr), 4.45 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 3.76 (1H, d, \downarrow 16Hz, CH_AH_Bpyr), 3.66 (1H, d, \downarrow 16Hz, NCH_AH_Bpyr), 3.28 (1H, dd, \downarrow 7.4, 11.6Hz, CHCH_AH_BS), 3.20 (1H, dd, \downarrow 5.5, 14Hz, CH_AH_BAr), 3.08-3.01 (2H, m, CHCH_AH_BS and CH_AH_BAr); m/z (ESI, 27V) 588 (MH⁺).

EXAMPLE 6

N-Acetyl-D-thiopropine-(N'-2,6-dichlorobenzoyl)-L-4-aminophenyl-alanine

Intermediate 16 (165mg, 0.31mmol) was treated with a solution of lithium hydroxide monohydrate (16mg, 0.38mmol) in dioxane (2ml), MeOH(2ml), and water (3ml) for 3h at room temperature. The pH was made slightly

acidic with a few drops of acetic acid and the solvent removed *in vacuo*. The residue was treated with water and the obtained solid was collected by filtration with further water washing. The title compound was isolated as a white powder (120mg, 75%) after drying *in vacuo* (50°, overnight):

5 δ H (DMSO- d_6 , 400K), 10.13 (1H, br s, ArNHCO), 7.69 (1H, br d, \downarrow ~8Hz, NHCO), 7.52 (1H, br d, \downarrow ~8Hz), 7.52-7.41 (3H, m, Ar(Cl)H), 7.19 (1H, d, \downarrow 8.4Hz, ArH), 4.84 (1H, dd, \downarrow 3.9, 7.4Hz, CH α -thioprop), 4.77 (1H, d, \downarrow 9.2Hz, NCH α H β S), 4.54 (1H, ddd, \downarrow 5.5, 8.1, 8.2Hz, CH α -tyr), 4.38 (1H, d, \downarrow 9.2Hz, NCH α H β S), 3.25 (1H, dd, \downarrow 7.4, 11.5HzCHCH α H β S), 3.12 (1H,

10 dd, \downarrow 5.5, 14.1Hz, CH α H β Ar), 3.01 (1H, dd, \downarrow 3.9, 11.5Hz, CHCH α H β S), 2.97 (1H, dd, \downarrow 8.2, 14.1Hz, CH α H β Ar) and 1.99 (3H, s, COCH $_3$); m/z (ESI, 27V) 510 (MH $^+$).

EXAMPLE 7

15 N-(Pyrid-3-ylacetyl)-D-thiopropine-(O-benzyl)-L-tyrosine

Intermediate 19 (190mg, 0.37mmol) was treated with a solution of lithium hydroxide monohydrate (19mg, 0.54mmol) in dioxane (2ml), MeOH (2ml) and water (2ml) at room temperature for 2.5h. The pH was made slightly acidic by addition of a few drops of acetic acid and the solvent removed *in*

20 *vacuo*. The obtained solid was treated with water and collected by filtration with further water washing. After drying *in vacuo* (50°, overnight) the title compound was obtained as a white amorphous solid (105mg, 57%). δ H (DMSO- d_6 , 400K), 8.46-8.40 (2H, m, pyr H), 7.75 (1H, br d, \downarrow 6.0Hz, NH), 7.61 (1H, d, \downarrow 7.9Hz, pyrH), 7.44-7.27 (6H, m, ArH and pyrH),

25 7.13 (2H, d, \downarrow 8.6Hz, ArH), 6.89 (2H, d, \downarrow 8.6Hz, ArH), 5.06 (2H, s, CH $_2$ O), 4.92 (1H, dd, \downarrow 7.4, 4.0Hz, CH α thioprop), 4.86 (1H, d, \downarrow 9.2Hz, NCH α H β S), 4.53 (1H, ddd, \downarrow 8.3, 8.1, 5.5Hz, CH α tyr), 4.43 (1H, d, \downarrow 9.2Hz, NCH α H β S), 3.75 (1H, d, \downarrow 16.1Hz, CH α H β pyr), 3.66 (1H, d, \downarrow 16.1Hz, CH α H β pyr), 3.27 (1H, dd, \downarrow 11.6, 7.4Hz, CHCH α H β S), 3.12-2.88 (3H, m,

30 CHCH α H β S and (CH $_2$ Ar); m/z (ESI), 506 (MH $^+$).

EXAMPLE 8

N-Acetyl-D-thiopropine-(N'-3,5-dichlorobenzoyl)-L-4-aminophenylalanine

35 Intermediate 5 was reacted with 3,5-dichlorobenzoyl chloride in a similar manner to that described for Intermediate 16. Subsequent hydrolysis as

described for the compound of Example 2, afforded the title compound as a white powder (925mg). δ H (DMSO- d_6) (1:1 mixture of rotamers) 10.36 (1H, s), 8.44 and 8.13 (1H, d, \downarrow 7.0Hz), 7.97 (2H, d, \downarrow 1.9Hz), 7.85 (1H, t, \downarrow 1.9Hz), 7.65 (2H, app.d, \downarrow 7.0Hz), 7.20 (2H, app.t, \downarrow 9.0Hz), 4.82-4.75 (1H, m), 4.73 (H, app.t, \downarrow 8.4Hz), 4.50-4.36 (1H, m), 4.46 (0.5H, d, \downarrow 8.9Hz), 4.25 (0.5H, d, \downarrow 8.9Hz), 3.30-2.85 (4H, m's), 2.06 and 1.85 (3H, s); m/z (ESI, 60V) 510 (MH⁺).

EXAMPLE 9

10 *N*-Acetyl-*D*-thioproline-[*N'*-2-fluoro-6-(trifluoromethyl)benzoyl]-*L*-4-aminophenylalanine

Intermediate 5 was reacted with 2-fluoro-6-(trifluoromethyl)benzoyl chloride in a similar manner to that described for Intermediate 16. Subsequent hydrolysis as described for the compound of Example 2, 15 afforded the title compound as a white powder (650mg). δ H (DMSO- d_6 , 400K), 10.18 (1H, s), 7.75-7.53 (4H, m), 7.51 (2H, d, \downarrow 8.4Hz), 7.19 (2H, d, \downarrow 8.4Hz), 4.83 (1H, dd, \downarrow 7.3, 3.9Hz), 4.77 (1H, d, \downarrow 9.2Hz), 4.57-4.50 (1H, m), 4.38 (1H, d, \downarrow 9.2Hz), 3.25 (1H, dd, \downarrow 11.6, 7.4Hz), 3.12 (1H, dd, \downarrow 14.1, 5.3Hz), 3.04 (1H, dd, \downarrow 11.6, 3.9Hz), 2.98 (1H, dd, \downarrow 14.1, 8.1Hz) and 20 1.99 (3H, s); m/z (ESI, 60V) 528 (MH⁺).

EXAMPLE 10

N-Acetyl-*D*-thioproline-(*N'*-2,4,6-trichlorobenzoyl)-*L*-4-aminophenylalanine

25 Intermediate 5 was reacted with 2,4,6-trichlorobenzoyl chloride in a similar manner to that described for Intermediate 16. Subsequent hydrolysis, as described for the compound of Example 2, afforded the title compound as a white powder (950mg). δ H (DMSO- d_6 , 1:1 mixtures of rotamers), 10.68 (1H, s), 8.46 and 8.15 (1H, d, \downarrow 8.0Hz), 7.82 (2H, s), 7.55 (2H, approximate d, \downarrow 7.0Hz), 7.19 (2H, approximate t, \downarrow 9.0Hz), 4.80-4.68 (2H, m), 4.46 (1H, d, \downarrow 9.0Hz), 4.46-4.35 (1H, m), 4.23 (1H, d, \downarrow 9.0Hz), 3.35-2.76 (4H, m), 2.05 and 1.84 (3H, s); m/z (ESI, 60V) 544 (MH⁺).

EXAMPLE 11**N-Acetyl-D-thiopropine-(N'-2,6-dichlorobenzyl)-L-4-aminophenyl alanine**

Intermediate 21 was hydrolysed and purified in a similar manner to that described for the compound of Example 5. Freeze-drying afforded the title compound as a white amorphous solid (206mg). δ H (DMSO-d₆, 390K), 7.62 (1H, br d, \downarrow 7.0Hz), 7.44 (2H, app.d, \downarrow 7.0Hz), 7.32 (1H, app.t, \downarrow 8.0Hz), 6.95 (2H, d, \downarrow 8.6Hz), 6.66 (2H, d, \downarrow 8.6Hz), 4.81 (1H, dd, \downarrow 7.4, 4.0Hz), 4.76 (1H, d, \downarrow 9.2Hz), 4.47 (2H, s), 4.46 (2H, m), 4.36 (1H, d, \downarrow 9.2Hz), 3.24 (1H, dd, \downarrow 11.5, 7.4Hz), 3.03-2.95 (2H, m), 2.83 (1H, dd, \downarrow 14.1, 8.1Hz) and 1.98 (3H, s); m/z (ESI, 30V) 496 (MH⁺).

EXAMPLE 12**N-Acetyl-D-thiopropine-(N'-acetyl-N'-2,6-dichlorobenzyl)-L-4-aminophenylalanine**

Intermediate 21 was N-acetylated with acetic anhydride in DCM and subsequently hydrolysed and purified in a similar manner to that described for the compound of Example 5. Freeze-drying afforded the title compound as a white amorphous powder (120mg). δ H (DMSO-d₆, 390K), 7.71 (1H, br d, \downarrow 8.0Hz), 7.28 (2H, app.d \downarrow 7.0Hz), 7.22 (2H, app.t, \downarrow 7.0Hz), 7.15 (2H, d, \downarrow 8.3Hz), 6.94 (2H, d, \downarrow 8.3Hz), 5.18 (2H, s), 4.79-4.75 (1H, m), 4.77 (1H, d, \downarrow 9.2Hz), 4.45 (1H, sym.m), 4.33 (1H, d, \downarrow 9.2Hz), 3.21 (1H, dd, \downarrow 11.4, 7.3Hz), 3.09 (1H, dd, \downarrow 14.1, 5.1Hz), 2.95-2.86 (2H, m) 1.97(3H, s) and 1.75 (3H, s); m/z (ESI, 30V) 538 (MH⁺).

EXAMPLE 13**N-Acetyl-D-thiopropine -(N'-2,4,6-trichlorobenzyl)-L-4-aminophenylalanine.**

Intermediate 5 was reacted with 2,4,6-trichlorobenzyl bromide in a similar manner to that described for Intermediate 21. Subsequent hydrolysis and purification as described for the compound of Example 5, followed by freeze drying afforded the title compound as a white amorphous solid (265mg). δ H (DMSO-d₆, 1:1 ratio of rotamers) 8.33 (0.5H, d, \downarrow 8.0Hz), 8.04 (0.5H, d, \downarrow 8.0Hz), 7.69 (2H, s), 6.93 (2H, app.t, \downarrow 8.0Hz), 6.57 (2H, app.d, \downarrow 8.0Hz), 5.62 (1H, br s), 4.82-4.68 (2H, m), 4.45 (0.5H, d, \downarrow 8.7Hz), 4.43-4.30 (1H, m), 4.31 (2H, s), 4.22 (0.5H, d, \downarrow 9.6Hz), 3.29 (0.5H, dd, \downarrow

11.7, 7.3Hz), 3.12 (0.5H, dd, \downarrow 11.4, 7.3Hz), 3.00-2.69 (3H, m), 2.05 (1.5H, s) and 1.84 (1.5H, s); m/z (ESI, 60V) 530 (MH⁺).

EXAMPLE 14

5 **N-Acetyl-D-thiopropine-(N'-2,6-dichlorobenzenesulphonyl)-L-4-aminophenylalanine**

Intermediate 5 was reacted with 2,6-dichlorobenzenesulphonyl chloride in a similar manner to that described for Intermediate 2. The crude product was chromatographed (silica; EtOAc) to purity then hydrolysed with
10 aqueous LiOH (as described for the compound of Example 5). Chromatography [silica; DCM (200), (MeOH (20), AcOH (3), H₂O (2))] and freeze-drying afforded the title compound as a white amorphous solid (270mg). δ H (DMSO-d₆, 400K) 7.62 (1H, br d, \downarrow 8.0Hz), 7.54 (2H, app.d, \downarrow 7.7Hz), 7.47 (1H, app.t, \downarrow 7.7Hz), 7.08 (2H, d, \downarrow (8.9Hz), 7.03 (2H, d, \downarrow 8.9Hz),
15 4.80-4.73 (1H, m), 4.74 (1H, d, \downarrow 9.2Hz), 4.47 (1H, m), 4.33 (1H, d, \downarrow 9.2Hz), 3.18 (1H, dd, \downarrow 11.5, 7.4Hz), 3.05 (1H, dd, \downarrow 14.2, 5.3Hz), 2.96-2.84 (2H, m) and 1.95 (3H, s); m/z (ESI, 60V) 546 (MH⁺).

EXAMPLE 15

20 **N-Acetyl-D-thiopropine-4-(2-methoxyphenylureido)-L-phenylalanine**

A solution of Intermediate 5 (500mg, 1.42mmol) and 2-methoxyphenyl isocyanate (233mg, 208 μ l, 1.56mmol) in dry DCM (10ml) was stirred under N₂ at room temperature for 2h. The volatiles were removed *in vacuo* and the residue suspended in Et₂O. The obtained solid was filtered off with
25 10% aqueous HCl and Et₂O washing and sucked dry. This intermediate (560mg, 1.12mmol) was treated with LiOH.H₂O (56mg, 1.33mmol) in dioxan (5ml), methanol (3ml) and water (5ml) at room temperature for 2h. A few drops of AcOH were added and the volatiles removed *in vacuo*. The residue was treated with Et₂O and water and filtered off with water
30 washing to afford the title compound as an off-white powder (325mg). δ H (DMSO-d₆, a 1:1 ratio of rotameric species) 9.28 (1H, s), 8.31 and 8.02 (1H, d, \downarrow 7.8Hz), 8.21 (1H, s), 8.11 (1H, d, \downarrow 7.6Hz), 7.40-7.28 (2H, m), 7.18-7.03 (2H, m), 7.02-6.86 (3H, m), 4.86-4.70 (2H, m), 4.46 (0.5H, d, \downarrow 8.8Hz), 4.43-4.31 (1H, m), 4.22 (0.5H, d, \downarrow 9.4Hz), 3.86 (3H, s), 3.37-2.78
35 (4H, m), 2.05 and 1.84 (3H, s); m/z (ESI, 60V) 487 (MH⁺).

EXAMPLE 16**a) N-(Pyrid-4-oyl)-D-thioprolin-(O-benzyl)-L-tyrosine**

Intermediate 18 was coupled to isonicotinic acid in a similar manner to that described for Intermediate 19, and subsequently hydrolysed with aqueous
 5 LiOH in a similar manner to that described for the compound of Example 2a) to afford the title compound as a white solid (175mg). δ H (DMSO- d_6 , 400K), 8.65 (2H, d, \downarrow 6.1Hz), 7.78 (1H, d, \downarrow 8.0Hz), 7.45-7.25 (5H, m), 5.35 (2H, d, \downarrow 6.1Hz), 7.13 (2H, d, \downarrow 8.6Hz), 6.90 (2H, d, \downarrow 8.6Hz), 5.06 (2H, s), 4.86-4.73 (1H, m), 4.73 (1H, d, \downarrow 9.5Hz), 4.56-4.48 (1H, m), 4.46 (1H, d, \downarrow
 10 9.4Hz), 3.29 (1H, dd, \downarrow 11.8, 7.4Hz) and 3.12-2.86 (3H, ms); m/z (ESI, 60V) 492 (MH⁺).

The following compounds of Examples 16 b) - g) were prepared in a similar manner from Intermediate 18 and the appropriate acid:

15

b) N-(Pyrid-2-acetyl)-D-thioprolin-(O-benzyl)-L-tyrosine

δ H (DMSO- d_6) 8.45 (2H, d, \downarrow 4.8Hz), 7.72-7.67 (2H, m), 7.42-7.19 (7H, m), 7.12 (2H, d, \downarrow 8.5Hz), 6.88 (2H, d, \downarrow 8.5Hz), 5.05 (2H, s, CH₂O), 5.02-4.96 (1H, m, CH α -thiopro), 4.87 (1H, d, \downarrow 9.0Hz, NCH_AH_BS), 4.57-4.51 (1H, m, CH α -tyr), 4.39 (1H, d, \downarrow 9.0Hz, NCH_AH_BS), 3.85 (2H, m, CH₂pyr, 3.26-3.20 (1H, m, CHCH_AH_BS), 3.09-3.03 (2H, m, CHCH_AH_BS + CH_AH_BAr) and 2.94-2.86 (1H, m, CH_AH_BAr). m/z (ESI, 27V) 506 (MH⁺).

20

c) N-(Pyrid-4-acetyl)-D-thioprolin-(O-benzyl)-L-tyrosine

25 δ H (DMSO- d_6) 8.46 (2H, dd), 7.77 (1H, br s), 7.43-7.29 (5H, m), 7.20 (2H, d), 7.13 (2H, d), 6.90 (2H, d), 5.05 (2H, s, CH₂O), 4.92-4.88 (1H, m), 4.42 (1H, d), 3.78-3.68 (2H, m), 3.28-3.22 (1H, m) and 3.09-2.87 (4H, m). m/z (ESI, 60V), 506 (MH⁺).

d) N-(Indolyl-3-acetyl)-D-thioprolin-(O-benzyl)-L-tyrosine

30 δ H (DMSO- d_6 , 400K) 10.51 (1H, br s, NH), 7.72 (1H, br d), 7.54 (1H, d, \downarrow 7.9Hz), 7.36 (6H, m), 7.18 (1H, d, \downarrow 2.3Hz), 7.11 (2H, d, \downarrow 8.6Hz), 7.07 (1H, m), 6.97 (1H, m), 6.89 (2H, d, \downarrow 8.6Hz), 5.05 (2H, s, CH₂O), 4.95 (1H, dd, \downarrow 7.4, 4.0Hz, CH α -thiopro), 4.87 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 4.51 (1H,
 35 m, CH α -tyr), 4.43 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 3.24 (2H, d, \downarrow 8.2Hz,

CHCH₂Ar), 3.19 (2H, dd, \downarrow 11.5, 7.4Hz, CHCH₂S) and 2.99 (2H, m, CH₂CO). m/z (ESI, 60V) 544 (MH⁺).

e) N-(Benzothiophenyl-3-acetyl)-D-thiopropine-(O-benzyl)-L-tyrosine

5 δ H (DMSO-d₆, 390K) 7.92 (1H, m), 7.80 (2H, m), 7.48 (1H, s), 7.37 (6H, m), 7.13 (2H, d, \downarrow 8.6Hz, Ar-H), 6.89 (2H, d, \downarrow 8.6Hz, Ar-H), 5.04 (2H, s, CH₂O), 4.97 (1H, dd, \downarrow 7.4, 4.0Hz, CH α -thiopro), 4.88 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 4.52 (1H, m, CH α -tyr), 4.48 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 3.94 (2H, m, CHCH₂Ar), 3.27 (1H, dd, \downarrow 11.5, 7.4Hz, CH_AH_BS) and 3.03 (3H, m, CH_AH_BS and CH₂CO). m/z (ESI, 60V) 561 (MH⁺).

f) N-(Pyrid-3-propionyl)-D-thiopropine-(O-benzyl)-L-tyrosine

15 δ H (DMSO-d₆) 8.46 (1H, d, 8.37 (1H, d, \downarrow 3.4Hz), 7.60 (1H, d, \downarrow 7.8Hz), 7.71 (1H, d, NH), 7.42-7.21 (6H, m), 7.12 (2H, d, \downarrow 8.6Hz), 6.89 (2H, d, \downarrow 8.6Hz), 5.06 (2H, s, CH₂O), 4.88-4.74 (1H, m, CH α -thiopro), 4.79 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 4.52 (1H, m, CH α -Tyr), 4.38 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 3.24-3.17 (1H, m), 3.10-2.85 (5H, m) and 2.68 (2H, m). m/z (ESI, 60V) 520 (MH⁺).

g) N-(Thiophen-3-acetyl)-D-thiopropine-(O-benzyl)-L-tyrosine

20 δ H (DMSO-d₆) 7.74 (1H, d), 7.44-7.22 (6H, m), 7.21 (1H, d, \downarrow 1.1Hz), 7.15-7.10 (2H, m), 7.01-6.99 (1H, m), 6.92-6.88 (2H, m), 5.06 (2H, s, CH₂O), 4.91 (1H, m, CH α -Thiopro), 4.88 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 4.55-4.47 (1H, m, CH α -tyr), 4.39 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 3.75-3.60 (2H, m), 25 3.25-3.19 (1H, m) and 3.11-2.87 (3H, m). m/z (ESI, 60V) 511 (MH⁺).

EXAMPLE 17

N-(4-Imidazoleacetyl)-D-thiopropine-(O-2,6-dichlorobenzyl)-L-tyrosine

30 *D*-Thiopropine-(*O*-2,6-dichlorobenzyl)-*L*-tyrosine methyl ester (prepared in a similar manner to Intermediate 18) was coupled to 1-trityl-4-imidazoleacetic acid in a similar manner to that described for Intermediate 19. Subsequent trityl removal (triethylsilane, TFA, DCM) and hydrolysis (aqueous LiOH; as described for the compound of Example 7) afforded the title compound as a white powder (235mg). δ H (DMSO-d₆, 390K) 8.1 35 (1H, very br s), 7.96 (1H, br d, \downarrow 8.0Hz), 7.52-7.48 (3H, m), 7.46-7.40 (2H, m), 7.15 (2H, d, \downarrow 8.4Hz), 6.94 (2H, d, \downarrow 8.4Hz), 6.89 (2H, s), 5.25 (2H, s),

5.01 (1H, dd, \downarrow 7.3, 3.7Hz), 4.86 (1H, d, \downarrow 9.0Hz), 4.58-4.47 (1H, m), 4.38 (1H, d, \downarrow 9.0Hz), 3.69 (1H, d, \downarrow 15.7Hz), 3.56 (1H, d, \downarrow 15.7Hz), 3.20 (1H, dd, \downarrow 11.4, 7.3Hz), 3.11-2.99 (2H, m) and 2.91 (1H, dd, \downarrow 14.0, 8.4Hz); m/z (ESI, 60V) 561 (MH⁺).

5

EXAMPLE 18**N-(Pyrid-3-oyl)-D-thiopropine-(O-benzyl)-L-tyrosine**

Intermediate 18 was coupled to nicotinic acid in a similar manner to that described for Intermediate 19, and subsequently hydrolysed with aqueous LiOH, as described for the compound of Example 7, to afford the title compound. δ H (DMSO-d₆) 8.78-8.55 (2H, br m), 8.38 (1H, br d \downarrow 7.8Hz), 8.21-7.25 (7H, m), 7.11 (2H, d, \downarrow 8.5Hz), 6.85 (2H, br d, \downarrow 8.0Hz), 5.02 (2H, s), 5.03-4.3 (4H, m), 3.40-3.22 (1H, br m), 3.03 (1H, dd, \downarrow 13.8, 4.6Hz) and 2.90-2.75 (2H, m); m/z (ESI), 492 (MH⁺).

15

EXAMPLE 19**N-Acetyl-D-thiopropine-L-4-benzoylphenylalanine**

Intermediate 20 (503mg, 1.14mmol) was treated with a solution of LiOH. H₂O(1.38mmol) in 50% aqueous dioxane (20ml) at room temperature for 2h. The pH was adjusted to 3 with concentrated HCl and the volatiles removed *in vacuo*. The residue was chromatographed [silica; DCM (200), MeOH (20), AcOH (3), H₂O (2)] to afford the product as a colourless oil. Freeze-drying from aqueous methanol afforded the title compound as a white amorphous solid: δ H (DMSO-d₆ approximately 1.6:1 ratio of rotameric species) 7.79-7.69(4H, m), 7.68-7.61 (1H, m), 7.58-7.48 (2H, m), 7.45-7.36 (2H, m), 4.85-4.68 (3H, m), 4.57-4.42 (1H, d, \downarrow 9.0Hz), 3.48-3.08 (3H, ms), 2.98 and 2.89 (1H, dd, \downarrow 11.9, 4.0Hz, 2.14 and 1.92 (3H, s); m/z (ESI, 27V) 427 (MH⁺).

EXAMPLE 20**N-(N-Acetyl-D-5,5-dimethyl-1,3-thiazolidin-4-oyl)-(O-benzyl)-L-tyrosine**

Intermediate 22 (340mg, 0.72mmol) was treated with a solution of LiOH. H₂O (36mg, 0.86mmol) in MeOH (2ml), dioxane (2ml) and H₂O (3ml) at room temperature for 1.5h. A few drops of acetic acid were added and the volatiles were removed *in vacuo*. The crude product was

chromatographed [silica; DCM (200), MeOH (20), AcOH (3), H₂O (2)] to afford the product as a colourless oil. Freeze-drying from aqueous methanol afforded the title compound as a white amorphous solid (240mg, 73%). δ H (DMSO-d₆, approximate 1.3:1 ratio of rotamers) 8.29 (1H major, d, \downarrow 8.4Hz), 8.06 (1H minor, d, \downarrow 8.0Hz), 7.44-7.28 (5H, m), 7.20-7.10 (2H, m), 6.93-6.85 (2H, m), 5.07 (2H major, s), 5.06 (2H minor, s), 4.73 (1H minor, d, \downarrow 8.7Hz), 4.70 (1H minor, d, \downarrow 8.7Hz), 4.63 (1H major d, \downarrow 9.8Hz), 4.55 (1H major, d, \downarrow 9.8Hz), 4.50-4.24 (2H, m's), 3.09 (1H major, dd, \downarrow 13.9, 4.1Hz), 2.96 (1H minor, dd, \downarrow 13.9, 5.1Hz), 2.85-2.75 (1H, m), 2.03 (3H minor, s), 1.81 (3H major, s) and 1.35, 1.00 and 0.91 (6H, singlets); m/z (ESI, 60V) 457 (MH⁺).

EXAMPLE 21

N-Acetyl-D,L-homothioproline-(O-2,6-dichlorobenzyl)-L-tyrosine

15 N-Acetyl-D,L-homothioproline (prepared via (1) bromopyruvate, 2-aminoethanethiol hydrochloride, EtOH; (2) NaBH₄, EtOH; (3) acetic anhydride, DCM; (4) LiOH, aqueous EtOH) was coupled to O-(2,6-dichlorobenzyl)-L-tyrosine methyl ester hydrochloride in a similar manner to that described for Intermediate 19, affording the methyl ester of the title compound. Subsequent hydrolysis with aqueous LiOH and purification, similar to that described for the compound of Example 5, afforded the title compound as a white amorphous solid (850mg). δ H (DMSO-d₆, 390K, mixture of diastereoisomers) 7.49 (2H, approximate d, \downarrow 8.7Hz), 7.45 (1H, br s), 7.43 (1H, approximate t, \downarrow 8.7Hz), 7.19 and 7.17 (2H, d, \downarrow 8.7Hz), 6.95 and 6.94 (2H, d, \downarrow 8.7Hz), 5.25 (2H, s), 5.02 (1H, br m), 4.60-4.52 (1H, m), 4.23-4.02 (1H, br m), 3.45-2.92 (4H, m), 2.81 and 2.77 (1H, d, \downarrow 4.7Hz) and 2.70-2.41 (2H, m); m/z (ESI, 60V) 511 (MH⁺).

EXAMPLE 22

N-(4-Morpholinoacetyl)-D-thiopropine-(O-2,6-dichlorobenzyl)-L-tyrosine hydrochloride

Intermediate 23 (618mg, 1.04mmol) was treated with LiOH.H₂O (96mg, 2.29mmol) in dioxane (10ml), MeOH (5ml) and water (5ml) for 1.5h at room temperature. A few drops of acetic acid were added and the volatiles removed *in vacuo*. The residue was chromatographed [silica; DCM (300 to 200), MeOH (20), AcOH (3), H₂O (2)] to afford the pure

product as an oil. This was dissolved in aqueous dioxane, acidified with a few drops of concentrated HCl and evaporated *in vacuo*. The HCl salt was re-dissolved in water and freeze-dried to afford the title compound as a white amorphous solid (302mg, 47%). δ H (DMSO- d_6 , 390K) 8.21 (1H, br s), 7.50 (2H, approximate t, \downarrow 8.0Hz), 7.41 (1H, approximate t, \downarrow 8.0Hz), 7.19 (2H, d, \downarrow 8.6Hz), 6.96 (2H, d, \downarrow 8.6Hz), 5.25 (2H, s), 4.98 (1H, dd, \downarrow 7.3, 4.3Hz), 4.79 (1H, d, \downarrow 9.2Hz), 4.58-4.49 (1H, m), 4.47 (1H, d, \downarrow 9.2Hz), 4.23-4.18 (1H, m), 4.05-3.90 (1H, m), 3.88 (4H, t, \downarrow 4.7Hz), 3.30 (1H, dd, \downarrow 11.6, 7.4Hz), 3.31-3.14 (4H, br m), 3.11 (1H, dd, \downarrow 14.2, 5.3Hz), 3.00-2.92 (2H, m); m/z (ES+, 60V) 582 (MH+).

EXAMPLE 23

N-Acetyl-*D*-thioprolin-(*N*'-2,6-dichlorobenzoyl-*N*'methyl)-*L*-4-aminophenylalanine

Intermediate 25 was reacted with 2,6-dichlorobenzoyl chloride in a similar manner to that described for Intermediate 2. Purification by flash chromatography (silica; 3:97 MeOH/DCM) and subsequent hydrolysis with aqueous LiOH (as described for the compound of Example 5) afforded the title compound as a white foam (750mg). δ H (DMSO- d_6 , (two pairs of rotameric species.) 8.50, 8.40, 8.22 and 8.16 (1H, d, \downarrow 8.0Hz), 7.62-7.08 (7H, m), 4.82-4.30 (3H, m), 4.45, 4.39, 4.21 and 4.17 (1H, d, \downarrow 8.4Hz), 3.34 and 3.10 (3H, s), 3.30-2.50 (4H, m), 2.05, 2.03, 1.83 and 1.79 (3H, s); m/z (ES1, 30V) 524 (MH+).

EXAMPLE 24

N-Acetyl-*D*-thioprolin-(*N*'-2,6-dichlorobenzyl-*N*'methyl)-*L*-4-aminophenylalanine

Intermediate 25 was reacted with 2,6-dichlorobenzyl bromide and purified in a similar manner to that described for Intermediate 21. Subsequent hydrolysis with aqueous LiOH (as described for the compound of Example 2a) afforded the title compound as an off-white solid (450mg). δ H (DMSO- d_6 , 1:1 ratio of rotamers) 8.38 and 8.10 (1H,d, \downarrow 8.3Hz), 7.51 (2H, d, \downarrow 7.9Hz), 7.38 (1H, t, \downarrow 7.9Hz), 7.05 (2H, app.t \downarrow 8.2Hz), 6.84 (2H, app. d, \downarrow 8.2Hz), 4.82-4.68 (2H, ms), 4.55 (2H, s), 4.44 (0.5H, d, \downarrow 9.2Hz), 4.45-4.32 (1H, m), 4.22 (0.5H, d, \downarrow 9.8Hz), 3.40-2.67 (4H, m), 2.60 (3H, s), 2.04 and 1.83 (3H, s); m/z (ESI, 60V) 510 (MH+).

EXAMPLE 25**N-Acetyl-D-thiopropine-4-(carbobenzyloxy)phenylalanine**

The title compound was prepared as a white solid by acylation of Intermediate 27 with *N*-acetyl-*D*-thiopropine in a similar manner to the preparation of Intermediate 1 followed by hydrolysis of the resulting ester in a similar manner to the compound of Example 2a) using potassium carbonate in place of lithium hydroxide. δ H (DMSO- d_6 , 390K) 7.9 (2H, dt, \downarrow 6.5, 1.8Hz), 7.46-7.31 (7H, m), 5.36 (2H, s), 4.80 (1H, m), 4.75 (d, \downarrow 9.1Hz) and 4.73 (d, \downarrow 9.2Hz) together (1H), 4.59 (1H, m), 4.41 (d, \downarrow Hz) and 4.34 (d, \downarrow 9.2Hz), together (1H), 3.30-3.19 (2H, m), 3.11-2.95 (2H, m), 1.98 (s) and 1.97 (s) together (3H); m/z (ESI, 60V) 457 (MH⁺).

EXAMPLE 26**N-Acetyl-D-thiopropine-(N-benzenesulphonyl)-L-4-aminophenylalanine**

A solution of Intermediate 61 (0.63g, 1.37mmol), in THF (20ml) and water (10ml) was treated with LiOH. H₂O (69mg, 1.65mmol) and stirred at room temperature for 16h. The reaction was acidified to pH1 with 10% HCl and extracted twice with DCM. The combined organic extracts were dried (MgSO₄) and evaporated *in vacuo* to give a foam that was purified by chromatography (SiO₂; DCM/MeOH/AcOH 90:10:1). The product was lyophilised from CH₃CN/ water (3:2, 20ml) to give the title compound as a fluffy white solid (0.25g, 41%). δ H (DMSO- d_6 , 390K) 7.77-7.73 (2H, m, Ar-H), 7.61 (1H, br s, NH), 7.58-7.47 (3H, m, Ar-H), 7.07 (2H, d, \downarrow 8.7Hz, Ar-H), 7.01 (2H, d, \downarrow 8.7Hz, Ar-H), 4.74 (1H, m, CH α -Thioprop), 4.76 (1H, d, \downarrow 9.2Hz, NCH α H β S), 4.42 (1H, dt, \downarrow 8.3, 5.3Hz, CH α -Ph), 4.32 (1H, d, \downarrow 9.2Hz, NCH α H β S), 3.20 (1H, dd, \downarrow 11.5, 7.4Hz, CHCH α H β S), 3.04 (1H, dd, \downarrow 14.1, 5.3Hz, ArCH α H β), 2.94 (1H, dd, \downarrow 11.5, 3.9Hz, CHCH α H β S), 2.88 (1H, dd, \downarrow 14.1, 8.5Hz, ArCH α H β) and 1.95 (3H, s, COMe). m/z (ESI, 30V) 478 (MH⁺).

The following compounds of Examples 27-52 were prepared by acylation of an appropriate amine starting material (deprotected as necessary) using the acid indicated in a similar manner to the preparation of Intermediate 1

followed by hydrolysis of the resulting ester in a similar manner to the preparation of the compound of Example 2a):

EXAMPLE 27

- 5 *N*-(*N*-Acetyl-2-phenyl-*D*-1,3-thiazolidin-4-oyl)-(*O*-benzyl-*L*-tyrosine
from Intermediate 53 and *O*-benzyl-*L*-tyrosine methyl hydrochloride ester
 δ H (DMSO- d_6) 7.82 (1H, br d, \downarrow 7.6Hz, NH), 7.61 (2H, m, Ar-H), 7.31 (8H,
m, Ar-H), 7.14 (2H, d, \downarrow 8.7Hz, Ar-H), 6.89 (2H, d, \downarrow 8.7Hz, Ar-H), 6.28
(1H, s, NCH(Ph)S), 5.04 (2H, s, CH₂O), 4.87 (1H, t, \downarrow 6.9Hz, CH α -thioprop),
10 4.59 (1H, m, CH α -tyr), 3.24 (1H, dd, \downarrow 11.8, 6.8Hz, CHCH_AH_BS), 3.05 (2H,
m, CHCH_AH_BS and CHCH_AH_BAr), 2.93 (1H, dd, \downarrow 14.1, 8.3Hz,
CHCH_AH_BAr) and 1.89 (3H, s, COMe). m/z (ESI, 160V) 505 (MH⁺).

EXAMPLE 28

- 15 *N*-(*N*-Acetyl-5-phenyl-1,3-thiazolidin-4-oyl)-(*O*-2,6-dichlorobenzyl)-*L*-
tyrosine
Prepared as 2-diastereomeric species, from Intermediate 55 and (*O*-2,6-
dichlorobenzyl)-*L*-tyrosine methyl ester hydrochloride.
- Diastereomer 1
20 δ H (DMSO- d_6 , 390K) 7.73 (1H, br s, NH), 7.51-7.40 (3H, m, Ar-H), 7.38-
7.23 (5H, m, Ar-H), 7.18 (2H, d, \downarrow 8.7Hz, Ar-H), 6.96 (2H, d, \downarrow 8.7Hz, Ar-
H), 5.26 (2H, s, CH₂O), 4.97 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 4.86 (1H, m,
CH α -thioprop), 4.76 (1H, d, \downarrow 3.5Hz, CH-Ph), 4.54 (1H, m, CH α -tyr), 4.53
(1H, d, \downarrow 9.2Hz, NCH_AH_BS), 3.11 (1H, dd, \downarrow 14.1, 5.3Hz, CH_AH_BAr), 2.96
25 (1H, dd, \downarrow 14.1, 8.6Hz, CH_AH_BAr), 2.00 (3H, br s, COMe). m/z (ESI, 60V)
573 (MH⁺)
- Diastereomer 2
30 δ H (DMSO- d_6 , 390K) 7.83 (1H, br s, NH), 7.51-7.40 (3H, m, Ar-H), 7.34-
7.27 (5H, m, Ar-H), 7.14 (2H, d, \downarrow 8.7Hz, Ar-H), 6.94 (2H, d, \downarrow 8.7, Ar-H),
5.25 (2H, s, CH₂O), 4.98 (1H, d, \downarrow 9.0Hz, NCH_AH_BS), 4.88 (1H, m, CH α -
thioprop), 4.68 (1H, d, \downarrow 3.6Hz, CH-Ph), 4.55 (2H, m, CH α -tyr and
NCH_AH_BS), 3.08 (1H, dd, \downarrow 14.2, 5.3Hz, CH_AH_BAr), 2.93 (1H, dd, \downarrow 14.2,
8.5Hz, CH_AH_BAr) and 2.01 (3H, br s, COMe). m/z (ESI, 60V) 573 (MH⁺).

EXAMPLE 29**N-Acetyl-(1-thia-3-azaspiro[4.4]non-4-oyl)-(O-2,6-dichlorobenzyl)-L-tyrosine**

- Prepared as 2 diastereomers [separated by fractional recrystallisation (isopropanol/water)] from Intermediate 57 and (O-2,6-dichlorobenzyl)-L-tyrosine methyl ester hydrochloride.

Diastereomer 1

- δ H (DMSO- d_6 , 390K) 7.56 (1H, br s, NH), 7.52-7.39 (3H, m, Ar-H), 7.20 (2H, d, \downarrow 8.7Hz, Ar-H), 6.95 (2H, d, \downarrow 8.7Hz, Ar-H), 5.25 (2H, s, CH₂O), 4.64 (2H, s, NCH₂S), 4.61 (1H, m, CH α -thioprop), 4.43 (1H, m, CH α -tyr), 3.11 (1H, dd, \downarrow 14.2, 5.2Hz, CHCH_AH_BAr), 2.94 (1H, dd, \downarrow 14.2, 8.6Hz, CHCH_AH_BAr) and 1.92-1.45 (11H, m, CH₂, COMe). m/z (ESI, 60V) 551 (MH⁺).

Diastereomer 2

- δ H (DMSO- d_6 , 400K) 7.51 (1H, br s, NH), 7.48-7.39 (3H, m, Ar-H), 7.17 (2H, d, \downarrow 8.7, Ar-H), 6.95 (2H, d, \downarrow 8.7Hz, Ar-H), 5.26 (2H, s, CH₂O), 4.69-4.45 (4H, m, CH α -thioprop, CH α -tyr, NCH₂S), 3.10 (1H, dd, \downarrow 14.2, 5.2Hz, CH_AH_BAr), 2.92 (1H, dd, \downarrow 14.2, 8.7Hz, CH_AH_BAr), 1.96 (3H, s, COMe), 1.95-1.54 (8H, m, CH₂). m/z (ESI, 60V) 551 (MH⁺).

EXAMPLE 30**N-(N-Acetyl-L-5,5-dimethyl-1,3-thiazolidin-4-oyl)-O-benzyl-L-tyrosine**

- from Intermediate 42a) and O-benzyl-L-tyrosine methyl ester hydrochloride as a white solid. δ H (DMSO- d_6 , 400K) 7.58 (1H, br d, CONH), 7.44-7.30 (5H, m, Ph), 7.17 (2H, d, \downarrow 8.7Hz, ArH), 6.91 (2H, d, \downarrow 8.7Hz, ArH), 5.08 (2H, s, OCH₂Ph), 4.73 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 4.65 (1H, d, \downarrow 9.1Hz, NCH_AH_BS), 4.93 (1H, dt, \downarrow 8.2, 5.5 CH α -tyr), 4.36 (1H, s, CH α), 3.08 (1H, dd, \downarrow 14.2, 5.4Hz, CHCH_AH_B), 2.93 (1H, dd, \downarrow 14.2, 8.2Hz, CHCH_AH_B), 1.90 (3H, br s, COCH₃), 1.50 (3H, s, CMe_AMe_B) and 1.28 (3H, s, CMe_AMe_B); m/z (ESI, 160V) 457 (MH⁺).

EXAMPLE 31**N-(N-Acetyl-D-5,5-dimethyl-1,3-thiazolidin-4-oyl)-O-(2,6-dichlorobenzyl)-L-tyrosine**

- from Intermediate 42b) and (O-2,6-dichlorobenzyl)-L-tyrosine methyl ester. δ H (DMSO- d_6 , 390K) 7.68 (1H, br s, CONH), 7.51-7.48 (2H, m, Cl₂ArH),

- 7.41 (1H, dd, \downarrow 9.3, 6.5Hz, Cl₂ArH), 7.18 (2H, d, \downarrow 8.6Hz, ArH), 6.95 (2H, d, \downarrow 8.6Hz, ArH), 5.26 (2H, s, OCH₂Ar), 4.74 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 4.64 (1H, d, \downarrow 9.3Hz, NCH_AH_BS), 4.6 (1H, br m, CH α tyr), 4.35 (1H, s, CH α), 3.11 (1H, dd, \downarrow 14.2, 5.3Hz, CHCH_AH_B), 2.92 (1H, dd, \downarrow 14.2, 8.7Hz, CHCH_AH_B), 1.95 (3H, s, COCH₃), 1.45 (3H, s, CMe_AMe_B) and 1.19 (3H, s, CMe_AMe_B); m/z (ESI, 60V) 525 (MH⁺).

EXAMPLE 32**N-Acetyl-D-thiopropine-4[2-(1-phenylethyl)]-L-phenylalanine**

- 10 from Intermediate 41 and *N*-acetyl-*D*-thiopropine. δ H (DMSO-d₆, 400K) 7.66 (1H, br d, CONH), 7.28-7.11 (9H, m, ArH), 4.82 (1H, dd, \downarrow 7.5, 3.8Hz, CH α thioprop), 4.76 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 4.53 (1H, dt, \downarrow 8.3, 5.4Hz, CH α Ph), 4.36 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 3.23 (1H, d, CHCH_AH_BS), 3.11 (1H, d, \downarrow 14.1, 5.4Hz, CHCH_AH_BAr), 3.00-2.93 (2H, m, CHCH_AH_BS + CHCH_AH_BAr), 2.90 (4H, s, CH₂CH₂) and 1.98 (3H, s COCH₃); m/z (ESI, 15V) 427 (MH⁺).

EXAMPLE 33**N-Acetyl-D-thiopropine-4-phenyl-L-phenylalanine**

- 20 from Intermediate 33 and *N*-acetyl-*D*-thiopropine. δ H (DMSO-d₆, 400K) 7.75 (1H, br d, CONH), 7.62-7.29 (9H, m, ArH), 4.83 (1H, dd, \downarrow 7.2, 3.9Hz, CH α thioprop), 7.76 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 4.59 (1H, dt, \downarrow 8.4, 5.4Hz, CH α Ph), 4.37 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 3.28-3.16 (2H, m, CHCH_AH_BS + CH_AH_BAr), 3.06-2.98 (2H, m, CHCH_AH_BS + CH_AH_BAr) and 1.98 (3H, s, COCH₃); m/z (ESI, 15V) 399 (MH⁺).

EXAMPLE 34**N-Acetyl-D-thiopropine-4-(3-prop-1-enyl)-L-phenylalanine**

- 30 from Intermediate 34 and *N*-acetyl-*D*-thiopropine. δ H (DMSO-d₆, 400K) 7.69 (1H, br d, CONH), 7.14 (2H, d, \downarrow 8.2Hz, ArH), 7.09 (2H, d, \downarrow 8.3Hz, ArH), 6.04-5.90 (1H, tdd, \downarrow 17.0, 10.2, 6.7Hz, CH₂CH=CH₂), 5.10-5.03 (2H, m, CH₂CH=CH₂), 4.81 (1H, dd, \downarrow 7.5, 3.9Hz, CH α thioprop), 4.76 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 4.53 (1H, dt, \downarrow 8.3, 5.4Hz, CH α Ph), 4.36 (1H, d, \downarrow 9.5Hz, NCH_AH_BS), 3.34 (2H, d, \downarrow 6.6Hz, CH₂CH=CH₂), 3.23 (1H, dd, \downarrow 11.5, 7.4Hz, CHCH_AH_BS), 3.11 (1H, dd, \downarrow 14.1, 5.5Hz, CHCH_AH_BAr),

3.00-2.91 (2H, m, CHCH_AH_BS + CHCH_AH_BAr) and 1.97 (3H, s, COCH₃); m/z (ESI, 15V) 363 (MH⁺).

EXAMPLE 35

- 5 **N-Acetyl-D-thiopropine-4-(2-benzo[b]furanyl)-L-phenylalanine**
from Intermediate 35 and *N*-acetyl-*D*-thiopropine. δ H (DMSO-d₆, 400K) 7.80 (2H, d, \downarrow 8.4Hz, ArH), 7.75 (1H, v br d, CONH), 7.65-7.55 (2H, m ArH), 7.35 (2H, d, \downarrow 8.5Hz, ArH), 7.33-7.22 (3H, m, ArH + C=CH), 4.84 (1H, dd, \downarrow 7.4, 3.9Hz, CH α thiopro), 4.76 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 4.60 (1H, dt, \downarrow 8.3, 5.4Hz, CH α Ph), 4.38 (1H, d, \downarrow 9.1Hz, NCH_AH_BS), 3.29-3.18 (2H, m, 2 x CHCH_AH_B), 3.09-3.01 (2H, m, 2 x CHCH_AH_B) and 1.99 (3H, s, COCH₃); m/z (ESI, 15V) 439 (MH⁺).

EXAMPLE 36

- 15 **N-Acetyl-D-thiopropine-4[2-(1-phenylethenyl)]phenylalanine**
from Intermediate 36 and *N*-acetyl-*D*-thiopropine. δ H (DMSO-d₆, 400K) (mixture of 2 diastereoisomers) 7.71 (1H, br, CONH), 7.57-7.21 (9H, m, ArH), 7.15 (2H, s, CH=CH), 4.82 (1H, dd, CH α thiopro), 4.77 and 4.75 (1H, each d, \downarrow 9.2Hz, NCH_AH_BS), 4.58 (1H, m, CH α Ph), 4.38 and 4.36 (1H, each d, \downarrow 9.2Hz, NCH_AH_BS), 3.29-2.96 (4H, m, CHCH₂Ar + CHCH₂S), 1.99 and 1.96 (3H, each s, COCH₃); m/z (ESI, 15V) 425 (MH⁺).

EXAMPLE 37

- 25 **N-Acetyl-D-thiopropine-4-(3-pyridyl)phenylalanine**
from Intermediate 37 and *N*-acetyl-*D*-thiopropine. δ H (DMSO-d₆, 400K) 8.82 (1H, d, \downarrow 1.8Hz, PyH), 8.53 (1H, dd, \downarrow 4.7, 1.5Hz, PyH), 7.96 (1H, ddd, \downarrow 8.0, 2.3, 1.8Hz, PyH), 7.53 (2H, d, \downarrow 8.2Hz, ArH), 7.5 (1H, br, CONH), 7.41 (1H, dd, \downarrow 7.9, 4.0Hz, PyH), 7.35 (2H, d, \downarrow 8.3Hz, ArH), 4.82 (1H, dd, CH α thiopro), 4.77 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 4.37 (1H, d, \downarrow 9.3Hz, NCH_AH_BS), 3.27-3.21 (2H, m, 2 x CHCH_AH_B), 3.10-3.04 (2H, m, 2 x CHCH_AH_B) and 1.97 (3H, s, COCH₃); m/z (ESI, 27V) 400 (MH⁺).

EXAMPLE 38

- 35 **N-Acetyl-D-thiopropine-L-phenylalanine**
from *N*-acetyl-*D*-thiopropine and *L*-phenylalanine methyl ester hydrochloride. δ H (DMSO-d₆, 400K) 7.69 (1H, br d, CONH), 7.29-7.17

(5H, m, ArH), 4.82 (1H, dd, \downarrow 7.4, 3.9Hz, CH α thioprop), 4.77 (1H, d, \downarrow 9.2Hz, NCH α H β S), 4.56 (1H, dt, \downarrow 8.3, 5.4Hz, CH α Ph), 4.37 (1H, d, \downarrow 9.3Hz, NCH α H β S), 3.24 (1H, dd, \downarrow 11.5, 7.4Hz, CHCH α H β S), 3.15 (1H, dd, \downarrow 14.1, 5.4Hz, CHCH α H β Ar), 2.99 (1H, dd, \downarrow 11.6, 3.9Hz, CHCH α H β S), 2.98 (1H, dd, \downarrow 14.1, 8.4Hz, CHCH α H β Ar) and 1.98 (3H, COCH₃); m/z (ESI, 27V) 323 (MH⁺).

EXAMPLE 39

N-Acetyl-D-thiopropine-N-methyl-N⁺(3,5-dichloro-isonicotinoyl)-L-4-aminophenylalanine

from Intermediate 51 and *N*-acetyl-*D*-thiopropine. δ H (DMSO- d_6 , 420K) 10.39 (1H, br s, CONH) 8.67 (2H, s, PyrH), 7.54 (2H, d, \downarrow 7.7Hz, ArH), 7.25 (2H, d, \downarrow 8.1Hz, ArH), 5.14 (1H, dd, CH α), 5.03 (1H, dd, CH α), 3.35-3.23 (2H, m, 2 x CHCH α H β), 3.05 (1H, dd, \downarrow 14.6, 10.2Hz, CHCH α H β), 2.93 (3H, s, NMe), 2.8-2.7 (1H, br m, CHCH α H β) and 1.91 (3H, br s, COCH₃); m/z (ESI, 70V) 525 (MH⁺).

EXAMPLE 40

N-Acetyl-D-thiopropine-4-(2-hydroxyhexafluoroisopropyl)-DL-phenylalanine

from Intermediate 67 and *N*-acetyl-*D*-thiopropine δ H (DMSO- d_6 , 390K) 7.90-7.75 (1H, m, NH), 7.59 (2H, d, \downarrow 7.9Hz, ArH), 7.35 (2H, dd, \downarrow 8.5, 3.3Hz, ArH), 4.90-4.80 (1H, m, NCH α H β S), 4.74 (1H, dd, \downarrow 9.2, 7.3Hz, NCH α H β S), 4.67-4.55 (1H, m, α -CH), 4.33 (1H, dd, \downarrow 11.1 and 9.2Hz, α -CH), 3.29-2.89 (4H, m, CH₂Ar and SCH₂CH) and 1.96 (s) and 1.93 (s); together (3H, COCH₃); m/z (ESI, 60V) 489 (MH⁺).

EXAMPLE 41

N-Acetyl-D-thiopropine-4-(trifluoromethyl)-DL-phenylalanine

from 4-(trifluoromethyl)-*DL*-phenylalanine methyl ester and *N*-acetyl-*D*-thiopropine δ H (DMSO- d_6) 8.56-8.12 (1H, m, NH), 7.68-7.55 (2H, m, ArH), 7.51-7.37 (2H, m, ArH), 4.85-4.15 (4H, m, NCH₂S and 2 x α -CH), 3.40-2.65 (4H, m, SCH₂CH and CH₂Ar), 2.06 (s) and 2.04 (s) and 1.80(s) and 1.71 (s); together (3H, COCH₃); m/z (ESI, 60V), 391 (MH⁺).

EXAMPLE 42**N-Acetyl-D-thiopropine-4-(tert-butyl)-DL-phenylalanine**

from 4-(tert-butyl)-DL-phenylalanine methyl ester and *N*-acetyl-*D*-thiopropine
 δ H (DMSO- d_6) 8.45-8.03 (1H, m, NH), 7.33-7.07 (4H, m, ArH), 4.87-4.17
 5 (4H, m, NCH₂S and 2 x α -CH), 3.90-2.51 (4H, m, CH₂Ar and SCH₂CH),
 2.07 (s) and 1.99 (s) and 1.79 (s) and 1.69 (s); together (3H, COCH₃) and
 1.25 (9H, s, ¹Bu). m/z (ESI, 60V) 379 (MH⁺).

EXAMPLE 43

10 **N-Acetyl-D-thiopropine-4-([(2,6-dichlorophenyl)sulphonyl]methyl)**
phenylalanine

from Intermediate 71 and *N*-acetyl-*D*-thiopropine δ H (DMSO- d_6) 8.60-8.14
 (1H, m, NH), 7.73-7.61 (2H, m, ArH), 7.54-7.37 (5H, m, ArH), 4.87 (2H, s,
 CH₂SO₂), 4.80-4.16 (4H, m, 2 x α -CH and NCH₂S), 3.40-2.72 (4H, m,
 15 SCH₂CH and CH₂Ar), 2.12-1.80 (3H, m, COCH₃) m/z (ESI, 60V) 545
 (MH⁺).

EXAMPLE 44

20 **N-Acetyl-D-thiopropine-4-([(2,6-dichlorobenzyl)-sulphonyl]**
phenylalanine

from Intermediate 72 and *N*-acetyl-*D*-thiopropine δ H (DMSO- d_6) 8.46-8.05
 (1H, m, NH), 7.65-7.61 (3H, m, ArH), 7.20-7.10 (4H, m, ArH), 4.82-4.61
 (4H, m, SO₂CH₂ and SCH₂N), 4.44-4.37 (1H, m, α -CH), 4.23 (1H, dd, \downarrow
 18.7, 9.8Hz, α -CH), 3.50-2.72 (4H, m, SCH₂CH and CH₂Ar) and 2.06 (s)
 25 and 2.05 (s) and 1.82 (s) and 1.77 (s) together (3H, COCH₃); m/z (ESI,
 60V) 545 (MH⁺).

EXAMPLE 45

30 **N-Acetyl-D-thiopropine-4-([(3,5-dichlorophenyl]carboxamido)phenyl]**
alanine

from Intermediate 30 and *N*-acetyl-*D*-thiopropine. δ H (DMSO- d_6 , 390K)
 10.1 (1H, br s), 7.9-7.8 (4H, m), 7.76 (1H, v br s), 7.39 (2H, m), 7.21 (1H, t,
 \downarrow 1.9Hz), 4.82 (1H, br m), 4.77 (d, \downarrow 9.2Hz) and 4.75 (d, \downarrow 9.2Hz) together
 (1H), 4.62 (1H, br m), 4.37 (1H, d, \downarrow 9.2Hz), 3.28-3.20 (2H, br m), 3.12-
 35 2.98 (2H, br m) and 1.99 (s) and 1.67 (s) together (3H). m/z (ESI, 60V) 510
 (MH⁺).

EXAMPLE 46**N-Acetyl-D-thioprolinone (N'-acetyl)-L-4-amino phenylalanine**

- from 4-(N-acetyl)-L-4-amino phenylalanine methylester and N-acetyl-D-thioprolinone δ H (DMSO-d⁶, 390K) 9.37 (1H, br s, NH), 7.8-7.62 (1H, m, NH), 7.44 (2H, d, \downarrow 8.5Hz, ArH), 7.10 (2H, d, \downarrow 8.5Hz, ArH), 4.88-4.71 (2H, m, NCH₂S), 4.58-4.45 (1H, m, α -CH), 4.36 (1H, d, \downarrow 9.2Hz, α -CH), 3.24 (1H, dd, \downarrow 11.5, 7.4Hz), 3.07 (1H, dd, \downarrow 14.1, 5.4Hz), 3.00 (1H, dd, \downarrow 11.5, 3.9Hz), 2.92 (1H, dd, \downarrow 14.1, 8.4Hz), and 2.02 (3H, s, COCH₃) and 1.98 (3H, s, COCH₃); m/z (ESI, 60V), 380 (MH⁺),

EXAMPLE 47**N-Acetyl-D-thioprolinone-(N'-2,6-dimethoxybenzoyl)-L-4-amino phenylalanine**

- from (N-2,6-dimethoxybenzoyl)-L-4-amino-phenylalanine methyl ester and N-acetyl-D-thioprolinone δ H (DMSO-d⁶) 10.10 (1H, s, NH), 8.44 (d, \downarrow 7.9Hz) and 8.12 (d, \downarrow 8.3Hz); together (1H, NH), 7.56-7.54 (2H, m, ArH), 7.33 (1H, t, \downarrow 8.4Hz, Ar(OMe)₂H), 7.20-7.05 (2H, m, ArH), 6.71 (2H, d, \downarrow 8.4Hz, Ar(OMe)₂H), 4.88-4.20 (4H, m, NCH₂S and 2 x α -CH), 3.75 (6H, s, OMe), 3.40-2.79 (4H, m, CH₂Ar and SCH₂CH) and 2.07 (s) and 1.87 (s); together (3H, COCH₃); m/z (ESI, 60V) 502 (MH⁺).

EXAMPLE 48**N-Acetyl-D-thioprolinone (N'-benzoyl)-L-4-amino phenylalanine**

- from (N-benzoyl)-L-4-amino phenylalanine methyl ester and N-acetyl-D-thioprolinone δ H (DMSO-d⁶, 390K) 9.72 (1H, s, NH), 7.66 (2H, d, \downarrow 8.5Hz, ArH), 7.68-7.49 (6H, m, ArH and NH), 7.19 (2H, d, \downarrow 8.5Hz, ArH), 4.85 (1H, dd, \downarrow 7.4, 3.9Hz, CH α -thiopro), 4.78 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 4.55 (1H, ddd, \downarrow 8.2, 8.2, 5.5Hz, CH α -Ph), 4.39 (1H, d, \downarrow 9.2Hz, NCH_AH_BS), 3.27 (1H, dd, \downarrow 11.7, 7.4Hz, SCH_AH_BCH), 3.13 (1H, dd, \downarrow 14.1, 5.4Hz, CH_AH_BAr), 3.06 (1H, dd, \downarrow 11.5, 3.9Hz, SCH_AH_BCH), 2.99 (1H, dd, \downarrow 14.1, 8.2Hz, CH_AH_BAr) and 2.01 (3H, s, COCH₃); m/z (ESI, 60V) 442 (MH⁺).

EXAMPLE 49**N-Acetyl-D-thiopropine-(N'-2,6-dimethylbenzoyl)-L-4-amino phenylalanine**

from (N-2,6-dimethylbenzoyl)-L-4-amino-phenylalanine methyl ester and
5 N-acetyl-D-thiopropine δ H (DMSO- d_6) 10.29 (1H, s, NH), 8.44 (d, \downarrow 8.0Hz) and 8.15 (d, \downarrow 8.3Hz) together (1H, NH), 7.62 (2H, d, \downarrow 6.5Hz, ArH), 7.29-7.02 (5H, m, ArH), 4.86-4.18 (4H, m, NCH₂S and 2 x α -CH), 3.22-2.71 (4H, m, SCH₂CH and CH₂Ar), 2.26 (6H, s, CH₃) and 2.06 (s) and 1.84 (s) together (3H, COCH₃); m/z (ESI, 60V) 470 (MH⁺).

EXAMPLE 50**N-Acetyl-D-thiopropine-(N'-isonicotinoyl)-L-4-amino-phenylalanine**

from (N-isonicotinoyl)-L-4-amino phenylalanine methyl ester and N-acetyl-D-thiopropine δ H (DMSO- d_6 , 390K,) 10.00 (1H, s, NH), 8.73 (2H, d, \downarrow
15 6.0Hz, ArH), 7.83 (2H, d, \downarrow 6.0Hz, ArH), 7.54 (2H, d, \downarrow 8.5Hz, ArH), 7.37 (1H, br s, NH), 7.17 (2H, d, \downarrow 8.5Hz, ArH), 4.85-4.73 (2H, m, NCH₂S), 4.36 (1H, d, \downarrow 9.3Hz, α -CH), 4.00 (1H, br s, α -CH), 3.22 1H, dd, \downarrow 11.3, 7.2Hz), 3.16-3.05 (2H, m), 3.10 (1H, dd, \downarrow 13.5, 5.2Hz) and 1.96 (3H, s, COCH₃); m/z (ESI, 60V) 443 (MH⁺).

EXAMPLE 51**N-Acetyl-D-thiopropine-(N'-tert-butylcarbonyl)-L-4-amino phenylalanine**

from (N-tert-butylcarbonyl)-L-4-amino phenylalanine methyl ester and N-acetyl-D-thiopropine δ H (DMSO- d_6) 9.10 (1H, s, NH), 8.40 (d, \downarrow 8.0Hz) and
25 8.10 (d, \downarrow 8.2Hz) together (1H, NH), 7.52 (2H, d, \downarrow 7.9Hz, ArH), 7.10 (2H, app.dd. \downarrow 9.3, 8.9Hz, ArH), 4.85-4.18 (4H, m, NCH₂S and 2 x α -CH), 3.29-2.76 (4H, m, CH₂Ar and SCH₂CH), 2.06 (s) and 11.5 (s) together (3H, COCH₃) and 1.21 (9H, s, ^tBu); m/z (ESI, 60V) 422 (MH⁺).

EXAMPLE 52**N-Acetyl-D-thiopropine-(N'-2,6-dichlorophenylacetyl)-L-4-amino phenylalanine**

from (N-2,6-dichlorophenylacetyl)-L-4-amino phenylalanine methyl ester
35 and N-acetyl-D-thiopropine δ H (DMSO- d_6) 10.22 (1H, s, NH), 8.42 (d, \downarrow 8.2Hz) and 8.12 (d, \downarrow 8.4Hz) together (1H, NH), 7.55-7.30 (5H, m, ArH),

7.13 (2H, dd, J 9.1, 9.1 Hz, ArH), 4.87-4.14 (4H, m, NCH_2S and 2 x $\alpha\text{-CH}$), 4.03 (2H, s, COCH_2Ar), 3.45-2.72 (4H, m, CHCH_2Ar and SCH_2CH) and 2.05 (s) and 1.84 (s); together (3H, COCH_3); m/z (ESI, 60V) 524 (MH^+).

5

The following assays can be used to demonstrate the potency and selectivity of the compounds according to the invention. In each of these assays an IC_{50} value was determined for each test compound and represents the concentration of compound necessary to achieve 50% inhibition of cell adhesion where 100% = adhesion assessed in the absence of the test compound and 0% = absorbance in wells that did not receive cells.

$\alpha_4\beta_1$ Integrin-dependent Jurkat cell adhesion to VCAM-Ig

96 well NUNC plates were coated with F(ab)_2 fragment goat anti-human IgG Fc γ -specific antibody [Jackson Immuno Research 109-006-098: 100 μl at 2 $\mu\text{g/ml}$ in 0.1M NaHCO_3 , pH 8.4], overnight at 4°. The plates were washed (3x) in phosphate-buffered saline (PBS) and then blocked for 1h in PBS/1% BSA at room temperature on a rocking platform. After washing (3x in PBS) 9 ng/ml of purified 2d VCAM-Ig diluted in PBS/1% BSA was added and the plates left for 60 minutes at room temperature on a rocking platform. The plates were washed (3x in PBS) and the assay then performed at 37° for 30 min in a total volume of 200 μl containing 2.5×10^5 Jurkat cells in the presence or absence of titrated test compounds.

25

Each plate was washed (2x) with medium and the adherent cells were fixed with 100 μl methanol for 10 minutes followed by another wash. 100 μl 0.25% Rose Bengal (Sigma R4507) in PBS was added for 5 minutes at room temperature and the plates washed (3x) in PBS. 100 μl 50% (v/v) ethanol in PBS was added and the plates left for 60min after which the absorbance (570nm) was measured.

30

$\alpha_4\beta_7$ Integrin-dependent JY cell adhesion to MAdCAM-Ig

This assay was performed in the same manner as the $\alpha_4\beta_1$ assay except that MAdCAM-Ig (150ng/ml) was used in place of 2d VCAM-Ig and a sub-line of the β -lympho blastoid cell-line JY was used in place of Jurkat cells.

35

The IC₅₀ value for each test compound was determined as described in the $\alpha_4\beta_1$ integrin assay.

$\alpha_5\beta_1$ Integrin-dependent K562 cell adhesion to fibronectin

- 5 96 well tissue culture plates were coated with human plasma fibronectin (Sigma F0895) at 5 μ g/ml in phosphate-buffered saline (PBS) for 2 hr at 37°C. The plates were washed (3x in PBS) and then blocked for 1h in 100 μ l PBS/1% BSA at room temperature on a rocking platform. The blocked plates were washed (3x in PBS) and the assay then performed at
10 37°C in a total volume of 200 μ l containing 2.5x 10⁵ K562 cells, phorbol-12-myristate-13-acetate at 10ng/ml, and in the presence or absence of titrated test compounds. Incubation time was 30 minutes. Each plate was fixed and stained as described in the $\alpha_4\beta_1$ assay above.

15 **$\alpha_m\beta_2$ -dependent human polymorphonuclear neutrophils adhesion to plastic**

- 96 well tissue culture plates were coated with RPMI 1640/10% FCS for 2h at 37°C. 2 x 10⁵ freshly isolated human venous polymorphonuclear neutrophils (PMN) were added to the wells in a total volume of 200 μ l in the
20 presence of 10ng/ml phorbol-12-myristate-13-acetate, and in the presence or absence of test compounds, and incubated for 20min at 37°C followed by 30min at room temperature. The plates were washed in medium and 100 μ l 0.1% (w/v) HMB (hexadecyl trimethyl ammonium bromide, Sigma H5882) in 0.05M potassium phosphate buffer, pH 6.0 added to each well.
25 The plates were then left on a rocker at room temperature for 60 min. Endogenous peroxidase activity was then assessed using tetramethyl benzidine (TMB) as follows: PMN lysate samples mixed with 0.22% H₂O₂ (Sigma) and 50 μ g/ml TMB (Boehringer Mannheim) in 0.1M sodium acetate/citrate buffer, pH 6.0 and absorbance measured at 630nm.

30

$\alpha_{IIb}\beta_3$ -dependent human platelet aggregation

- Human platelet aggregation was assessed using impedance aggregation on the Chronolog Whole Blood Lumiaggregometer. Human platelet-rich plasma (PRP) was obtained by spinning fresh human venous blood
35 anticoagulated with 0.38% (v/v) tri-sodium citrate at 220xg for 10 min and diluted to a cell density of 6 x 10⁸/ml in autologous plasma. Cuvettes

contained equal volumes of PRP and filtered Tyrode's buffer (g/liter: NaCl 8.0; $\text{MgCl}_2 \cdot \text{H}_2\text{O}$ 0.427; CaCl_2 0.2; KCl 0.2; D-glucose 1.0; NaHCO_3 1.0; $\text{NaHPO}_4 \cdot 2\text{H}_2\text{O}$ 0.065). Aggregation was monitored following addition of $2.5\mu\text{M}$ ADP (Sigma) in the presence or absence of inhibitors.

5


In the above assays the compounds of the invention generally have IC_{50} values in the $\alpha_4\beta_1$ and $\alpha_4\beta_7$ assays of $1\mu\text{M}$ and below. The compounds of the Examples typically had IC_{50} values of 500nM and below in these assays. In the other assays featuring α integrins of other subgroups the

10

same compounds had IC_{50} values of $50\mu\text{M}$ and above thus demonstrating the potency and selectivity of their action against α_4 integrins.

CLAIMS

1. A compound of formula (1)



wherein

R^1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group;

Alk^1 and Alk^2 , which may be the same or different, is each an optionally substituted aliphatic or heteroaliphatic chain;

L^1 is a linker atom or group;

r , s , t and u is each zero or an integer 1;

Alk^3 is a straight or branched alkylene chain;

m is zero or an integer 1;

R^4 is a hydrogen atom or a methyl group;

R^5 is a hydrogen atom or a straight or branched alkyl group;


A is a chain $-[C(R^7)(R^8)]_pY[C(R^9)(R^{10})]_q-$ in which Y is a sulphur atom or a $-S(O)-$ or $-S(O)_2-$ group, R^7 , R^8 , R^9 and R^{10} , which may be the same or different, is each a hydrogen atom or a straight or branched alkyl or optionally substituted aromatic group, or R^7 and R^8 together with the carbon atom to which they are attached, or R^9 and R^{10} together with the carbon atom to which they are attached, each forms a C_{3-7} cycloalkyl group, and p and q , which may be the same or different, is each zero or an integer 1 or 2, provided that when one of p or q is zero the other is an integer 1 or 2;

L^2 is a linker group selected from $-C(O)-$, $-C(O)O-$, $-C(S)-$, $-S(O)_2-$, $-CON(R^{11})-$, [where R^{11} is a hydrogen atom or a straight or branched alkyl group], $-CSN(R^{11})-$, $-SON(R^{11})-$ or $SO_2N(R^{11})-$;

- R^2 and R^3 , which may be the same or different is each an atom or group $-L^3(CH_2)_pL^4(R^{2a})_q$ in which L^3 and L^4 is each a covalent bond or a linker atom or group, p is zero or the integer 1, q is an integer 1, 2 or 3 and R^{2a} is a hydrogen or halogen atom or a group selected from straight or branched alkyl, $-OR^{12}$ [where R^{12} is a hydrogen atom or an optionally substituted straight or branched alkyl group], $-SR^{12}$, $-NR^{12}R^{13}$, [where R^{13} is as just defined for R^{12} and may be the same or different], $-NO_2$, $-CN$, $-CO_2R^{12}$, $-SO_3H$, $-SO_2R^{12}$, $-OCO_2R^{12}$, $-CONR^{12}R^{13}$, $-OCONR^{12}R^{13}$, $-CSNR^{12}R^{13}$, $-COR^{12}$, $-N(R^{12})COR^{13}$, $N(R^{12})CS^{13}$, $-SO_2N(R^{12})(R^{13})$, $-N(R^{12})SO_2R^{13}$, $-N(R^{12})CONR^{13}R^{14}$ [where R^{14} is a hydrogen atom or an optionally substituted straight or branched alkyl group], $-N(R^{12})CSNR^{13}R^{14}$ or $-N(R^{12})SO_2NR^{13}R^{14}$; R is a carboxylic acid or a derivative thereof;
- R^6 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group, provided that:
- (1) when $R^1(Alk^1)_r(L^1)_s-$ is $R^1(Alk^1)_rO-$, $R^1(Alk^1)_rC(O)O-$, $R^1(Alk^1)_rNHC(O)O-$ or $R^1(Alk^1)_rS(O)_2O-$, [in which R^1 is a hydrogen atom or an optionally substituted aromatic group and Alk^1 is an optionally substituted alkyl group] and $R^6(Alk^2)_u(L^2)_t-$ is $R^6(Alk^2)_uCO-$, $R^6(Alk^2)_uC(O)O-$, $R^6(Alk^2)_uNHCO-$ or $R^6(Alk^2)_uS(O)_2-$ [in which Alk^2 is an optionally substituted alkyl chain], then R^6 is an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic or heteroaromatic group; and
 - (2) Alk^2 , when present is not a $-(CH_2)_nS-$, $-(CH_2)_nSS-$ or $-(CH_2)_nSC(O)-$ chain, where n is an integer 1, 2 or 3; and the salts, solvates and hydrates thereof.

2. A compound according to Claim 1 in which R is a $-CO_2H$ group.
3. A compound according to Claim 1 or 2 in which Alk^3 is a $-CH_2-$ chain and m is an integer 1.
4. A compound according to any one of Claims 1 to 3 in which R^4 and R^5 is each a hydrogen atom.

5. A compound according to any one of Claims 1 to 4 in which the chain A is a $-C(R^7)(R^8)SC(R^9)(R^{10})-$ chain.
6. A compound according to any one of Claims 1 to 5 in which R^1 is an optionally substituted aromatic or heteroaromatic group.
7. A compound according to Claim 6 in which R^1 is an optionally substituted phenyl, pyridyl or pyrimidyl group.
8. A compound according to anyone of Claims 1 to 7 in which t is an integer 1.
9. A compound according to any of the preceding Claims in which $R^1(Alk^1)_r(L^1)_s-$ is a $R^1CH_2L^1$ or R^1L^1 group where R^1 is an optionally substituted aromatic or heteroaromatic group, Alk^3 is a $-CH_2-$ chain, m is an integer 1, R is a $-CO_2H$ group, R^4 and R^5 is each a hydrogen atom and $-(L^2)_t(Alk^2)_uR^6$ is a $-L^2CH_2R^6$ group where R^6 is a hydrogen atom or an optionally substituted aromatic or heteroaromatic group.
10. A compound according to Claim 9 in which $R^1(Alk^1)_r(L^1)_s-$ is a $R^1CSN(R^{11})-$, $R^1N(R^{11})-$, $R^1N(R^{11})CO-$, $R^1N(R^{11})CS-$, $R^1S(O)N(R^{11})-$, $R^1S(O)_2N(R^{11})-$, $R^1N(R^{11})SO-$, $R^1N(R^{11})S(O)_2-$ or $R^1CON(R^{11})-$ group.
11. A compound according to Claim 10 wherein $R^1(Alk^1)_r(L^1)_s-$ is a $R^1CON(R^{11})-$ group.
12. A compound according to any one of Claims 9 to 11 wherein R^6 is an optionally substituted heteroaromatic group.
13. A compound according to Claim 1 which has the formula (1a):



5 wherein -W= is -CH= or -N=; R¹⁵ and R¹⁶, which may be the same or different, is each an atom or group -L³(CH₂)_pL⁴(R^{2a})_q as defined for R² and R³ in Claim (1); Alk¹, r, L¹, s, R², R³, Alk³, m, R, R⁴, R⁵, A, L², t, Alk², u and R⁶ are as defined in Claim (1); and the salts, solvates, hydrates and N-oxides thereof.

- 10 14. A compound according to Claim 13 wherein R is a -CO₂H group, Alk³ is a -CH₂- chain, m is an integer 1, R⁴ and R⁵ is each a hydrogen atom, -(L²)_t(Alk²)_uR⁶ is a L²CH₂R⁶ group where R⁶ is a hydrogen atom or an optionally substituted aromatic or heteroaromatic group and the chain A is a -C(R⁷)(R⁸)SC(R⁹)(R¹⁰)- chain.
- 15 15. A compound according to Claim 13 or Claim 14 wherein (Alk¹)_r(L¹)_s is a -SO₂NH-, -C(O)O-, -NH- or -CONH- group.
- 20 16. A compound according to any one of Claims 13 to 15 wherein each of R¹⁵ and R¹⁶ is a substituent -L³(CH₂)_pL⁴(R^{2a})_q in which R^{2a} is not a hydrogen atom when L³ and L⁴ is each a covalent bond and p is zero.
- 25 17. A compound which is:
N-(Pyrid-3-ylacetyl)-*D*-thioproline-(*N*-2,6-dichlorobenzoyl)-*L*-4-aminophenylalanine;
N-Acetyl-*D*-thioproline-(*N*-3,5-dichloroisonicotinoyl)-*L*-4-amino phenylalanine;
N-(Pyrid-3-ylacetyl)-*D*-thioproline-*O*-(2,4,6-trichlorobenzyl)-*L*-tyrosine;
N-(Pyrid-3-ylacetyl)-*D*-thioproline-(*O*-2,4,6-trichlorobenzoyl)-*L*-tyrosine;
30 *N*-(Pyrid-3-ylacetyl)-*D*-thioproline-(*O*-2,6-dichlorobenzoyl)-*L*-tyrosine;

N-Acetyl-*D*-thioprolin-(*N*'-2,6-dichlorobenzoyl)-*L*-4-aminophenylalanine;

N-Acetyl-*D*-thioprolin-[*N*'-2-fluoro-6-(trifluoromethyl)benzoyl]-*L*-4-aminophenylalanine;

5 *N*-Acetyl-*D*-thioprolin-(*N*'-2,4,6-trichlorobenzoyl)-*L*-4-aminophenylalanine;

N-Acetyl-*D*-thioprolin-(*N*'-2,6-trichlorobenzyl)-*L*-4-aminophenylalanine;

and the salts, solvates, hydrates and *N*-oxides thereof.

10

18. A pharmaceutical composition comprising a compound according to Claim 1 together with one or more pharmaceutically acceptable carriers, excipients or diluents.